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Abstract 
There is a need for new agents or combination of agents for treatment of serious 
infections caused by gentamicin and vancomycin-resistant enterococci, which may be 
resistant to all available antimicrobial agents. The enterococci resistance against 
antimicrobial agents may be due to both intrinsic and acquisition of the resistance 
genes to counter antibiotics which were once effective. However, there have been 
only a few antimicrobial agents which have any activity against these resistant 
organisms and it is likely that the pathogens wi ll soon become resistant to these as 
welL One strategy to preserve the efficacy of these new compounds may be to use 
them in combination. Similarly, combination therapy might be the only strategy that 
might be effective against some strains, particularly those responsible for endocarditis, 
intra-abdominal sepsis and urinary tract infections. It is therefore, impottant to study 
further the combination of agents against enterococci especially those with high-level 
resistant to gentamicin to establish the synergistic activities of the antibiotics. Also to 
identify by PCR techn ique the existence of some resistance genes involved, for 
example, in gentamicin and ciprofloxacin antibiotics. The aim of this study was to 
investigate synergistic activities of the combined antibiotics against the gentamicin 
resistant Enterococcus faecalis and Enterococcus faecium and to establish the 
existence of some genes involved in the resistance of enterococci against gentamicin 
and ciprofloxacin. The total of 81 clinical isolates were collected for the study and all 
were found to be resistant to gentamicin ( MICs range 32->256mg/1 ). 50 isolates 
were found to be resistant to ciprofloxacin with MICs range 64->256mg/1. The 
synergistic activities of the antibiotics combinations were establ ished against 
E.faecalis and E.faecium clinical isolates. The combination between amoxicillin and 
gentamicin against Efaecalis resulted into synergy wi th MIC at 90% of 0.5mg/l and 
for E.faecium MIC at 90% was 2mg/l. Vancomycin and gentamicin combination had 
MIC at 90% of 2mg/l for E.faecalis and 1 mg/1 for E.faecium. Teicoplanin and 
synercid combination showed synergistic acti vity of MlC at 90% of 0.5mg/1 for 
E.faecalis while E.faeciurn had also 0.5mg/1. The combination between teicoplanin 
and ciprof1oxacin had synergy with MIC at 90% of <0.25mg/1 for E.faecalis and 
E.faecium had the same activity MIC at 90% of <0.25mg/1. The combination between 
amoxicillin and synercid resulted into synergistic activity at MIC at 90% of 4mg/l for 
E.faecalis and also 4mg/l for E.faecium. The antagonistic activity was observed 
between the combination of vancomycin and synercid with MIC at 90% of 32mg/l for 
E.faecalis and MIC at 90% of 16mg/l for E.faecium. The combination between 
synercid and ciprofloxacin resulted into synergistic activi ty at 90% M IC of 4mg/1 for 
E.faecium. The checkerboard test of the combination between synercid and 
ciprofloxacin against four clinical isolates of E.faecium resulted into FIC indices of 
0.4 for iso late D002 and 0.4 for isolate 0051. While isolate 788/5/95 had 0.3 and 
NCTC 12202 had also 0.3. These indices confirm the synergistic activ ity of the 
combined antibiotic of the two drugs. Of 27 clinical isoaltes tested for the presence of 
aminoglycoside modifying enzymes using PCR technique, only 8 ( 2 E.faecium and 6 
E.faecalis ) showed the positive results of the presence of AME. However, the 
presence of the AME did not prevent the synergistic acti vities of the combined drugs 
against E.faecafis and E.faeciurn. The PFGE study showed the heterogeneous 
existence of these gentamicin resistance isolates from RJE. Also, of the isolates ( all 
E.faecalis ) tested for the presence of gyrA and parC among the iso lates with MICs 
>256mg/1 and one with MIC of 0.5mg/ l against ciprofloxacin, 6 ( 5 with MICs > 
ii 
256m gil and one with MTC of 0.5mg/l ) were found to have parC mutation and 7 were 
found to have gyrA mutation. 
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The prevalence of enterococci as nosocomial pathogens has increased over the past 15 
years. They are now well established as the third most common etiology of 
endocarditis (Murray and Weinstock, 1999 ) and are second most common cause of 
surgical wounds infections and nosocomial l.uinary tract infections and the third most 
common cause of nosocomial bacteraemias in USA ( Tenover eta!, 1993; Emori and 
Gyanes, 1993 ). However, enterococcal resistance to antimicrobial agents has emerged 
resulting in serious therapeutic difficulties. 
1.1.1 Historical View 
"Enterococcus" was first termed as "Micrococcus zymogenes" by MacCallum and 
Hastings in 1899 at Johns Hopkins Hospital-USA, identified in the fatal case of 
endocarditis. In 1906, the name " Streptococcus fa ecalis" was coined by Andrews 
and Herder referring to a faeces organism. ln 1930s, enterococci were grouped into 
group D streptococci based on serological typing by Rebecca Lancefield showing the 
difference in the cell-wall polysaccharide antigen ( Lancefield, 1933 ). Sherman created 
two groups of streptococci in 1937 and named one group that grew at 1 0°C and 45°C, 
in broth containing 6.5% NaCI, at pH9.6 and survived heating at 60°C for 30 minutes as 
Streptococcus faecalis and Streptococcus faecium . The second group that did not grow 
in broth containing 6.5% NaCl was named as Streptococcus bovis and Streptococcus 
equinus. In 1970, Kalina proposed the generic name "Enterococcus", which included 
two species ( ie Efaecalis and Efaecium ). Schleifer and Kilpper-Balz gave genetic 
evidence in 1984 that Streptococcus faecal is and Streptococcus faecium were different 
from other members of the Streptococcus based on DNA-DNA and DNA-RNA 
hybridization studies and therefore they should be in a separate genus ( ie Enterococcus). 
The genus Enterococcus emphasises the intestinal origin of gram-positive diplococucus 
( Murray, 1990 ). 
1.1.2 Enterococcus species 
Since Kalina proposed in 1970 that genus "Enterococcus" be named based on 
cellular and phenotypic characteristics also confirmed by Schleifer and Kilpper-
Balz in 1984 based on DNA-DNA, DNA-RNA hybridization and 16s rRNA 
sequencing , 17 other species ofthe same genus have been included based on 
chemotaxonomic and phylogenetic studies ( Devriese et al, 1993). However, many of 
the recently included species (Table l.l ) based on 16s rRNA sequencing studies do not 
give typical reactions of the genus described by Shem1an (Sherman, 1937 ). The 
descriptions of E. seriolicicla and E.solitarius and the phylogenie studies indicate that 
they are more closely related to Lactococcus and Tetragenococcus species respectively 
(Collins et al, 1990; Kusuda, 1991). 
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Table 1.1 List of Enterococcus species described. 
Present name Description of the species 
*Enterococcus species *By 




faecalis Schleifer & Kilpper-Balz (1984) Williams et a/, 1991 
faecium Schleifer & Kilpper-Balz ( 1984) Williams eta/, 1991 
avium Collins eta!, (1984) Williams et a/, 1991 
casseliflavus Collins et a/, (1984) Williams et al, 1991 
gallinarum Collins et a!, ( 1984) Williams et a/, 1991 
durans Collins et a!, (1984) Williams et al, 1991 
malodoratus Collins eta/, ( 1984) Williams eta/, 199 1 
hi rae Farrow & CoUins (1985) Farrow & Coltins, 1985 
mundtii Collins et a/, ( 1986) Collins el al, 1986 
pseudoavium Collins et a!, ( 1989) Collins eta/, 1989 
raffinosus Collins et a/, ( 1989) Collins et a/, 1989 
solitarius Collins et a!, ( 1989) .Patel et a!. 1998 
cecorum Williams et a/, ( 1989) Devriese et a/, 1983 
co1umbae Devriese eta/, ( 1990) Devriese et a!, I 990 
saccharo1yticus Rodrigues & Collins ( 1990) Rodrigues & Collins, 1990 
suJfureus Martinez-Murcia & Collins (I 99 1) Martinez-Murcia & Collins ( 199 I) 
seriolicida Kusuda et a/, ( 1991 ) Domenech eta/, 1993 
dipar Collins et a/, ( 199 1) Collins eta!, 199 1 
tlavescens Pompei et a!. 1992 Patel et a/, 1998 
- -------------
*Adapted from Devriese et a/, 1993 
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1.1.3 Habitat of Enterococci 
The nature of these bacteria, which allows them to grow and survive in harsh 
environments, makes them persist almost everywhere. They can be found in soil , 
food, water, plants, birds, insects, humans and anjmals ( Devriese et al, 1992; Dutka 
and Kwan, 1978; Kjbbey et al, 1978 ). In humans as well as in other animals, the 
enterococci inhabit the gastrointestinal tracts and female genital tracts. Enterococcus 
faecalis is one of the most common bacteria isolated from gastrointestinal tracts of 
humans. Efaecium is commonly found in the gastrointestinal tract of humans as well 
( Endtz et at, 1997 ). 
1.1.4 Identification of the Enterococcus species 
The identification of enterococci to species level plays one of the crucial roles in 
proper patient management and for epidemiologic purposes. Although the current 
tests can identify most of the Enterococcus species related to human infections, many 
of the recently established enterococca] species cou.ld not be readily identified by 
such tests. The two species (ie Efaecalis and Efaecium) have common 
characteristics that allow them to be distinguished from other catalase-negative, 
gram-positive facultative cocci. They include ability to grow at 1 0°C and 45°C, at pH 
9.6, and 6.5%sodium chloride broth (Schleifer and Kilpper-Balz, 1984) and also the 
presence ofLancefield group D antigen. However, newly established enterococcal 
species fail to react in the presence Lancefield group D antisera and also fail to grow 
in the conditions that show characteristic of E.faecalis and Efaecium (Collins eta/, 
1989; Devriese et al, 1990; Facklam and Collins, 1989; Martinez-Murcia and 
Coll ins,1991). However, not only enterococci show positive reactions to 
4 
these tests, several streptococcal species, pediococci , lactococci, aerococci and 
leuconostoc can also react positively with the tests ( Facklam et al, 1989 ). Other 
routine tests include hydrolysis of esculin in the presence of 40% bile, 
presence of pytTolidonyl aryl amidase (PYR), tests for urase, ~-glucosidase and ~-
glucuronidase activities and an array of carbohydrate acidification tests ( Devriese et 
al, 1993 ). These tests remain valid when seeking only the classical Enterococcus 
species. 
1.1.4.1 Intragenic Regions of 16s rRNA gene sequences-useful for Identification of 
enterococcal species 
The tests for identification of enterococcal species mentioned in section 1.1.4 remain 
valid when seeking only classical Enterococcus species. The molecular technique such 
as PCR devised by Dutka-Malen et al, 1995 fails to identify some enterococcal species 
outside the reach of the primers and it is necessary, therefore, to include molecular 
technique such as 16s rRNA gene sequences for enterococcal species identification. All 
the known enterococcal species have had their small-subunit 16s rRNA gene sequenced 
(Table 1.1 ). The analysis of the regions of 16s rRNA gene sequences shows the 
phylogenie relationship among the eli fferent enterococcal species based on on homology 
detem1inations (Fig 1.1). The homology values derived from 16s rRNA sequences can 
be used to show the percentage homology among the enterococcal species (Table 1.2 ) 
as well as useful for identification of Enterococcus species ( Baele et al, 2000; Patel et al, 
1998 ). The comparative analysis of sequence ofEnterococcus species based on 16s 
rRNA analysis has grouped the species into three groups within the genus ( Williams el 
a!, 1991 ). The first group consists of E.durans, Efaecium, E.hivae and E.mundtii. The 
second group consists of E.pseudoavium, E.raffinosus, E.avium and E. malodoratus. The 
5 
third group consists of E.columbae, Efaecalis and E.saccharolyticus, which formed 
distinct lines within the genus. Patel et al, 1998, using this teclmique, confirmed the 
identity of two nonmotile E.gallinarium isolates which were misidenti.fied as E.faeciwn. 
Williams et al, 1991 showed that relatively low RNA sequence homologies between 
Efaecalis and other enterococcal species was due to phenotypic distinctiveness of type 
species. The identification of E.seriolicida as belonging to a separate genus and 
subsequently renaming it as Lactococcus garvieae ( Patel et al, 1998) indicates the 
usefulness of the teclmique. However, the precise phylogene placement of E.solitarius 
remains unclear although it appears to be related to Tetragenococcus (Collins et al, 
1991). It is acceptable generally that if the 16s rRNA gene sequence of a strain is Jess 
than 97% similar to its neighbour, it indicates that it is not the same species. However, 
97% or higher may indicate that it belonges to the same species. 
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Fig 1.1 Phylogenie Relationships of Enterococcus species derived from 16s rRNA 
sequences 
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Adapted from Patel R et a/,1998. 
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Adapted from Patel Ret al, 1998 
1.2 Enterococcal Infections 
Most of the clinical infections are due to either E.faecalis or E.faecium ( Mundy et al, 
2000 ). E.faecalis has been found to cause around 80-90% of the enterococcal 
infections and Efaecium accounts for most of the remainder (Moellering, 1992 and 
Gray et al, 1991 ). The distribution ofEJaecalis in healthy adu lt faeces and 
the presence of only 25% of E.faecium in individual faeces may account for the 
common infection by E.faecalis ( Shah et al, 1987 ). E.faecalis has also been found to 
have virulence factors; for example, haemolysin which can lyse both bacte1ial and 
eukaryotic cell membranes (Brock and David, 1963 ). These factors appear not to be 
present in E.faecium. Other enterococcal species appear to be infrequent 
causes of infections in humans ( Facklam and Collins, 1989 ). The use of antibiotics 
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such as cephalosporins, latamoxefand aztreonam which suppress much ofthe normal 
human flora and to which enterococci are resistant against them could promote 
enterococci to overgrow other intestinal bacteria thus enabling them to cause infections 
in the nosocomial settings (Morrison and Wenzel, 1986; Moellering, 1982; 
Chandraseken et al, 1984 ). Infection may also occur in indwelling devices such as intra-
vasculas carvulae; ambulatory peritioneal diaylsis catheter and biliary T-tubes in liver 
transplant. The most commonly found in enterococcal infections are endocarditis, urinary 
tract infections, bacteraemia and intra-abdominal infections. Other infections such as 
neonatal and meningitis in older adults caused by enterococci are rare ( Eigler et al, 
1961 ). 
1.2.1 Infective Endocarditis 
Enterococci are estimated to cause between 5 and 20% of infective endocarditis 
( Watanakunakom and Burket, 1993; Megran, 1992 ) . The disease is more common 
in the elderly, with an average age over 60, and in patients with degenerative valvular 
disease of genitourinary condition (Mandell et af, 1970 ). It may occur occasionally 
in children and rarely in infants (Teixeira et af, 1982 ). Enterococci can also cause 
endocarditi s in drug addicts (Reiner et al, 1976 ). Efaecafis causes 85% of the cases 
of infection while E.faecium involves only in 10% of the cases. 
1.2.2 Bacteraemia 
The role of the enterococcal bacteraemia in morbidity and mortality has been difficult 
to determine because both bacteraemia and colonization are associated with mixed 
infections except in the cases of endocarditis or meningitis ( Gullberg et al, 1989 ). 
Enterococci are the third most important cause of nosocomial bacteraemia in the USA 
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(Schaberg el a/, 1991 ). Efaecalis and Efaecium account for most infections which 
usually originate in the abdominal or the urinary tract. However, some cases of 
bacteraemia originate from the medical devices such as percutaneously-inserted 
central venous catheter or atterial catheter left in place for a prolonged period of 
hospitalization ( Maki , 1988 ). Thirty-one percent mortality rate was found to be 
directly attributed to enterococcal blood stream infections (Landry eta/, 1989 ). 
1.2.3 Urinary Tract Infections 
Enterococc i arc involved in 10% of all urinary tract infections ( Fclmingham et 
al, 1992 ). The UTI usually occurs in patients who have either gone through 
manipu lation or underlying urogenic structural abnormalities involving the bladder, 
kidney and prostate ( Moelleting, 1992 ). Among the young women who are healthy, 
enterococci cause 5% of urinary tract infections. 
1.2.4 Intra-abdomina l Wound Infections 
Intra-abdominal infections extend beyond the site of original inc luding peritonitis, 
abscess formation and perforation diverticu litis abscess ( Solomkin et aL, 1990 ). The 
infections are polymicrobial and the role of enterococci in the in fcctions remains 
controversial (Nicholas and Muzik, 1992 ). Despite the difficulty in establishing pure 
enterococcal infections, it is clear that enterococci can contribute in abdominal 
abscess and sepsis. 
1.2.5 Other Infections 
A lthough group B streptococci and £.coli are the most common cause of neonatal 
infections, an outbreak of enterococcal sepsis in neonates has been reported in USA ( 
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Luginbuhl et al, 1987 ). Also neonatal enterococcal sepsis was repOiied between 1970 
and 1976 ( Buchino et al, 1979 ). In addition to causing sepsis in neonates, enterococci 
can also cause meningitis in older children and adults due to an underlying disorder 
(Bayer et al, 1976 ). 
1.3 Enterococcal Pathogenicity 
Although enterococci cause a wide variety of diseases in humans such as urinary tract 
infections, infective endocarditis, nosocomial bacteraemia and biliary tract infections, 
the factors that determine the pathogenicity of enterococci are not well understood ( Jett 
et al, 1994 ). The role of enterococcal virulence has been documented and several 
properties of enterococci have been suggested as potential virulence factors including cell 
surface adhesion molecules as well as extracellular products ( Jett et al, 1994 ). 
1.3.1 Cell Surface Adhesins 
The first step in infection ofhuman by bacteria involves adherence through surface 
adhesins to epithelial cells, endothelial cells or extracellular matrix. Since enterococci are 
normal flora of gastrointestinal tract ofhuman, it appears as if they have adhesins that 
promote binding to htm1an receptor cells of mucosal surfaces which play a role in the 
maintenance of colonization. h1 Ejaecalis, Antigen A (EfaA) found in individuals with 
infective endocarditis plays a role as adhesions in the infection (Lowe et al, 1995 ). 
Efaecalis also has plasmid-mediated aggregation substance (pADI), which is a 
pheromone-inducible surface protein that promotes mating aggregate fom1ation during 
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conjugation (Clewell, 1993 ). But, in vitro, the substance mediates adhesin to a variety 
of eukaryotic cell sLUfaces; for example pig's renal tubular cells (Kreft eta/, 1992 ). It 
has been found that the substance also promotes direct opsonin-independent binding of 
E.faecalis to human neutrophils via complement receptor type3 and other receptors on 
the neutrophil surface (Vanek et al, 1999 ). Olmested et al in 1994, suggested that the 
aggregation substance may also enhance the ability of Efaecalis to associate with 
intestinal epithelial cells. While Huycke et al found in 1991 that aminoglycoside-
resistant lineage of Efaecalis expressing cytolysin and aggregation substance proved 
pmiicularly virulent. 
1.3.2 Enterococcal Extracellular Products 
They are substances produced or secreted by enterococci into extracellular 
environment such as gelatinase, hyaluronidase, cytolysin, superoxide and 
lipoteichoic acid. 
1.3.2.1 Gelatinase 
The metalloproteinase (gelatinase) from Ejaecalis was first described more than 30 
years ago ( Bleiweis and Zimmerman, 1964 ). In 1989, Makinen eta! published a 
description of substrate specifyi ng protease produced by E.faecalis OG 1-10 called 
Metalloendopeptidase 11 obtained :fi·om a human mouth. This enzyme was capable of 
hydrolyzing gelatine, collagen, casein, haemoglobin and other smal l biological active 
peptides. Su et al, 1991 , reported the sequence of protease gene,ge!E, which encoded 
prezymogen now called gelatinaseE. A potential contribution of enterococcal 
protease to virulence was first suggested in 1975 by Gold et al who found that a 
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gelatin-liquefying of human oral from Efaecafis induced caries formation in germ 
free rats while non proteolytic strains did not. Although epidemiologic studies only 
suggest associations between protease production and infection, the sequence analysis 
of gelE showed amino acid similarity to zinc-metal loprotease ( elastase )of P.aeru.ginosa 
(Fukushima et al, 1989; Suet al, 1991 ). This enzyme ( zinc-metalloprotease) is 
considered a virulent factor in severe pseudomonal infections, especially patients with 
cystic fibrosis (Doring et al, 1985; Vasil, 1986 ). The studies by Holder & Haidaris in 
1979, using burned mouse model, showed that extracellular protease and elastase (zinc-
metalloprotease) were the vimlence factors in P.aeruginosa infections. G elatinase-
producing strains of Efaecalis have been shown to contribute to virulence of endocarditis 
in animal model (Gutschik et al, 1979) 
1.3.2.2 Hyaluronidase 
Although the studies by Rosan and Williams in 1964, found that some enterococci 
(oral ) especially Efaecalis produced hyaluronidase, less is known about the 
contribution of the enzyme in enterococcal virulence. 
1.3.2.3 Cytolysin 
It is a haemolytic, post-translationally-modified protein toxin that occurs in up to 60% of 
E.faecalis retrieved from outbreak investigations ( Jett et al, 1992 ). Cytolysin is distantly 
related to streptolysin S and also to members of a class of bacteriocins known as 
!antibiotics displaying both haemolytic and bacteticidal activity (Hancock & Gilmore, 
2000). It is either coded within large, pheromone responsive plasmids (pADJ) (Clewell , 
1981 ) or on the chromosome (Ike and Clewell, 1992). Jett & Gi lmore, 1990 found that 
cytolysin possesses plasmid (pADI) encoded bacteriocin which is lethal to wide range of 
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gram-positive bacteria. Independent studies, using different models, have found that 
cytolysin plays a role in Efaecalis infection ( Callegan et al, 1999 ). 
1.3.2.4 Extracellular Superoxide 
It is associated with enterococcal virulence in bacteraemia ( Huycke et al, 1996 ). 
Both Efaecalis and Efaecium produce extracellular superoxide during the infection 
by the invasive strains than the commensal iso lates. 
1.3.2.5 Lipoteichoic Acids 
This substance may function in viru lence by inducing the production of tumour 
necrosis factor ( TNF ) and interferon leading to modulation of the immune response 
(Wickenetal, 1963; Tsutsui eta!, 1991 ). 
1.3.3 Enterococci Infections and Immunity 
Infection can occur if other defences of the host are neutralised, avoided or restricted 
and the pathogens breached mucosal or skin baiTiers and adhere to the host tissues or 
cells. However, the studies by Bhakdi et al in 1991, had shown that lipoteichoic acids 
produced by Efaecalis stimulate production of Il-~ , 11-6 and TN Fa from the cultured 
human monocytes. Similarly, Tsutu i eta! in 1991 found that enterococcal lipoteichoic 
acid was a potent inducer of tumour necrosis factor and interferon. The tissue damage 
sites of infection could result from activation of complement by the host cell-membrane-
associated bacteriallipoteichoic acid (Hummell and Winkelstein, 1986 ). The interaction 
between complement , human neutrophils and enterococci has been examined by Harvey 
et al, 1992 who found that it enhanced neutrophi l killing of enterococci in the presence of 
complement and specific rabbit antienterococcal immunoglobin. Arduino et af in 1994, 
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suggested that neutrophil killing depended ptimarily on complement activation and not 
specific immune- globulin. Efaecalis secrete small peptides seven to eight amino acid 
in length called pheromones that promote conj ugation transfer of plasmid DNA between 
strains. These pheromones possess additional role as chemoath·actants ofneutrophils 
which induce a respiratory burst (Ember and Hugli, 1989 ). Enterococci also possess an 
oxygen-inducible superoxide dismutase which catalyzes conversion of superoxide to 
hydrogen. 
1.4 Drug Resistance in enterococci 
Bacterial resistance to antibiotics has been recognised since the first drugs were 
introduced for clinical use. The consequences of the bacterial resistance to antibiotics 
must be considered medically and economically in tenus of the patients infected with 
antibiotic resistant pathogens. However, the increasing role of nosocomial 
infect ions and the resistance to antibiotics has been documented. The emergence 
and the spread of E.faecalis and E.faecium strains with multiple antibiotic resistance 
continues to be a medical problem ( Seetulsingh et al, 1996; Huycke et a/,1998 ). 
Enterococci are intrinsically resistant to many commonly-used antibiotics and have 
the ability to acquire resistance by mutations in the chromosome or through the genes 
coding resistance from external source via plasmid or transposon (Table 1.3 ). 
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1.4.1 In trinsic Resistance In Enterococci 
This type of resistance is also termed "umate" or·' Inherent". The resistance indicates 
the characteristics present in all or most of the strains of Enterococcus species and the 
genes for resistance appear to reside on chromosomes. The various intrinsic traits 
expressed by enterococci include resistance to cephalosporins, low- level 
aminoglycosides and clindamycin (Murray, 1990 ). Enterococci resistance to 
~- l actams is a characteristic feature due to low affi nity of penicillin-binding protein 
(Wi lliamson eta/, 1985 ). The low-level aminoglycoside resistance involves the 
reduced uptake of aminoglycos ide and enzymatic inactivation of aminoglycos ide by 
chromosome-encoded enzyme ( Simjee and Gill , 1997 ). The in vitro and in vivo 
activities of trimcthoprim-sulfamethoxazole ( TMP/SMX) are controversial. In 
vitro, the media containing thymidine allow many bacteria to escape the inhibition of 
TMP/SMX by converting thymidine to thymidylate used by the bacteria ( Amyes 
and Sm ith, 1974; Tofte eta/, 1984 ). 
1.4.2 Genetically acquired Resistance In Enterococci 
The three c lements involved in acqu ired resistance in enterococci are : broad-
host range plasmids, narrow-host range plasmids and conjugate transposons. 
1.4.2.1 Broad-host Range Conjugate Plasmids 
The plasmids which can mediate their own transfer are termed conjugate plasmids. 
Both gram-positive and gram-negative bacteria have the abi lity to conjugate. In 
enterococci, the broad-host range conjugate plasmid was o ri g inall y identified in 
16 
E.faecalis ( pAM131 ) and now occurs across the genus Enterococcus. They can also 
be h·ansfen·ed to other gram-positive bacteria including streptococci, S.aureus and 
B.subtilis (Clewell, 1981 ). However, such plasmids transfer poorly (usually less 
than 10"6 per donor) in broth and require filter mating for efficient transfer. It has 
been suggested that broad-host range plasmids may be the reason that staphylococci 
and enterococci share so many resistance genes to gentamicin, erythromycin and 
penillinase ( Murray,1990; Schaberg and Zervos, 1986 ). The conjugation of broad 
host-range plasmids is less well understood. 
1.4.2.2 Narrow-Host Range or Pheromone Plasmids 
The p]asmids pAD1 and pAMY1, carry genes for UV light resistance, haemolysin 
and bacteriocin. In E.faecalis, four plasmids ( pADI, pCFlO, pPDI and pAM373) 
encoding aggregation substances (AS) have been described (Clewell and Dunny, 2002). 
However, plasmids pAD I and pAMYl transfer with high frequencies ( 10·3 - 1 o·1 per 
donor) in broth, higher than the broad-host range conjugate plasmids (Clewell, 1981). 
Such high transfer is due to chromosomally-encoded oligopeptides called sex 
pheromones. Thus, the recipient cells secrete the pheromones into the surrounding 
media, which attracts the donors. Donors then respond by producing aggregation 
substance ( AS ) which allows both the donors and the recipients to be in contact and 
allows the transfer of genetic materials. The recipient then shuts off the system to 
prevent self-clumping (Dunny et al, 1995 ). Sex pheromone plasmids have also been 
described in E.faecium in which they have been found to be associated with vancomycin 
resistance ( Handwerger et al, 1990; Heaton and Handwerger, 1995; Magi et al, 2003). 
However, the role of pheromone plasmids in the spread of resistance genes beyond this 
species is not clear. 
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1.4.2.3 The Con,jugative Transposons 
They are gene sequences or DNA elements that move from the genome of a donor 
bacterium to the genome of a recipient bacterium by the process of intercellular 
transposition based on excision, conjugation and re-integration (Clewell and Gawron-
Burke, 1986; Clewell et a1, 1995; Salyers et ai, 1995; Scott and Churchward, 1995; 
Mun·ay, 1998 ). For example, the most studied conjugative transposon, Tn916 carrying 
the tetracycline resistance determinant tetM (Franke and Clewell, 1981), moves via a 
circular intermediate produced by excision of the integration element from the donor 
chromosome (Scott et al, 1988) which is then transferred from donor to recipient 
initiating at or iT ( Scott et al, 1994 ). Once in the recipient, the circular intermediate 
reforms and integrates into recipient's genome. This process does not generate 
duplication at the target site into which it inserts. The conjugative transposons have a 
broad-host range and are found in gram-positive ( ie particularly common in enterococi 
and streptococci) and gram-negative. They play an important role in dissemination of 
antibiotic resistance in these organisms. Many other conjugative transposons related to 
Tn916 have since been described ( Salyers et al, 1995). On the other hand, transfer of 
DNA elements in pheromone-inductive plasmids differ from the conjugative transposons 
in that they are pheromone-responsive conjugation (see section 1.4.2.2) and are 
restricted to Ejaecalis (Clewell, 1981; Dunny et al, 1995 ). While conjugation in the 
broad host-range plasmids is less well understood (Clewell, 1981; Murray, 1998 ). 
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Fl uoroq uinolones 
Chloramphenicol 
Trimethoprim 
Mechanisms of Resistanmce 
Production of aminoglycoside-modifying enzymes. 
Ferretti et al, 1986; Horodniceanu eta!, 1979; Shaw 
et a/,1993 
Alteration of the target (leading to impermeability) 
Moellering and Weinberg,l971 
Alteration of target site ( leading to cell wall 
Modification). 
Woodford (1998). 
Alteration of target site (ie penicillin-binding 
proteins) 
Fontana et af, 1996. 
Production of P-lactamase 
Murray & Mederski-Samoraj,l983; Murray(l992) 
Alteration of target sites ofGyrA & ParC 
Kanematsu et af, 1998; El-Amin et a/, 1999. 
Production of acetyl transferase. 
Triuecuot et al, 1993. 
The use of exogenous fo lates in vivo 
Grayson et al, 1990. 
Acquisition of dihydrofolate reductase genes 
Coque et a!, 1999. 
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Tetracyclines Ribosomal protection by Tet determinants. 






Production of methylating enzymes (ermB) 
Portillo eta/, 2000; Schmitz et al, 2000. 
Efflux ofMacrolides (msrC) 
Portillo eta/, 2000. 
Inactivation of lincosamides (linB). 
Bozdogan et al, 1999. 
Inactivation ofstreptogramin A (vatD & valE) 
Rende-Fournier et al, 1993; Werner and 
Witte, 1999 
1.5 The Aminoglycoside Antibiotics 
Several am inoglycoside antibiotics have been introduced into use since the discovery 
of streptomycin in 1943 from Streptomyces griseus. Kanamycin was introduced in 
1957 and became the aminoglycoside drug of the choice until 1963 when the 
gentamicin was discovered and used for the treatment of gram-negative bacillary 
infections. Subsequently, amikacin ( 1976 ), tobramycin and neti lmicin ( 1983) 
were developed for cl inical use (Zembower et a/,1998 ). Aminoglycosides have the 
potential of nephro-toxicity and their use has been enhanced by dose 
management by monitoring both serum levels and renal function. Aminoglycosides 
have less allergic reactions and other adverse effects. However, despite the advent of 
new P-lactams and fluoroquinolones, the aminoglycosides remain useful agents 
against serious infections such as infective endocarditis and bacteraemia caused by 
the same strains of Enterococcus species. Structurally, am inoglycosides consist of a 
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six-membered amino group which contain an aminocylitol ring that is linked to two 
sugars (Fig 1.2 ). The aminocylitol ring of streptomycin is a streptidine and other 
aminoglycosides consist of2-deoxystreptamine (Fig 1.2 ). The 2-deoxystreptamine is 
further subdivided on the bases of their 4,5 and 4,6 oftheir substitutuents on 2-
deoxystreptamine ring ( Courvalin and Carlier, 1981 ). The aminoglycosides are 
highly polar, water soluble polycation and are generally stable to heat and pH change 
ranging from 5 to 8. 
1.5.1 Mechanism of Action in Aminoglycosides 
Aminoglycosides inhibit protein synthesis by binding in-eversibly to the bacterial30s 
1ibosome and thereby interrupting the flow of genetic information. Streptomycin's 
sensitivity to 30s ribosome subunit has been shown to be determined by binding to a 
single proteinS 12. The uptake of aminoglycosides for various organisms especially 
gram-positive cocci is facilitated by the presence of inhibitor of synthesis of the 
bacterial cell wall such as P-lactam antibiotics and glycopeptides (Moellering et al, 
1971 ). The active uptake of aminoglycoside across the plasma membrane takes place 
in tlu·ee stages. The first phase uptake is the rapid energy-independent binding to cell 
surface( EIP) ( Nakae and Nakae, 1982 ). The second phase involves electrical 
potential across the plasma membrane generated by aerobic metabolism ( EDPl) 
( Byran and Kwan, 1983 ). The third phase is triggered by interaction of aminoglycoside 
with ribosome ( EDPll ) (Busse et al, 1992 ). However, under anaerobic conditions, the 
rate of uptake of aminoglycoside into the cell is diminished and therefore bacteria 
become relatively resistant to aminoglycoside. 
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1.5.2 Spectrum of Antimicrobial Activity In Aminoglycosides 
Antibacterial activity of aminoglycosides is directed against a broad spectrum of 
aerobic and facultative anaerobic gram-negative bacilli and many staphylococci and 
certain mycobacteria. However, gentamicin is the choice for the treatment of serious 
hospital-acquired infections caused by enterobacteriaceae and P.aeruginosa. In 
addition, gentamicin can be combined with ~-lactams or glycopeptides to provide 
synergy in the treatment of serious infections such as infective endocarditis and 
bacteraemia caused by enterococci, staphylococci and viridans streptococci. 
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1.6 Resistance of Enterococci to Aminoglycosides 
The aminoglycosides act by interfering with protein synthesis by binding to l6S rRNA of 
the 30s ribosomal subunit (Kotra et al, 2000; Mingeot-Leclercq et al, 1999). Enterococci 
possess intrinsic low-level of resistance to aminoglycoside which limit transport ofthe 
drug across the cell membrane or due to mutation in clu·omosome reducing the uptake of 
aminoglycoside (Lef01t et al, 2000). The low-level resistance of enterococci against 
gentamicin, usually, has MIC range of 8-64mg/l (Murray, 1990; Bantar et al, 1993). 
Aminoglycosides are not so effective against enterococci when used alone. However, the 
addition of an agent that interferes with cell-wall synthesis such as amoxicil lin or 
vancomycin increases the uptake of aminoglycoside and enhances the killing of the 
Enterococcus (Moellering and Weinberg, 1971). Enterococci have acquired 
aminoglycoside resistance genes that encode various aminoglycoside-modifying enzyn1es 
resulting in a very high resistance to aminoglycoside, with MICs usually >2000mg/l 
(Mmny, 1990), thereby eliminating the synergistic killing effect of the combined 
aminoglycoside with/3-lactam or glycopeptide. The most clinically important of AME is 
the bifunctional gene aac(6 ')-le-aph(2 ") -la (Ferretti eta!, 1986) that possesses both 
acetylating and phoshorylating activity (Azucena et af, 1997; Ferretti et al, 1986). The 
gene appears to have occurred from a fusion of two ancestral genes which mediates 
resistance to a broad range of aminoglycosides including gentamicin, tobramycin, 
kanamycin and dibekacin. This gene has also been detected in S.aureus and several 
Streptococcus species (Galimand eta/, 1999). It has been reported recently of the nevv 
aminoglycoside resistance genes such as aph(2 ')-lc (Chow et al, 1997), aph(2 ")- ld (Tsai 
eta!, 1998) and aph(2 ")-lb (Kao et al, 2000) which can confer the resistance to 
gentamicin by enterococci just like aac(6 ')-Le-aph(2 ')-La gene. The aph(2 ')-lc gene 
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encodes an aminoglycoside phosphotransferase that mediates clinical resistance to 
gentamycin, tobramycin, kanamycin and dibekacin but not amikacin or netilmacin 
(Chow et a/,1997). Although the gene was first detected in a conjugative plasmid from 
E.gallinarum, it has now been detected in both E.faecalis and Efaecium with MIC range 
of 256-384mg/1. The aph(2 ")-ld gene encodes an aminoglycoside phospho transferase 
that mediates high-level resistance to gentamicin, tobramycin, kanamycin, netilmicin and 
dibekacin ( Tsai eta!, 1998). The gene initially cloned from E.casseliflavous and now 
detected in E.faecium clinical isolate with MIC >2000mg/1. The aph(2 ")-lb gene 
mediates high-level resistance to gentamicin, tobramycin, kaamycin, netilmicin and 
dibekacin. It has been detected in VRE Efaecium clinical isolate (Kao eta/, 2000). 
Resistance of enterococci to streptomycin is based on change(s) in the target site of 
proteinS 12 of the 30s ribosomal subtmit that results in decreases binding of streptomycin 
(Eliopoulous et al, 1984). The resistance to aminoglycoside by enterococci associated 
with a change in the 1ibosome has not been reported other than in streptomycin. The 
ant(6 ')-Ia and ant(3 ") -fa genes which encode streptomycin nucleotidyltransferase 
[A NT(6')-la and ANT(3 ")-La respectively] can confer hgh-level streptomycin resistance 
in enterococci with MICs range of 4000-16000mg/1 (Clark et al, 1999; Eliopoulos eta!, 
1984) 
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Fig 1.3 The Chemical Structures Of Gentamicin 
CHJ ~ .. 111 2" 








AAD=Aminoglycoside adenyltransferase same as ANT=Adenyltransferase 
1.6.1 Molecular Basis of Aminoglycoside AAC(6 :>-APH(2':> (AMEs) 
The molecular basis of resistance is the covalent modification of the drugs. 
Specifically, AAC(6')-APH(2 ") which harbours both acetyl COA-dependent N-
acetyl transferase and ATP-dependent 0-phosphotransferase activities (Ferretti et al, 
1986) ( Fig 1.3 ). This indicates that the gene has arisen by fusion of aac and aph 
genes. The amino-acid sequence alignment-analysis has revealed homology to other 
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aminoglycoside N-acetyltransferases in the amino-terminal region and 
aminoglycoside kinases in the carboxy-terminal truncated enzymes (Ferretti et 
al, 1986 ). This bifunctional enzyme is very effective at conferring resistance 
to virtually all aminoglycosides that incorporate a 2-deoxystreptamine ring including 
the clinically important antibiotics such as gentamicin C, tobramycin and amikacin. 
Fig 1.4 Biochemical Mechanisms of Aminoglycoside Modification 
* 0 
AMINOGLYCOSIDE + ATP--APH-->AMINOGLYCOSIDE-0-P-OH + ADP 
OH 
* 
AMINOGL YCOSIDE + ATP-AAD-7 AMINOGLYCOSIDE-0 -ADENOSINE +PPi 
* 
AMINOGLYCOSIDE + ATP-AA C->AMINOGL YCOSIDE-NH-CO-CH3+COA-SH 
*Modification of aminoglycosides by AP H, AAD & AA C. A PH=Phosphotransferases, 
AAD or ANT = Adenyltransferases & AAC= Acetyltransferases. 
1.7 Quinopristin (Sn)-Dalfopristin (SA) Resistance in Enterococci 
The combination of quinup1istin and dalfopristin called "Synercid" is used in the 
treatment of multidmg-resistance Efaecium infections. Dalfopristin is a streptogramin A 
while quinupristin is a streptogramin B. The two compounds act synergistically by 
streptogramin A binding to 50s ribosomal subunit causing a confonnational change in 
the peptidyltransferase domain of the ribosome which increases affinity of streptogramin 
B to its target site resulting in the inhibition ofprotein synthesis ( Vannuffel et al, 1994). 
Al l Efaecahs iso lates are intrinsically resistance to streptomycin A compounds which 
make them resistance to synercid. However, resistance to synercid by E.faedurn can be 
due to a single gene (vatD) that mediates resistance to streptogramin A or to synercid 
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(Q/D) resistance. The vatD gene, formerly sat A, cloned from Efaecium encodes an 
amino acid sequence that is closely related to acetyltransferase which mediates resistance 
to streptogramin A compounds (Rende-Fournier el al, 1993). VatE (formerly satG) gene 
encodes a putative acetyltransferase and appears to be prevalent in Efaecium (Werner 
and Witte, 1999). Plasmid mediated genes (vatD & vatE) are related to acetyltransferase 
genes vat (7), vat (2) and vat (C) reported in staphylococcal resistant to quinupristin B 
(Cocito et al, 1997). Thai and Zervos, 1999 reported Efaecium resistance to synercid 
with MIC of32mg/1. The same year, Arum, this thesis, (unreported)-found Efaecium 
clinical isolates resistant to synercid with MIC of 64mg/1. Although, it has not been 
studied much in Efaecium, the active efflux associated with ATP-binding cassette 
transporters were reported to confer resistance to streptogramin A (Ailignet and Solh, 
1997). 
1.8 Quinolones Resistance In Enterococci 
The first fluoroquinolone widely used in the clinical treatment was ciprofloxacin and 
developed for use against gram-negative bacte1ial infections. However, the activity of 
ciprofloxacin against the enterococci is moderate. Quinolone resistance is common in the 
clinical enterococcal isolates. The newer fluoroquinolones such as moxifloxacin has 
slightly enJ1anced in vitro activity against enterococci although isolates resistant to 
ciprofloxacin are also resistant to moxifloxacin. Quinolones inhibit bacteria by 
interacting with type 11 topoisomerase (gyrA) subunit and topoisomerase 1 V (parC) 
subunit which are responsible for bacterial DNA replication. In E. coli, quinolones bind 
to a complex ofDNA and DNA gyrase and not DNA alone (Shen et al, 1989). The 
primary target for quinolones against gram-negative bacteria such as E. coli is gyrA 
subunit of DNA gyrase while parC subunit of topoisomerase IV is the primary target for 
quinolones against gram-positive bacteria such as S.aureus and E.faecalis ( get al, 
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1996). DNA gyrase is composed of two A and two B subunits ( gyrA and gyrB) (Wang, 
1996). Topoisomerase 1 V is composed of two subunits (pare and parE) which are 
homologous to gyr A and gyrB (Kato et al, 1990).The studies by Kanamatu et al, 1998 
found an isolate with an alteration only in topoisomerase l V and none in gyrA. Brisse et 
al, 1999 found some isolates of E.faecium with alterations only in pare and not in gyrA 
suggesting that pare is the primary target of ciprofloxacin in E.faecium. However, other 
studies have shown that either gyrA or pare can be the primary target depending on the 
structure offluoroquinolones (Pan and Fisher, 1997 ). Quinolone resistance has not been 
well studied .in enterococci in comparison to that in staphylococci and pneumococci. 
However, mutations in the pare gene resulting in substitution of one or two amino acids 
corresponding to E. coli gyrA quinolone resistance determining region( QRDR) could be 
the first step in quinolone resistance. An additional mutation in QRDR in enterococcal 
gyrA may then follow resulting in a high-level resistance to quinolone. No gyrB or parE 
resistance due to mutations have been reported in enterococci (Hooper, 2000). The 
demonstTation of the importance of gyrA mutation contributing to quinolone resistance 
was done by showing that gyrA subunit purified from a quinolone resistant E.faecalis 
combined with wild type gyrB subunit confened quinolone resistance (Nakansishi et al, 
1991). 
1.9 Penicillin Resistance in Enterococci 
The target sites for penicillin and other 13-lactam antibiotics are the final cross-linking 
reaction that gives the bactetial cell-wall rigidity and penicillin-binding proteins (PBPs). 
Penicillin can also facilitate the access of compounds acting on intemal targets, 
potentiating inhibition or killing, as in classical synergy with aminoglycosides. 
Enterococci are relatively resistant to ~-lactams. E.faecium being inherently more 
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resistant to penicillin ( MIC 16-32mg/l ) than Efaecalis ( MICs 2-4mg/l )( Gordon et 
al, 1992; Moellering et al, 1979 ). The intrinsic resistance as well as high levels of 
resistance to penicillin has been associated with overproduction oflow-affinity to 
penicillin-binding protein 5 ( PBP5) and the production of /3-Iactamase (Murray, 
1992 ). Also amino acid substituted within the PBP causes further decrease in affinity 
in penicillin associated with a deletion upstream of the P BP 5 gene ( Fontana et al, 
1996 ), /3-lactamase production in Efaecalis was first reported in 1983 (Murray & 
Mederki, 1983 ). This enzyme is produced by enterococci constitutively instead of 
inducible fOt:md in staphalococci. However, it has been repo1ied that non 13-lactamase 
producing Efaecium also confer high-level penicillin resistance associated with the 
overproduction of low-affinity PBP5 ( Bush et al, 1989; Sapico et al, 1989). In vitro, 
enterococcal /3-lactamase bas greater activity against penicillin and ampicillin but little 
or no activity against most cephalospotins and imipenem. /3-lactamase is encoded on 
transferable plasmids in a number of E.faecalis (Markowitz et al, 1991 ). /3-lactamase 
production in enterococci has not been isolated in Europe but only in USA. 
1.10 Glycopeptide Resistance in enterococci 
The activity of glycopeptide antibiotics is restricted to gram-positive organisms whether 
anaerobes or aerobes because antibiotics cannot penetrate the outer membrane of gram-
negative organisms due to being large polar molecules. Although, both vancomycin and 
teicoplanin are glycopeptide antibiotics, their spectrum activity is not identical 
(Greenwood, 1988). Teicoplanin is more active against gram-positve anaerobes and 
streptococci than vancomycin; but vancomycin is more active against coagulase-negative 
staphylococci. All glycopeptide antibiotics inhibit the latter stages of cell wall synthesis 
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by fonning complexes with peptidoglycan precursors (Arthur eta!, 1996b). It occurs by 
binding the antibiotics to D-Ala-D-Ala-terminating peptide stems within nascent 
peptidoglycan which is believed to inhibit cell wall synthesis tlu·ough inhibition of the 
transpeptidase and carboxypeptidase steps of cell wall synthesis. Glycopeptide-resistant 
enterococci was first detected in UK and in France in 1 986 ( Leclercq eta!, 1 988; Uttley 
et al, 1988 ). In the same year ( 1986 ), vancomycin resistance in enterococci was 
described in USA in broiler chickens and pigs in the reports on tetracycline feeding trials 
( Molitoris eta!, 1986 ). Various types of vancomycin-resistant enterococci ( VRE) 
have been characterised on phenotypic and genotypic bases ( Perichon eta!, 1997; Fines 
et al, 1999; Arthur and eourvalin, 1993 Mckessar et al, 2000 ). There are five recognized 
phenotypes ofvancomycin resistance: vanA, vanB, vane, vanD, and vanE. However, 
Mckessar et al, in 2000 isolated and sequenced putative vancomycin resistance that they 
designated as vanG. Four of these ( ie vanA, vanB, vanD and vanE) have the acquired 
resistance mechanisms and vane is an intrinsic resistance mechanism. The vanA and 
vanB types were described mainly in Efaecalis and Efaecium. VanA resistant strains 
possess inducible, high-level-resistance to vancomycin ( Mie >64mg/l ) and teicoplanin 
( Mies > 16mg/l ) (Arthur and eourvalin, 1993 ). The genes for vanA resistance 
phenotyope are located on transposable element Tn 1546. They encode 7 polypeptides 
which involve in res istance to both vancomycin and teicop lanin (Evers and Courvalin, 
1996). However, mutants derived from vanB strains may exhibit resistance to 
teicoplanin and are thus phenotypically indistinguishable from vanA (Hayden et al, 
1993). Vane resistance phenotypes are characterized by low-level resistance to 
vancomycin but are susceptible to teicoplanin (Arthur et al, 1996 ). The van A gene and 
other genes are involved in regulation and expression of vancomycin resistance ( vanR, 
vanS, vanH, vanX, vanY and vanZ ). They are all located on Tnl 546 of Ejaecium ( 
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Arthur et al, 1993 ). The presence of variable amount ofD-Ala-D-Ala relative to D-Aia-
D-Ser could account for variab le levels of vancomycin resistance observed among the 
isolates ofVRE carrying the vane phenotype (Murray, 1997 ). VemA, vanB & vanD 
have altered substrate specificity preferentially producing D-Ala-D-Lac precursors whi le 
vane ligase produces D-Ala-D-Ser depeptide. The vanD phenotype resistance shows 
67% identity with vanA and vanB (Ostrowsky et al, 1999). The vanE phenotype 
resistance has been described in Efaecalis recently. It is resistant to low-levels of 
vancomycin (Mie 16mg/l) and teicoplanin ( MIC O.Smg/1) (Fines et al, 1999 ). 
1.11 Oxazolidinone resistance in Enterococci 
The oxazolidinones are a new class of antimicrobial agents developed for use 
against multidmg-resistant gram-positive bacteria. Linezolid was the first compound 
to be approved for clinical use in USA. Oxazolidinone acts by inhibiting bacterial 
translation in the initiation phase of protein synthesis thus preventing formation ofN-
formyl-metionyl-tRNA-ribosome-temary complex ( Swaney et aL, 1998 ). Resistance 
to linezolid by E.faecium has been reported by Gonzales et al, 2001. 
1.12 The AAC(6')-APH(2'') Transposon Tn5281 
In 1990, Holdel-elu·istian and Murray identified a composite transposon designated 
Tn5281 responsible for conferring high-level gentamicin resistance in Efaecalis by 
the virtue of the 2kb bifunctional gene ( aac6 '-aph2") flanked by 1.35kb IS element 
designated IS256 ( Hodel-eiu·istian and Murray, 1990 ). Rice eta! in 1995, reported a 
26kb composite transposon in E.faecalis designated Tn5384 conferring high-level 
gentamicin and erythromycin resistance. Two ofiS256 which flank the aac6 '-aph2" 
gene conferring the HLGR phenotype appear to be conserved in all enterococcal species 
but differ in the flanking regions immediately adjacent to the fused gene. 
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1.12.1 The Origin of AME Resistance Genes 
Aminoglycoside-modifying enzyme genes in enterococci appear to have originated 
from staphylococci because hybridization studies, using Enterococcus-derived probes 
for AMEs ( ant6', aph3', aac6 '-aph2" and an/4' ), demonstrated an extremely high 
degree of homology between those of staphylococci and enterococci AME genes 
(Ounissi et at, 1990 ). Similarities were also observed between staphylococcal HLGR 
transposon for Tn4001 and Tn4031 and the enterococcal HLGR transposon Tn 5281 
( Hodei-Christian and Murray, 1991 ). However, how the AME genes found their 
way into enterococci remains unclear but is likely due to inter-genus transfer. 
1.1 2.2 Regulation of Aminoglycoside Resistance Genes 
The aminoglycoside resistance genes in general, do not appear to be regulated. The 
transcription of these genes is apparently constitutive and provides constan t protection 
against the presence of aminoglycosides. However, the exception to this 
generalization is that, the expression of the chromosomal aac(6 ')- fc genes of 
S.marcescens and the gene of Providencia stuartii appear to be tightly regulated 
(Rather et a l, 1992 ). 
1.13 The impact of Aminoglycoside Resistance in Enterococci 
The high- level aminoglycoside resistance among enterococci is increasingly being 
reported world-wide ( Huycke et al, 1998 ). Nicole van den Braak et a/ in 1999, 
reported the prevalence of HLGR enterococci in the patients with blood infections 
with significant increase from 14% in 1991 to 3 1% in 1997 at the Dutch University 
Hospital. An increase in HLGRE isolates fTom 17% to 60% in two Dublin 
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Hospi tals from 1991 to 1994 (Lavery et al, 1997) has been reported. 
1.13.1 Aminoglycoside-Resistant Enterococci Mortality Rates 
The mottality among patients whose bacteraemia was due to HLGRE infections in 
Chicago Memorial Hospital was found to be higher than those caused by susceptible 
enterococci (Noskin et al, 1995 ). All four bacteraemia patients who had E.faecium 
infections with high levels of both vancomycin and gentamicin resistance died ( Noskin 
et al, 1995 ). 
1.14 The Impact of Glycopeptide Resistance in Enterococci 
The percentage of vancomycin-resistant enterococci increased from 0.3% to 7.9% in 
USA between 1989 to 1993 ( MMWR, 1993 ). The increase has been most profound 
in Intensive Care Units where a 34-fold increase in the incidence has been noted 
( MMWR, 1993) 
1.14.1 Glycopeptide-Resistant Enterococci Mortality Rates 
The mottality associated with bacteraemia caused by VRE has been rep01ted in USA 
to be 37% as compared with 16% for susceptible ones ( MMWR,1993 ). Similar 
trends could be expected to occur in UK although I could not obtain any data to 
support this view. 
1.15 
1.15.1 
Treatment of Infections caused by HLGRE and GRE 
Treatment of Infections caused by HLGRE 
Enterococci with high-level resistance to gentamicin are usually resistant to all other 
aminoglycosides but occasionally are susceptible to streptomycin ( Spiegel and 
Huycke, 1989 ). However, cell-wall active agents such as ampicillin, penici llin or 
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vancomyc in may be used a lone in an attempt to cure certain cn terococcal infections such 
as urinary tract infections. But the cell-wall antibiotics must be combined w ith 
anaminoglycoside in the treatment ofbacteraemia and infective endocard itis ( Shlaes et 
al, 1981; Nackamkin et a/, 1988; Mal<i and Agger, 1988 ). 
1.15.2 Treatment of Infections caused by GRE 
The treatment of the infections caused by VRE especially Efaecium is ex tremely 
difficult because the organisms are resistant to mu ltiple antibio ti cs ( Cctinkaya et al, 
2000 ). However, successful treatment depends on laborato ry antibiotic test 
against VRE. 
1.16 Antimicrobial Synergism 
The increased inc idence of resistant strains of microorgan isms, fo llowing the use and 
misuse of an timicrobial drugs on a large scale, had led to the administration of 
combinations of drugs ( Jawetz et al. 1955; Moellering eta!, 197 1; Simmons, 1975; 
Berenbaum, 1978; Rahal, 1978 ; Lambert eta!, 2003 ). The most appealing 
reason to utilize antimicrobial combinations is to produce enhanced (synerg istic) 
antimicrobial acti vity. rn many instances, this has been demonstrated by in vitro tests. 
The term synergy has been defined as the effect obtained from the use of 
A combination of antib iotics having greater than the sum of the effects of each of the 
component agents acting alone (Dowling, 1957; Moun ton, 1975; Berenbaum, 1978; 
Lambert et a/2003). On the other hand, ifthe effects of each of the component 
agents is greater than the effect of the combined agents, then it would indicate 
antago nism. Usuall y antagonism occurs between predominantly bacteri ostati c agents 
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and bactericidal agents ( Fig 1.5 ). Antibiotic combinations are widely prescribed 
for the following reasons: to treat mixed infections, to prevent or delay the 
appearance of resistant strains, to treat serious infection such as meningitis before the 
results of laboratory tests are known and in the use of non-toxic combined drugs instead 
of a single toxic drug (Rahal, 1978 ) and to produce synergistic activity. The combination 
of a cell-wall agent such as penicillin or vancomycin with an amino glycoside is widely 
accepted in the treatment of enterococcal endocarditis (Rahal, 1978). Antagonism has 
been observed between penicillin and tetracycline in pneumococcal meningitis ( Lepper 
and Dowling, 1951; Mounton, 1975 ). Shlaes et al, ( 1991 ) demonstrated synergy 
between penicillin plus vancomycin plus gentamicin against enterococcal clinical 
isolates. Vancomycin combined with aminoglycoside has shown synergistic activity 
against enterococci both in vivo and in vitro (Westenfelder eta!, 1973 ). However, the 
presence ofhigh-level gentamicin- resistant enterococci renders all the aminoglycoside 
antibiotics inactive and also the presence of VRE with multiple antibiotic resistance 
renders most of the antibiotics, currently used at present inactive. Therefore, new drug(s) 
or combinations must be found to cure the serious infections caused by the highly drug-
resistant enterococci. 
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1.17 Epidemiology of HLGRE and GRE 
1.17.1 Tbe Epidemiology of GRE 
Nosocomia l outbreaks of vancomycin- resistant strains of enterococci have been 
reported througho ut the USA and other parts of the world ( Swartz, 1994 ). l he 
o utbreaks of GRE infec tion mainly occur in renal, haemato logica l and intensive care 
units ( Wood[ord, l998) ofthe hospi tal. A predominant strain ofGRE may be 
responsible for such outbreaks. However, strains from different hospitals may not be 
the same and the sporad ic strains tend to be unique when observed by PFGE 
technique (Woodford, 1998 ). In USA, most hospitals usually report a predominant 
single strain (Murray, 1997 ). In UK, the GRE isolated in hospitals across the 
country appears to suggest that they emerged independently at di ffercnt centres based 
on thei r endemicity in the community and subsequent selection due to antibiotic 
therapy in the hospital settings (Woodford, 1998 ) . Enterococc i appear to have 
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evolved perfectly to spread and transmit vancomycin-resistance genes and other 
resistance genes within both hospital and community settings ( French, 1998 ). There 
is a real danger that vanA resistance will spread from enterococci to staphylococci 
and pneumococci in future ( French, 1998 ). 
1.17.2 The Epidemiology ofHLGRE 
The high-level gentamicin-resistant ( HLGR; MIC >lOOOmg/1) strains of 
Enterococcus faecalis were first reported in France in 1979 ( Horodniceanu et al, 
1979) and have subsequently become disseminated worldwide (Murray, 1990 ). In 
Efaecium, HLGR appeared in USA in 1986 (Eliopoulos et al. 1988 ). The emergence 
of such strains (ie Efaecium ) had been predicted previously from in vitro transfers of 
gentamicin resistance ( Gmr) plasmids from Efaecalis to Efaecium (Chen and 
Williams, 1985 ). Casetta et al in 1998 detected 20 strains of Efaecalis carrying Gmr 
plasmids (piP655) with Tn4001-truncated elements. However, there are now a number 
of reports of the isolation ofHLGR Efaecium in several countries including UK, Ireland, 
Singapore and Australia (Bendall et al, 1991; Lin and Tan, 1991; Wade et al, 1991, 
Woodford et al, 1991; Woodford et al, 1993). In Greece, high-level gentamicin 
resistance is encountered in 15.4% ofnosocomja] Efaecalis and 11% ofEjaecium 
( Paparaskevas et al , 2000 ). In both Efaecalis and Efaecium, HLGR is often 
disseminated by plasmid or transposon. In five Nordic hospitals Simonsen et al, 2003, 
found the prevalence of HLGR to be low at Reykjavik ( 1.1% ), Troms0 ( 3.6% ) and 
Aarhus ( 1.2% ). However, the prevalence ofHLGR of Efaecalis in Uppsala was found 
to be 27.6%; while in Bergen it was 15.7%. In E.faecium in Aarthus, HLGR was found 
to be 58.8% in comparison to the situation reported in other countries. 
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Aims of This Thesis 
1. To establish whether the clinical isolates are P-lactamase producers or not. 
2. To characterise the differences in antimicrobial susceptibility among the 
isolates. 
3. To characterise the pattern of synergy of the combination of antibiotics 
against Efaecalis and Efaecium. 
4. To establish the patterns of resistance among the clinical isolates of 
Efaecalis and Efaecium. 
5. To characterise the haemolytic patterns of Efaecalis and Efaecium on 
Horse- blood media. 




MATERIALS AND METHODS 
2.1 MATERIALS 
2.1.1 Bacterial isolates 
Clinical isolates of gentamicin-resistant and vancomycin-resistant enterococci were 
obtained from the collection ofDr. Ngozi Elumogo,Clinical Bacteriology, Edinburgh 
University Medical School. Tlu·ee enterococcal isolates of vanB were kindly donated by 
Dr. Karen McGregor of the Department of Biological Sciences, University of Dundee. 
The strains used as reference or control organisms indicated in Table 2.1 were kindly 
donated by Dr. Alan Brown ofthe Dept of Medical Microbiology, Edinburgh University 
Medical School. Strains NCTC 50192 (39R861), NCTC 50193 ( V517) and NCTC 
50265 were obtained from the Central Public Health Laboratory, Colindale. 
Table 2.1 : Reference Bacterial Strains 
Bacterial Strains 
Ejaecium NCTC12202 
Efaecafis ATCC 51299 
Efaecalis CTC 12697 







Efaecium NCTC 7171 Sensitive 
Efaecium 788/5/95 (Clinical ) VanA Phenotype 
2.1.2 Chemical Reagents 
Unless otherwise stated, all chemicals used were provided by Sigma-Aldrich Coy Ltd, 
Poole, Dorset, UK 
2.1.3 Media 
Unless otherwise stated, all media were obtained from Oxoid, Basingstoke, UK. 
Media used were Brain Hea11 Infusion ( BHI ) Agar/Broth, lsosensitest Agar ( ISTA ), 
and Mueller-Hinton Agar ( MHA) and prepared according to the manufacturer's 
instructions. In most cases, all cultures were prepared in BHl media unless otherwise 
stated and sterili zed by autoclaving at 121 °C at 15 psi for 15 minutes. Beads media 
were obtained from Microbank, PROLAB Diagnostics, UK. 
2.1 .4 Antimicrobial Agents 
Antimicrobial agents listed in Table 2.2 were used in this study. All were stored at 
4°C and fresh stock solution prepared as required in sterile deionized water. 
40 
Table 2.2 Antimicrobial agents 
Antibiotic Supplier 
Amoxicillin CP Pharmaceuticals Ltd, Wrexham, UK 
Augmentin Beecham Research, Hertfordshire, UK 
Vancomycin Eli Lilly and Co Ltd, Basingstoke, UK 
Teicoplanin Marion Merrel, Uxbridge, UK 
Piperaci !lin Generic (UK) Ltd, Hertfordshire, UK 
Piperacillin/Tazobactam ( Tazocin ) Cyanamid of Great Britain Ltd, Rants, UK 
Gentamicin David Bull Labs, Warwick, UK 
Ciprofloxacin Bayer AG, Germany 
Moxifloxacin Bayer AG, Getmany 
Synercid Rh6ne-Poulene Rover, France 
Linezolid Pharmacia and Upjohn Ltd (UK) 
2.1.5 Oligonucleotide primers 
All the primers used were synthesized by Oswel DNA Service Ltd, Southampton and 
MWG-Biotech AG, UK. Primers for sequencing were HPLC purified. 
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2.2 METHODS 
2.2.1 Storage of Clin ical Isolates 
All the isolates including the controls were first subcultured onto BHIA and incubated 
at 37°C for 18-24 hours. After overnight incubation, a loopful of growth from each 
plate was placed into each medium containing beads, labelled with each isolate 
number and stored at -70°C for the future use. Identification of the isolates was 
based on conventional test schemes recommended by Facklam and Coll ins, 
( 1989 ) and Ruoff et al, ( 1990 ) and confinned with the aid of A PI 20 Streps 
( bioMeriux, Basingstoke, UK). 
2.2.2 Iden tification of E.faecalis and E.faecium by PC R 
The differences between Efaecalis and Efaecium were established by PCR based on 
ddl E.fnecnlis and ddl E::.fneciwn with the p1imers described by Dutka-Malcn eta/ in 1995 
as indicated in Table 2.3. 
Table 2.3 : Primers for ddl £.fnecalis and ddl E::.faecium 
Amplified gene Primer Sequence 5'- 3' 
ddl E.fnecnlis E, ATCAAGTACAGTTAGTCTT 
E2 ACGATTCAAAGCTAACTG 












I = Forward Primer, 2 = Reverse Primer, dd l = 0 -Aianyl-D-Ligase. 
N/A = Not Avialable. 
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2.2.3 Minimum Inhibitory Concentrations ( MICs ) Determination By Agar 
Dilution Method. 
Minimum inhibitory concentrations of antibiotics were determined by the agar method 
based on the guideline of the National Co nun ittee for Clinical Laboratory 
Standards [ NCCLS, ( 1997 )], on BHIA blood plates. One ml of each of serial doubling 
dilutions oftest antibiotics from the fresh stock was added to 18 ml volume of molted 
BHIA ( Oxoid ) cooled at 50°C and adding 1 ml of defribrinated horse blood ( E & 0 
Laboratory, UK) and mixed before pouring into each Petri dish. The control plate 
without antibiotic was also prepared. The plates were allowed to dry for 2 hours and 
bacterial inocula were prepared by appropriate dilutions of ovemight BHI broth cultures 
subcultured and incubated at 37°C from the isolates stored at -70°C and 
applied to antibiotic-containing plates with a 36 prong inoculating device (Denley 
A400) yielding final inocula of approximately 104 CFU per spot. The plates were 
allowed to dry and incubated at 37°C for 18-24 hours. The presence or absence of 
growth on each plate was noted and recorded for each antibiotic dilution. The lowest 
concentration of antibiotic which inhibited growth was designated the MIC. The 
concentration of antibiotic required to inhibit 50% ( MIC5o ) and 90% ( MIC9o ) of 
isolates were detem1ined when required. 
2.2.4 ~-lactamase T est 
The confirmation of presence or absence of P-lactamase production by clinical 
isolates was done by using nitrocefin-based cJu·omogenic cephalosporin method first 
described by O'Callaghan et al, 1972. It involved transferring 50!11 of nitrocefin 
solution to each well of a microtitre tray. A dense suspension of several colonies 
from the overnight growth of each isolate was made in each small volume of saline. 
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Fifty microliters of each suspension was then mixed with solution of nitrocefin and 
incubated at 37°C for 30 minutes. Absence or presence of colour change from 
yellow to red within 30 minutes by the isolates was recorded. 
2.2.5 Synergy/Antagonism Testing 
2.2.5.1 By Agar· dilution method 
MICs for the combined antimicrobial activity to demonstrate synergy/antagonism 
were performed using fresh stock solutions. In each case, one ml of each serial 
two-fold dilution of one antimicrobial agent (range 256mg/l-0.25mg/I) was mixed 
with one ml of fixed concentration of another antimicrobial agent ( ie 4 mg/1 ) in 
18m! of molted agar cooled at 50°C and adding defribinated horse blood and poured 
into each Petri dish. The control plate without antibiotic was also prepared. The 
plates were allowed to dry for 2-3 hours before inoculating and incubating isolates as 
indicated in section 2.2.3 by agar method. The absence or presence of the growth was 
recorded for each plate. 
2.2.5.2 By Checkerboard agar dilution method 
The MIC for each antibiotic was measured for each isolate by doubling agar dilution 
and then the known MIC for each dmg was fine-tuned by re-measuring in an 
arithmetical progression as in Fig 2.1 (shaded areas indicated single antibiotic A orB 
concentrations as controls ). The MIC was taken as fractional inhibitory 
concentration ( FIC ) of 1.0 for antibiotic. Agar plates each containing a mixture of 
both drugs were made up as shown in unshaded areas ( Row/Column ) in Fig 2.1 . 
The plates were inoculated with isolates using a multiple inoculating device (Denley 
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A400) yielding final inocula of approximately 104 cfu per spot. The plates were 
examined and recorded for absence or presence of growth after 24 hours of incubation 
at 37°C. 
Fig 2.1 Diagram of a typical Checkerboard 
1.0 
0.8 
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2.2.5.3 By Killing Curves technique 
The rate of killing of the clinical isolates by antimicrobial agents alone and by 
combination with another antimicrobial agent was determined for the selected strains of 
enterococci ( 17 Efaecium and 22 Ejaecalis) based on their MICs as well as limited 
financial resources avai lable to complete the remaining strains by performing colony 
counts. The following concentrations were used: gentamicin (64mg/l), amoxic illin ( 8, 16 
and 32mg/l),teicoplanin (2mg/l), vancomycin (4 and 8mg/l), synercid (2,8, 16,32 and 
64mg/l) and ciprofloxacin ( 4,16 and 64mg/l). Ten aliquots of Brain Heart Infusion broth 
each was inoculated with each isolate subcultured on BHIA w hich had been incubated at 
37°C previously. The inoculated aliquots were incubated at 3 7°C. One ml of a 102 
dilution of a culture of each iso late from the overnight incubation was pi petted into a 
series of tubes containing 9ml ofBHI broth each into which known concentration of 
antibiotic(s) had been incorporated. The final 1 0-ml volumes contain approximate ly 105 
to 107 organisms per millilitre together with antib iotic alone or combined with another 
antibiotic. One tube of each isolate without antibiotic was used as control. Tubes were 
incubated at 37°C during the petiod of experiment with respect to the removal of O. lml 
each and serial dilutions. Tests were carried out in triplicate. The colony counts were 
performed at time: 0, 4, 8 and 24 hours by removing 0.1 ml each from the broth and 
setially diluting approximately in saline to produce 10 fold serial dilutions (e .g 10"1, 10"2, 
10"3 and 10"4 in order to eliminate potential canyover effect) and put one drop 
(approx.20j..d) of each diluted saline in each corner oftri angle for the marked bottom of 
each BHIA plate (i.e a total of three drops per triangle for each 10 fold dilution) and 
allowed to absorb and dry without streaking. The plates were incubated at 37°C for 24-48 
hours before colonies were counted. The activity of antimicrobial alone and in 
combination was detennined by plotting log10 colony counts (cfu/ml) against time. 
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Synergy and antagonism were defined as a greater than 2 log1o cfu/ml decrease or 
increase respectively from the original inoculum at time zero. 
2.2.6 Selection of Gentamicin-resistant strains 
Clinical strains were selected for further study with respect to aminoglycoside 
modifying enzymes ( AMEs ) on the basis of their MICs to gentamicin as determined 
by the agar dilution method in section 2.2.3. In this case, if the MIC of gentamicin 
exceeded 8 J.lg/ml. 
2.2.7 Identification of Aminoglycoside Modifying Enzymes by PCR 
The presence or absence of the genes that encode ACC(6')+APH(2 ") for HLR to 
gentamicin in the clinical isolates was confirmed by amplifying specific region(s) 
using multiplex PCR technique. The primers used in the amplifica6on are indicated in 
Table 2.4. The strain NCTC 29212 was used as the control organism. Briefly, crude 
DNA template for the PCR reaction was made for each isolate by boiling 0.8ml bacterial 
cells in 0.2ml sterile deionized water ( l.Oml ) obtained from the overnight culture for 10 
minutes in boiling water, centrifuged for 5 minutes to remove the debris and us 20J.ll of 
supematant used as a template in the PCR reactions. PCR was perfom1ed in 
1 00J.llchilled reaction mixture containing 2.5 J.ll of 1 Ox PCR buffer, l.OmM MgCh for 
aac(6 ') +aph(2 "), 0.2mM deoxynucleoside triphosphates ( dATP, dCTP, dGTP and 
dTTP ), 0.5uM each primer and 2.5U of Taq DNA polymerase ( Advanced 
Biotechnologies, Dorking, Surrey). PCR was performed in a Techne Cyclogene 
Thermal Cycler ( Cambridge) with the fo llowing conditions:-! 0 min at 95°C, 30s at 
94°C, and 30s at 58°C and 30s at 72°Cfor 30 cycles: 10 min at 72°C and then maintained 
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at 4°C until analysis PCR products were electrophoresed on horizontal slab gels in the 
Bio-Rad subcell® GT agarose gel-electrophoresis method. The samples were first mixed 
with the loading buffer containing mixture of0.25% w/v bromophenol blue, 0.25% w/v 
xylene cyanol , and 30% w/v sucrose to the ratio of 5:1 before loading onto the gel 
including an appropriate molecular weight marker. Electrophoresis was run at a constant 
voltage of 1 OOV until the loading buffer fronts had moved two-third down the gel. Gels 
were stained fo llowing electrophoresis with the solution containing concentration of 
0.5J.!g/l ethidium bromide and visualized on a UV transilluminator. Photographs were 
taken using a Polaroid camera fitted with an orange filtrer. 
Table 2.4 Primers for detection of aminoglycoside resistance genes 
Resistance gene Size Position Primer Sequence ( 5' - 3 ' ) 
(bp) 
aac(6 ')-le-aph(2 ")-la 369 N/ A CAGGAA TTT A TCGAAAA TGGT AGAAAAG 
N/A CACAATCGACTAAAGAGTACCAATC 
aph(2 ")-lb 867 N/A CTTGGACGCTGAGATATATGAGCAC 
N/ A GTTTGTAGCAA TTCAGAAACACCCTT 
aph(2 ")- lc 444 N/A CCACAATGATAATGACTCAGTTCCC 
N/A CCACAGCTTCCGATAGCAAGAG 
aph(2 ")-Ld 641 N/A GTGGTTTTTACAGGAATGCCATC 
N/A CCCTCTTCATACCAATCCATATAACC 
N/ A:;::; Not available 
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2.2.8 Screening of E.f aecalis for a Tn528J-Iike Transposon by long-PCR 
Method 
The chromosomal DNA was used as template to amp li fy a 3.5 kb fragment of Tn528 1 
by the Expand Long Temple PCR System ( ABgene, Epsom, Surrey, UK) 
according to manufacturer's instructions. Because Tn5281 has a gene 
aac(6 ') +aph{2 ") fl anked by TS256 sequence in inverse orientation, therefore, any 
PCR primer used to act as a ' forward primer· described by Dyke eta/, 1992, wou ld 
a lso anneal to the inverted IS256 sequence and subsequently act as a ' reverse primer' . 
There fore, the L-PCR method utilized only a single 18256 primer 
(5-' CAGAACAGCTGGATCCTATGG-3 restricted with Bam HI or 5" 
GTCGACTTTTAGCCTCACGCG-3' restricted with Sail ) for the amplification of a 
468-bp sequence from within ORF390 ofiS256. Each PCR reaction had contained 
350 j..tM ofeach dNTP, 300nM of IS256forward primer, 5 j..tl ofx iO reaction buffer 
in 1.75 mM magnes ium chloride concentration, 250ng of chromosome DNA and 2.5 
units of reaction enzyme ( Taq and Pwo DNA polymerase). The final volume was 
made up to 50 J .. tl with sterile distilled water. The ampli fication was performed with 
one cycle of94°C for 2 min, 10 cycle of92°Cfor I Os, 57°C for 30s and 68°Cfor 45s, 
30 cycles of92°C for lOs , 57°C for 30s and 68°C for 8 min (with the elongation time 
increased by 20s per cycle ) and a final elongation cycle of 68°C for 7 min. 
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2.2.9 Detection of IS256 Elements By L-PCR 
To establish if1S256 elements were present in the clinical isolates, L-PCR amplification 
of a 468 bp fragment specific to IS256 was performed as described by Dyke etal (1992) 
indicated in section 2.2.8. 
2.2.1 0 Bacterial genomic DNA extraction 
High quality bacterial genomic DNA was extracted with guanidium thiocyanate as 
described by Pitcher et al ( 1989 ). A single colony from each plate grown overnight 
was inoculated into each 10m! BID broth and grown ovemight on shaker at 37°C. 
The broth cultures were then harvested by centrifugation and washed in TE buffer 
before resuspending in 1 OOJ.!l TE supplemented with 50mg/mllysozyme. The cell 
pellet was incubated at 37°C for 30 minutes and then lysed with addition of0.5ml 
GES reagent ( SM guanidium thiocyanate, 1 OOmM EDTA and 0.5% v/v sarkosyl ). 
Lysates were cooled on ice before add ing 0.25ml of7.5M ammonium acetate kept on 
ice for 10 minutes. DNA was precipated by addition of0.54 vo lumes of2-propanol 
kept at -20°C and collected by centrifugation. DNA pellets were washed in 70% 
ethanol prior to redissolving in 1 OOul of sterile deionized water. 
2.2.11 Examination of DNA Preparation By Agarose Gel Electrophoresis 
DNA preparations were examined based on their purity, quantity and size by 
conventional agarose-gel e lectrophoresis. Gel electrophoresis was performed in T AE 
(lOx TAE pH 7.6: 40 mM Tris-acetate, lmM EDTA) buffer. The gels were made by 
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melting 1% agarose in 1 x T AE in a microwave oven. Gels were cast in an appropriate 
casting tray and after so lidifying, placed in a gel electrophoresis tank containing 1 x TAE 
buffer. Six ~tl of each PCR sample containing I ul of tracking dye( 30%glycerol, 0.25% 
bromophenol blue and 0.25% xylene cyanol ) were loaded in a well at one end of the tray 
along with 1 OObp DNA ladders ( GibcoBRL, Montgomery, Maryland) as molecular 
weight reference. Electrophoresis at 1 OOV was then performed for 20-30 minutes. The 
samples were examined by UV visualization on UV transillumination ( UV Products, 
Cambridge). A good purity DNA showed only one band and their quality and size 
were estimated by comparing with the standard DNA marker(s) on the same gel. 
2.2.12 Pulsed-Field Gel Electrophoresis 
In order to estab lish relatedness among the clinical isolates, Pulsed-fi eld gel 
electrophoresis ( PFGE ) was used to analyse the difference or non-difference among 
the isolates. Harvesting of cells was done by vortexing for 5 minutes the overnight 
BHT broth culture (2ml ) each inoculated with a single colony the previous day and 
standardized to McFarland's 4 opacity. 400!-!1 were transfe1Ted each to l.Sml Eppenclorf 
tube and spun down on microcentrifuge for 2 minutes at maximum speed ( 15,000 rpm ), 
discarded the supernatant and added 800~d each ofTE buffer [ 10 mMTris-HCL ( pH 
7.5 ) ], 0.1 mM EDT A ] vortexed properly and spun for 2 minutes. The supernatant was 
discarded and 200ul each of TE buffer and 20)-.tl each of achromopeptidase was added 
and vo11exed thoroughly. The added 220~Ll seaplaque agarose ( Bio-Rad Laboratories, 
UK), vortexed briskly and loaded each to block mould. Plugs were allowed to set in 
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fridge for 15 minutes before dislodging the plugs from each mould into each bijou tube 
containing pre-warmed lysis buffer in 50°C water bath and left for one hour. Washing 
plugs was done by first discarding lysis buffer and adding 2 ml of pre-warmed TE buffer 
while keeping the plugs at 50°C water for 15 minutes. The TE buffer was changed with 
fresh 2ml TE buffer and the plugs left at room temperature for 15 minutes. Fresh 2ml 
TE buffer was added and left at room temperature for another 15 minutes before storing 
in TE buffer ( 2ml ) at 4°C indefinitely. DNA digestion was done by first labelling 0.5ml 
Eppendorftubes accordingly. Agarose plugs were cut approximately 5mm x 3mm in size 
each and placed into each tube then 1 oo, .. d of a 111 Odilution of Sma 1 buffer A was 
dispensed into each tube before adding 2f..l l Smal restriction endonuclease ( Promega 
Southampton, UK) into each tube. Tubes were incubated at 30°C ovemight. 
Prepared 1.2% PFGE certified agarose in x 0.5 TBE buffer ( ie 1.2g agarose in l OOml 
of half strength TBE) before dissolving in the microwave oven and pouring into tray. 
A comb was inserted and the gel allowed to set. Lambda molecular weight markers 
were added and pre-warmed at 52°Cfor 8 minutes. Each we]] was loaded with each 
restticted product including marker. All wells were sealed with the saved agarose 
and the gel kept for 10 minutes in the fridge to solidify before putting into PFGE tank 
and secured. TBE ( 1900ml) was poured into the tank and covered the tank. 
Electrophoresis was perfonned in a contour-clamped homogeneous electric 
fields device ( CHEF-DRll; Bio-Rad Laboratories LTD, UK). The gel was set to 
run at initial pulse of 5s and final pulse of 40s for 24 hours. Pump was set at 65, 
12°C, voltage at 200V. At the end of run, gels were stained with solution containing 
concentration of ethidium bromide ( 0.5ug/ml) for 15 minutes and destainecl in 
distilled water ( 2x 15 minutes) before being visualized under UV illumination and 
took photographs or scanned gel image in computer. 
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2.2.1 3 Interpretation of PFGE Banding Patterns 
2.2.13.1 PFGE banding patterns by visual comparison 
PFGE banding patterns were compared visually based on the interpretation by the 
criteria ofTenover et al (1995 ). Thus, isolates are deemed indistinguishable if they 
have identical PFGE banding pattems. Isolates with differing banding patterns by 
up to three bands are considered to be closely related and four to six banding 
differences arc assumed to be ' possibly related·. Isolates '"' ith seven or more bands 
bands difference are considered to be unrelated. 
2.2.13.11 Comparing PFGE Banding Patterns with aid of Computer 
Banding patterns were compared with the Bionumeric Software version 3.0 Diversity 
Database software based on introduction of gel images into the Diversity Database 
from the original Polaroid photographs. Analysis was then performed based on 
gu idelines from themanufacturer resulting into phylogenie trees. 
2.2.14 Random Amplification Polymorphic DNA ( RAPD) PCR 
RAPD also known as arbitrarily primed PCR was to show similarities or differences 
between £.faecal is and E.faecium with respect to bandings. Extraction of DNA was 
done based on the method in section 2.2 .1 0. A single primer sequence used was 5 '-
GAGGTGGCGGTTCT-3'. PCR reaction mixture consisted of2J ..tl or sample, 2.5~d 
primer, 2.5~tl Taq, 2 . 5~tl of lOx PCR buffer. I p MgCl2. l O~tl each of dNTPs, 20~.!1 
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tris-Hel at pi 18.3 and 32~d MQ H20. Amplification was done by one cycle at 90°e 
for 10 minutes, 94°e for 1 min, 45°e for 20s, 72°e for 54s in 40cycles and then 
followed by one cycle at 72°e for 2 rninutes. The PeR products were run on 
electrophoresis before staining with ethidium bromide so lution ( 0.5~g/ml) and 
visualized by UV. Photographs were taken using a Polaroid camera and the 
bandings were compared with those obtained from PFGE method. 
2.2.15 Identification of gyrA and parC resistance among the isolates by PCR 
The objective was to ampli fy the QRDR segment of gyrA and pare genes of the 
isolates in order to sequence the QRDR. The PCR was pcrfom1ed using the primers 
indicated in Table 2.5. A 0 A fragment of241 bp from gyrA gene corresponding to 
quinolonc resistance dete1mining region was amplified wi th primers indicated in 
Table 2.5 equivalent to nucleotide positions 150 to 172 and 368 to 390 of E.cofi gyrA 
gene respectively. A 191-bp parC fragment was amplified with the primers also 
indicated in Table 2.5 with position 10 to 229 and 181 to 200 of the Ejaecalis pare 
respective ly. One-step PeR was performed for each gene in a 50~ 1 reaction mixture 
containing 1.25 U ofTaq 0 A polymerase, 200~m each deoxynucleoside 
triphosphate, 45pmol of each primer, 1.5mM MgCI2 and I Ox Pe R buffer ( Sigma ). 
Each reaction was run for 30 cycles with the fo llowing temperature profile : 
denaturation at 94°e for l min, annealing at 55°e for gyrA and 48. 7°C for pare for I 
min; and then extention at 72°efor 1 min. ATee 292 12 was used as a reference. 
The amplified fragments were analysed in ABI 377 prism automated sequencer. 
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3.1 Characterization of clinical isolates of Enterococci 
Enterococci, especially Efaecalis and Efaecium, are the second leading cause of 
nosocomial infections (Schaberg et al., 1991). The identification of an Enterococcus 
isolate to species level is clinically crucial for the proper patient management and for 
the epidemiology purposes. 
3.1.1 Speciation of the clinical isolates by API 20 Strept system 
The APT 20 Strept system is one of a series of miniaturized classical biochemical 
tests from commercial sources widely used by clinical laboratories across the world 
fo r the identification of many groups of organisms ( bio-Merieux ). The system is 
simple and gives consistent results although it may not recognize some of the more 
recently described enterococcal species because of the phenotypic similarities among 
the strains and has failed to identify E.gallinarurn and E.casseliflavus (Hamilton-
Miller & Shah,1999). Therefore, further testing is necessary to confirm the species 
identification. 81 clinical isolates (ie 55 E.faecalis and 26 E.faecium) were 
identified by the API 20 Strept system based on profile index in the computer-based 
identification services and were found to be E.faecalis ( 67% ), Efaecium ( 32% ), 
and E.durans (1%) (Fig 3.1 ) and (See also Appendix A). The isolates were 
previously identified with the aid of API20 S by the clinicallaborat01ies as either 
Ejaecalis or Ejaecium at the time of their isolation from the clinical specimen. 
Further identification of isolates was confirmed by PCR (section 3.1.2 ). Many 
pathogens including Efaecalis produce haemolysis capable of destroying erythrocytes , 
for example on horse blood agar. The significance of haemolysis in pathogenicity is not 
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yet understood. However, such haemolytic patterns could be used as a cultural 
characteristic on the blood agar which gives one of the clues of the identification 
processes of the isolates in the clinical laboratory settings which frequently receive and 
process such samples. The clear haemolytic zone around the colony in the blood agar 
indicates a complete haemolysis of red blood cells ( erythrocyes) called "P-haemolysis". 
The greenish-grey zone around colonies on the blood agar attributed to partial lysis of 
RBCs is called "a-haemolysis". All Efaecium ( 26) showed a- haemolytic on horse 
blood agar and Efaecalis (55) showed mixture of a ( 21 ) and P ( 34) haemolysis on 
horse blood agar (appendix A). 






3.1.2 Identification of two enterococcal species by PCR method 
The use ofPCR for identification of enterococcal species was based on specific 
detection of genes that encoded D-Alanine:D-Alanine ( D-ala:D-ala) ligases. The 
PCR assay relies on specific amplification of fragments intragenic to ddlEfaecntis and 
ddhfnecium. Dutka-Malen et al. ( 1995 ), showed that the ddlEfaecium and ddhfaecalis 
genes are specitic for Efaecium and Efaecalis and, therefore, could be used for 
identification ofthe two species. The two pairs of primers (Table 2.3 ), each 
intended to prime amplification of a fragment internal to a gene, were selected based 
on nonconserved regions and each amplification product was assigned to a gene on 
the bases of its size that can be readily identified by migration electrophoretic gel 
analysis ( Dutka-Malen et al, 1995 ). PCR was performed with DNA from every 
isolate as template against the primers (Table 2.3 ) . One band was generated as PCR 
product with size of 550 bp resulting from amplification portion of the ddlefaecium 
observed with each DNA template from Ejaecium isolates (Fig 3.2). The quality of 
gels with respect to one E.durans isolate-17B/377 and Ejaecium iso lates 17B/235, 
17B/721, 17B/849, l8B/33, NCTC12202*, 18B/89*, 18B/149, 18B/234, 18B/254, 
18B/294 and 18B/298 appear to be very good but there was no banding from isolates 
with *(astetick) mark due to non reactivity between extracted isolates DNA with primers 
in the PCR mixture or otherwise. Similarly, one band of 941 bp was generated from 
amplification of ddle.;aecalis when each DNA template from Ejaecalis isolates was used 
(Fig 3.2 ). The quality of gels for Efaecalis isolates l?B/407*, l ?B/452, 17B/686, 
17B/76 1, 17B/819, NCTC29212, lSB/309*, l SB/314, 18B/329*, 18B/337*, 18B/358* 
and 18B/376* appear to be ranging fi·om good to very good and again each isolate with 
58 
astrerick mark did not produce banding due to inactivity in the PCR mixture. However, 
there was no difference between Efaecium and E.durans by PCR method (lane 2-
E.faecium and lane 3-E.durans Fig 3.2 ). Both had shown a band size of 550bp. This 
contrasted to identification of E.faecium and E.durans by API 20 Strept system ( Section 
3. 1.1 )and reveals a flaw in the PCR method . An attempt to sequence both species from 
the PCR product to differentiate the two species did not produce a clear result. Thjs 
investigation could not show that this method was sufficiently reliable for the 
differentiation of E.faecium and E.durans, but it was useful to distinguish E.faecium from 
Efaecalis. Tbis distinction of E.faecium from E.durans has been from phenotypic 
methods only. Lane 4, 8,12 &13 in Fig 3.2 (a) and lane 8, 10-13 of(b) had no banding. 
NCTC29212 & NCTC12202 were used instead ofNCTC 12697 and NCTC 7171 as 
controls because all isolates were found to be gentamicin resistance. 
Fig 3.2 (a) & (b) Analysis of agarose gel electrophoresis of amplified ddl E.faecium and 
ddh.Jaecatis PCR Products 
(a) 
1 2 3 4 5 6 7 8 9 10 11 12 13 14 
Lanel-A. ladder; 2-RIE-17/235; 3-RIE-17/377; 4-RIE-17/407;5-RIE-17/452; 6-RIE-
17/686; 7- RIE-17/721; 8-RIE-171761;9-RIE-17/819; 1 0-RIE-17/849; 11-RIE-18/33; 12-
NCTC12202;13-NCTC29212; 14-A. ladder 
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(b) 
1 2 3 4 5 6 7 8 9 10 11 12 13 14 
Lane 1-A. ladder; 2- RIE-18/89; 3-RIE-18/149;4-RIE-18/234; 5-RIE-18/254; 
6-RIE-18/294; 7-RIE-18/298; 8-RIE-18/309; 9-RIE-18/314; 10-RIE-18/329; 
11-RIE-18/337; 12-RIE-18/358; 13-RIE-18/376; 14-A. ladder 
3. 2 Analysis of the Isolates by PFGE Method 
Several techniques have been used in medical microbiology for acqui1ing infonnation 
on the spread of pathogenic bacteria within the hospital envu·onment and outside in 
the community ( Antonishyn et al, 2000 ). The PFGE technique used in this study 
was to analyze the degree of clonality with the gentamicin-resistant isolates (52 
E.faecalis and 21 Efaecium ) obtained from RIE. The PFGE technique is considered to 
be most reliable due to its discriminatory power, sensitivity and reproducibility ( Gordi.llo 
et a/,1993; Munay et al, 1990; Chiew & Hall,1998) The interpretation was done based 
on the criteria described by Tenover et al, (1995). The criteria are only used in the 
hospital laboratories when examining relatively small sets of isolates ( ie not more 
than 30 ) which are related to putative outbreak of the disease. The interpretation 
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criteria was used to show the number of fragment differences that would be expected 
within the PFGE patterns showing a defined number of genetic occunences either as 
point mutation resulting in the creation or loss of restliction sites and insertions or 
deletion of DNA. Thus, PFGE patterns that differ by two or tlu·ee fragments are 
deemed to be closely related on the differences that occur through a single genetic 
event. According to Tenover et al, 1995, two genetic events would result into four to 
six fragment differences showing unrelatedness and these criteria are reliable ifPFGE 
resolves at least ten distinct fragments. Accordingly, a point mutation that would lead to 
the criteria of an additional restliction site may result in a three fragment differences. 
This might be taken as closely related to the original pattern. However, transfer of large 
chromosomal elements associated with vancomycin resistance could alter the 
biochemical properties of the strain ( McAshan et al, 1999 ). The study by Morrison et al, 
1999 showed that a single strain can differ by up to seven fragments based on the 
temporal, association of the isolates representing a single strain. If the criteria defined 
by Tenover et al, 1995, were widely accepted, they would not be applied to all bacterial 
species. Therefore, it was with the hope or anticipation that isolates would fail to be 
recognized as related by the Bionumeric Software version 3.0. Indeed, that was whal 
had occuned in the visual comparison with the Bionumeric Software version 3.0 
computer among the E.faecium isolates involved in this study. The computer software 
identified E.faecium isolates RIE-17B/849 and RIE-18B/33 with 80% similarity while 
RIE-18B/517 and RIE-18B/567 were identified with 70% similarity. RIE-18B/815 and 
RIE-19B/47l were identified with 66% similarity. Isolates RIE-18B/536 and RIE-
18B/632 had only 64% similarity. RIE-17B/235 and RIE-18B 149 were identified as 
40% similarity. On the other hand, E.faecalis isolates RIE-17B/761 and RIE- 1 7B/819 
were identified by computer software with similarity of 90% while RIE-17B/686 and 
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RIE-18B/329 identified with 80% similarity. RIE-18B/337 and RIE-18B/358 had 76% 
similarity. All the isolates identified as unrelated to any other isolates by visual 
comparison ofPFGE patterns were confirmed by computer software as unrelated. 
However, the computer software calculates that the two isolates, for example, have 66% 
similarity, such a percentage similarity shows that the strains are not related at all 
although it may be that the percentage may be significant given the variety observed in 
the percentage similarity of identical strains. The PFGE technique is considered to be 
most reliable due to its discriminatory power, sensitivity and reproducibility (Gordillo et 
al, 1993; Murray et al, 1990; Chiew & Hall,1998 ). Twelve of the 52 Efaecalis, 21 
Efaecium and one E.durans isolates were analysized by PFGE method to explore 
relatedness among the strains. 
3.2.1 Visual analysis of PFGE Patterns 
Initiaily banding patterns were compared by eye and interpreted using criteria described 
by Tenover et al, 1995. These criteria indicate that isolates are deemed to be 
indistinguishable if they have identical banding patterns. Isolates with upto three bands 
differences are considered to be closely related and with four to six bands differences 
would indicate ' possibly related' . Isolates are considered unrelated if they have bands 
differences of seven or more. To overcome difficulties in comparing banding patterns on 
different gels, the different PFGE types identified were re-run on the same gel. Fig 3.3 
shows the main PFGE types recognized and Table 3.1 (a) & (b) and Table 3.2 assigned 
PFGE types as determined in the visual comparison of restricted patterns. All isolates 
were obtained from the Royal Infitmary of Edinburgh (RIE). Visual comparison of the 
PFGE pattems for Efaecalis [Fig 3.3(c) ] showed that all isolates were identical except 
RIE-18/309 lane-7. The identical isolates appeared to be the outbreak strain and were 
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from the same ward. However, RIE-18/309 appeared to have come fi·om a different 
ward. There were variations with regards to Efaecium isolates and they were collected 
from different wards within the RIE [Fig 3.3 (a)]. Isolates in Lanes 3&12 had no band. 
RIE-17/849, RIE-18/33 and RIE-18/234 appeared to be identical. RIE-17/235, RIE-
18/149, RIE-17/721 each showed different bands from the rest of the isolates thus 
indicating the heterogeneity of the isolates. Fig 3.3 (b) also showed heterogeneity with 
respect to the bandings. 






1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 
Lane 1-A- ladder; 2-RIE-17/235; 3-RIE- 17/377; 4-RIE-17/721; 5-RIE-
17/849;6-RIE-18/33; 7-RIE-181149; 8-A. ladder;9-RIE-18/234; 10-RIE-
18/254; 11-RIE-18/294; 12-RIE-18/298;13-RIE-18/487; 14-NCTC122202; 
15-A. ladder ( All Efaecium) 
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(b) 
I 2 3 4 5 6 7 8 9 10 11 12 13 14 15 
Lane 1-'A ladder~ 2-RIE-188/517; 3-RIE-18B/536; 4-RIE- 188/567; 5-
RlE-188/632; 6-RIE- 188/662; 7-RIE-1881749; 8-RIE-'A ladder; 9-












I 2 3 4 5 6 7 8 9 10 ll 12 13 14 15 
Lane 1-/.. ladder; 2-RfE-178/407; 3-RIE-178/686; 4-RIE-1781761; 5-RlE-
178/819; 6-RIE-188/89; 7-RIE-188/309; 8-/..ladder; 9-RIE-188/314; 1 0-RlE-
188/329; 11-RIE-188/337; 12-RIE-188/358; 13-RIE-188/376; 14-RJE-188/379; 
15-/.. ladder (All Efaecalis) 
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Table 3.1 PFGE patterns of E.faecium 
(a) Lane# Isolate# Species PFGE pattern 
--------------------------------------------------------------------------------
1 A ladder 
2 17B/235 Efaecium A 
3 17B/377 E.durans 
4 17B/721 Efaecium B 
5 17B/849 Efaecium At 
6 18B/33 Efaecium At 
7 18B/149 Efaecium D2 
8 A ladder 
9 18B/234 Efaecium A2 
10 18B/254 Efaecium A3 
11 18B/294 Efaecium ~ 
12 18B/298 Efaecium 
13 18B/487 Efaecium At 
14 NCTC12202 Efaecium c3 
15 A ladder 
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(b) Lane# Isolate# Species PFGE pattern 
1 A ladder 
2 18B/517 Efaecium c2 
3 18B/536 Efaecium c2 
4 18B/567 Efaecium c2 
5 18B/632 Efaecium c2 
6 18B/662 Efaecium c 
7 18B/749 Efaecium c 
8 A ladder 
9 18B/813 Efaecium Ct 
10 18B/815 Efaecium Ct 
11 18B/960 Efaecium Dt 
12 19B/391 Efaecium D 
13 19B/471 Efaecium Ct 
14 NCTC 12202 Efaecium c3 
15 A ladder 
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Table 3.2 PFGE pattern of E.faecalis 
Lane# Isolate# Species PFGE pattern 
1 A ladder 
2 17B/407 Efaecalis A2 
3 17B/686 Efaecalis A2 
4 17B/761 Ejaecalis A 
5 17B/819 Efaecalis A 
6 18B/89 Efaecalis AI 
7 18B/309 Efaecalis B 
8 A ladder 
9 18B/3 14 Efaecalis 
10 18B/329 Efaecalis A2 
11 18B/337 Ejaecalis ~ 
12 18B/358 Efaecalis ~ 
13 18B/376 Efaecalis A3 
14 18B/379 Efaecalis 
15 A ladder 
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3.2.2 Computer-Aided Analysis of PFGE Patterns 
The Bionumeric software version 3.0 (Applied Maths, Ghent, Belgium) was used in 
the PFGE computer-aided ana lysis. The software possesses the algo1ithms necessary 
for gel analysis. The comparison and preparation of a dendogram and cluster analysis 
of digested profiles of isolates were based on the Dice coefficient using the hierarchic 
un-weighted pair arithematic average algorithm with 1.6% tolerance. Fragments 
smaller than 48.5kb in length were not used in analysis. The criteria defined by 
Tenover et al, ( 1995) are intended for use in the investigation ofrelatively small sets 
of isolates ( approx S30 ) related to the putative outbreaks of infection (Tenover et 
al, 1995 ). Therefore, they are not suitable for the study of all the isolates. The PFGE 
interpretation wi ll be given in the discussion (Chapter 7 ). The gel images 
introduced into Bionumeric software version 3.0 were taken from the original 
Polaroid photographs. Unfort1mately, gels were not initially run with a view to making 
the computer-aided comparison. However, in a good setting, the gels should be run 
using two DNA ladders flanking the samples and another DNA ladder situated in the 
middle of the gel. The cluster analysis of data was performed on two gel photographs 
indicated in Fig3.4 (a) and (b). It was with the hope that isolates deemed to be related by 
visual comparison ofPFGE patterns would fail to be recognized as related by the 
computer software. [ndeed, that was what had occurred in the results indicated in Fig 3.4 
(b). Instead of having one outbreak strain as indicated in the visual comparison, the 
phylogenetic tree obtained through Bionw11eric software version 3.0 suggested several 
small clusters of related isolates . Similari ty judged by eye as identical range 
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approximately 58% to 95%. However, when analysed by Software, similarity appears to 
be different [ F ig3.4 (b)). Bionumeric software identified RIE-17B/761 and RIE-
17B/819 [Fig3 .4 (a) Efaecalis] as identical ( 90% similarity ). Isolates RIE-l7B/686 and 
RIE-18B/329 were identified as identical ( 80% similarity). RIE-18B/337 and RIE-
18B/358 had only 76% similarity. In Fig 3.4 (b) for Efaecium, Bionumeric software 
identified RIE-17B/849 and RIE-18B/33 as identical ( 80% similarity). RIE-18B/517 
and RIE18B/567 showed similarity of70% and closely related isolates RIE-18B/815 and 
RIE-19B/471 showed 66% similarity. Isolates RIE-18B/536 and RIE-18B/632 had only 
64% similarity. Isolates 17B/235 and 18B/33 showed 40% similarity All the isolates 
identified as wu·elated to any other isolates by visual comparison ofPFGE patterns were 
confirmed by Bionumeric software version 3.0 analysis as unrelated. When the 
calculation by Bionumeric software analysis shows that the two isolates have 66% 
similarity, such percentage simi larity would mean that strains are not related although it 
might be that the percentage may be significant given the variation observed in the 
percentage similarity of identical strains. 
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Fig 3.4 (a) Cluster analysis of DNA Banding Patterns of E.faeca/is 
Fig 3.4 (b) Cluster analysis of DNA Banding Patterns of E.faecium 
... -... .... ..,,. ... , (flll.tMO<IIol 
""01!!·1 PFG-61 
17[ll:l3$ E f&eetum A 
1691149 e., tlHK:t\lf'n A 
1791840 e_ t,ooelvm AI 
18El/33 e to~iurn AI 
16BI234 £ f.6<)1U I'n A2 
1781721 e fef)Cium B 
1881815 e foeclum C l 
19el471 E t..c•um Cl 
1881813 e t.-.ctUfn Cl 
1881662 e toocium c 
1881749 e r.oe.".n c 
1991391 c caac"·'"' 0 
1881538 E.._. ..... C2 
180103:l E. Je«•urn C2 
1881517 E ,ftee~Yf"" C2 
1881567 E t.aec•um C2 
NCfC 12202 E 13octUnl C3 
* Isolate 18B1149 had visual banding pattern of D2 instead of A 
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17B/761 + 17B/819 90% 
l?B/686 + 18B/329 80% 
18B/337 + 18B/358 76% 
(b) Efaecium 
I I so ate p ercentage 
17B/235 + 18B/149 40% 
17B/849 + l8B/33 80% 
18B/815 + 19B/471 66% 
18B/536 + 18B/632 64% 
l8B/517 + 18B/567 70% 
3.3 The Comparison of RAPD method with PFGE Technique 
Both RADP and PFGE techniques have been used to investigate the epidemiology of 
enterococcal infections ( Chiew and Hall, 1998). PFGE technique is based on the 
digestion of chromosomal DNA with a restriction endonuclease that cleaves infrequently 
and produces only a few high-molecular-weight fragments that can be separated under 
special conditions of electrophoresis. On the other hand, AP-PCR (RAPD) is based on 
non-specific random ampli fications by PCR of the bacterial chromosome using a short 
primer under low-stringency conditions. The RAPD method was compared with the 
PFGE method with respect to equal Discrimination (Bingen et al, 1996 ). The banding 
system was used as a way of showing the discriminating systems between the two 
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techniques. Few isolates were selected for the comparison of the two techniques (Fig 
3.5 ). The comparison was done using PFGE (a) for the strains RIE-17/235, RIE-17/377, 
RIE-1 7/407, RlE-17/452, RIE-17/686 and RIE-17/721. and with the RAPD (b) for the 
strains RIE-17/849, RIE-18/33, RIE-18/89, RIE-18/149, RIE-18/234, RIE-18/254, RIE-
18294, RIE-18/294,RJE-18/309 and RIE-18/314. Banding between lane 2(a)-RIE-
17/235 ( Efaecium) and lane 2(b)-RIE-18/33 ( Efaecium) showed that strain RIE-
17/235 had the same bandings (15) with the strain18/33 ( 15 bandings). There was no 
banding observed between strain RIE- 17/377 ( E.durans) in lane 3 (a) and strain 17/849 
( Ejaecium) in lane l(b). The strain RIE-17/407 ( Efaecalis) in Jane 4(a) had 12 
band.ings as compared to strain RIE-1 8/89 ( Efaecalis) with 15 bandings. The strain 
RIE-17/452 ( E.faecium) in lane 5(a) had 13 bands compared to strain RIE-18/149 ( 
Efaecium) in lane 4(b) which had 14 bandings. The strain RIE- 17/686 ( Efaecalis) in 
lane 6(a) had 12 bands as compared with strain RIE-18/234 (E.faecium) in lane 5(b) 
which had 10 bands. The strain RIE-17/721 ( E.faecium) in lane 7(a) had 17 bandings 
as compared to strain RJE- 18/254( E.faecium) in lane 6(b) with 14 bandings. RTE -
17/294 (E.faecium) lane 7(b) had 7 bandings. Lane 8(b) RIE-18/298 ( Efaecium) had 8 
bands whi.le RIE-18/309 (Efaecalis) lane 9(b) had six bands. RlE- 18/314 
( E.faecalis ) lane lO(b) had only three bandings. The differences between the 
bandings among the compared strains appeared not to be large. In all, PFGE generated 
more bandings than RA PD observed between the two techniques. One potential 
criticism ofRAPD ( AP-PCR) is that, the bands generated are the result of arbitrary and 
potentially mismatching priming events (Collier et al, 1996 ). The differences in 
banding patterns may occur as a consequence of variations in experimental conditions 
beyond the control of the operator (Collier et al, 1996 ). These artificial variations would 
compromise the values of interference made regarding the extent of genetic variation 
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among the strains based on similarity or lack of AP-PCR pattems. However, in order to 
reduce operator induced variability such as found in RAPD, a technique such as 
Multi locus sequence typing (MLST) could, instead, be used since it has a low level of 
nucleotide variation. The procedure is essentially an updated version of multi locus 
enzyme electrophoresis (MLEE) which indexes variation within multiple core metabolic 
(housekeeping) genes on the basis of differing electrophoretic mobilities of the gene 
products (Feil et al, 2004). Whistle, the drawback ofMLEE and other gel-based 
methods, for example pulsed-field gel electrophoresis, is that it is often difficult to 
compare resu lts between laboratories. Whereas such a problem does not arise with MLST 
because of indexing directly housekeeping genes by nucleotide sequencing the internal 
gene fragments. Although RAPD analysis is rapid and cost effective, its reproducibility 
is subject of debate. The factors affecting reproducibility are extraction methods 
employed for DNA (Gomez-lus et al, 1993 ), concentration of template DNA (Davin-
Repli et al, 1995 ) and selection of primer, polymerase and cycling conditions ( Kerr, 
1994 ). On the other hand, PFGE has been described as being nearly the optimal typing 
method (Maslow et al, 1993 ). It provides a highly reproducible restriction profile that 
shows distinct well-resolved fragments of the entire bacterial chromosome in a single gel. 
Several studies showed that PFGE in comparison to a variety of phenotypic and other 
molecular epidemiological typing methods is more superior ( Goering and Duensing, 
1990; Saulnier eta!, 1993 ). PFGE has also been refeJTed to as the gold standard for 
epidemiological analysis of nosocomial infection ( Goering, 1993 ). The disadvantages 
ofPFGE technique include the time-cosuming aspects, technical difficulty demanding 
and the need for expensive equipment 
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Fig 3.5 Comparison of Bandings between (a) PFGE and (b) RAPD of 
Clinical Isolates 
(a) 
2 3 4 5 6 78 
Lane-1- ladder; 2-RlE- 17 /235; 
3-RJE-17/377; 4-Rl E-17/407; 
5-RIE-1 7 /452; 6-RlE- 17/686; 
7-RIE-17/721; 8- ladder. 
(b) 
1 2 3 4 5 6 7 8 9 10 
Lane- 1-RIE-17/849; 2-RIE- 18/33 ; 
3-RIE- 18/89; 4-RIE-1 8/149; 
5-RJE- 18/234; 6-RIE-18/254; 
7-RIE- 18/294; 8-RlE-1 8/298; 
9-RIE-18/309; 10-RlE-18/314. 
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CHAPTER 4 RESULTS: Susceptibility Testing 
4.1 T he in vitro Susceptibility Tests 
In vitro susceptibility testing of bacteria remains one of the most important functions 
of the clinical microbiology laboratories. The central focus is on the interaction 
between the "bacteria" and the "drug" in the in vitro s.ituation. The results of such 
tests have enormous hospital-wide implications, influencing decisions on the 
treatment of individual patients, development of antibiotic formularies and application 
of infection control policies ( Johnson,1993 ). 
4.1.1 Agar dilution method 
The agar dilution procedure has been successfully adapted for routine use in large 
laboratories. This involves testing various concentrations of antibiotic based on 
standardized suspension of bacteria inoculated onto a series of agar plates each 
containing a different concentration of antibiotic encompassing the therapeutic range 
of the drug. The plates are then incubated at 37°C for 18-24hours. The results are 
interpretated in MIC showing the lowest concentration of drug preventing visib le 
growth after incubation. All the clinical isolates ( i.e 55 E.faecalis and 26 Efaecium ) 
were tested against the antibiotics indicated in section 2.1.4 . The results were shown 
at MICso and MIC90 [Table 4.1 (a) and (b); and a combined graph Fig 4.1]. The MICso 
indicated values of strains at the median of the series but on its own, is not significant 
with respect to sensitivity or resistance. On the other hand, the more significant values 
were at MlC9o which shows the concentration required to inhibit 90% of the bacteria. 
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This is a much more sensitive indicator as to whether resistance was beginning to emerge 
in a bacterial population. 
Table 4.1 (a) & (b) Antibiotics at MIC5o and MIC9o for E.faecalis and E.faecium 
(a) Enterococcus faecalis 
Antibiotic MIC Range MICso 
(mg/1) 
Gentamicin 32->256 64 256 
Synercid 4-128 16 64 
Teicoplanin <0.25-16 0.5 2 
Vancomycin 4-8 4 8 
Ciprotloxacin <0.25->256 0.5 >256 
Moxifloxacin <0.25-64 4 32 
Amoxicillin 0.5-32 2 16 
Piperacillin 1-16 2 8 
Linezolid 2-4 2 4 
Augmentin 0.5-32 4 8 
Tazocin 1-32 4 16 
(b) Enterococcus faecium 
Antibiotics MIC Range MICso 
(mg/1} 
Gentamicin 128->256 128 256 
Synercid 4-64 8 32 
Teicoplanin <0.25-2 0.5 1 
Vancomycin 4-8 4 8 
Ciprofloxacin 0.5->256 8 >256 
Moxifloxacin <0.25-64 1 32 
Amoxicillin 0.5-64 4 32 
Piperacillin 1->256 8 256 
Linezolid 2-4 2 4 
Augmentin 0.5-64 4 32 
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Antibiotics 
Ejcl = Ejaecalis, Ejcm = Ejaecium 
In this study, as expected, ciprofloxacin resistance, besides the gentamicin resistance , 
was more common ( 36 Ejaecalis and 14 Ejaecium with each MIC >256rng/l ). Both 
Ejaecalis and Ejaecium were sensitive to teicoplanin in agreement with the findings by 
Cercenado et al, 2001. All the isolates were found to be sensitive to linezolid in 
agreement offmdings by Eliopoulos et al, 2002. Both Ejaecalis and Ejaecium were 
found to be moderately resistant to moxifloxacin (MIC =32mg/1 ). Ejaecium isolates 
were more resistant to piperacillin than Ejaecalis. Both Ejaeca/is and Ejaecium were 
found to be moderately sensitive to vancomycin in agreement with the findings of 
Cercenado et a/,200 1. Both Efaecium and Ejaecalis were found to be moderately 
resistant to synercid (MIC=32mg/l for Ejaecium and MIC=64mgll for Ejaecalis). 
However, Ejaecium were found to be more resistant to tazocin than Ejaecalis and also 
Efaecium were found to be more resistant to augrnentin than Ejaecalis. The 
characteristics of Ejaecium isolates being more resistant to jJ-lactam drugs than 
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Efaecalis appear to reflect the intrinsic resistance of Efaecium to the drugs. Ln this 
study, isolates with MICs >256mg/J (ie 512mg/1) were regarded as HLGR and those 
with MICs 8mg/l to <256mg/l were regarded as Moderately resistant to gentamicin ( 
MLGR) in line with the findings of other researchers (Traub et al, 1993; Bantar et 
a/,1993; Ferrara et al,1996; Kao et al, 2000 ). The high-level gentamicin resistance (MIC 
2: l OOOmg/1 ) was first reported in France in 1979 ( Horodniceanu et al, 1979 ). This 
resistance is often associated with the production of a bifunctional enzyme that confers 
resistance to aminoglycosides except streptomycin ( FetTetti et al, 1986 ). But in 
streptomycin, adenyltransferase enzyme which causes the resistance to isolates is 
produced by HLGR strains in addition to the bifunctional enzyme. Fifty-five Ejaecalis 
were found to be resistant to gentamicin (MICso=64mg/l and MIC9o =256mg/l; range 32-
>256mg/l;Breakpoint = 4mg/l ). 26 E.faecium were also found to be resistant to 
gentamicin (MICso = 128mg/1 and MIC9o = 256mg/1; range 128- >256mg/l; breakpoint 
=4mg/l ). Both Efaecalis and Efaecium were highly sensitive to teicoplanin ( MIC50 
=<0.25mg/l and MIC9o =0.5mg/l; breakpoint =2mg/l for Efaeclis; MICso =<0.25mg/l 
and MIC9o = 1 mg/1 for Efaecium; breakpoint =2mg/l). All the isolates were sensiti ve to 
vancomycin ( MlC50 =4mg/l and MIC90 =8mg/l; breakpoint =4mg/l ). Some Isolates 
were resistant to ciprofloxacin ( MIC5o =4mg/l and MIC9o = >256mg/l; range <0.25-
>256mg/l; breakpoint =2mg/l for Efaecalis and for Efaecium MlCso =8mg/l and MIC9o 
= >256mg/l; range 0.5 - >256mg/l; breakpoint =2mg/J ). Some isolates were moderately 
resistant to moxifloxacin ( MIC50 =4mg/l and MIC90 =32mg/l; range <0.25 -64mg/l; 
breakpoint =4mg/l for Efaecalis while E.faecium had MIC5o =2mg/1 and MIC9o =32mg/l; 
range <0.25- 64mg/1; breakpoint =4mg/1 ). Some isolates were also moderately resistant 
to amoxicill in (for E fa ecalis MIC50 =2mg/1 and MIC90 = 16mg/l; range 0.5 -32mg/l; 
breakpoint =4mg/l and E.Jaecium had M1C50 =4mg/1 and MIC90 =32mg/l; range 0.5 -
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32mgll; breakpoint =4mg/l ). Some isolates, particularly among the E.faeciwn, were 
highly resistant to Piperacillin (MIC5o = 2mg/l and MIC9o =256mg/l; range 1 - 256mg/l; 
Breakpoint =4mg/l). Efaecalis were slightly resistant to piperacillin ( MIC5o=2mg/1 and 
MIC9o =8mg/l; range 1 -16mg/l; breakpoint =4mg/l ). Some isolates were moderately 
resistant to augmentin (E.faecium had MIC5o =4mg/l and MIC9o =32mg/l; range 0.5 -
64mg/l; breakpoint =4mg/l and Efaecalis had MIC50 =4mg/l and MIC9o =8mg/l; range 
0.5-32mg/1; breakpoint =4mg/l). Some isolates appeared to be highly resistant to tazocin 
( E.faecalis MIC5o =4mg/l and MIC9o =16mg/1; range 1 - 32mg/l; breakpoint =4mg/l. 
For E.faecium M IC50 =4mg/l and MIC90 =256mg/1; range 4->256mg/l; breakpoint =4mg/1 
). All isolates were found to be sensitive to linezolid (Zyvox ) ( MIC5o =2mg/l and MIC9o 
=4mg/1; breakpoint =2mg/l ). All isolates were moderately resistant to synercid ( MICso 
=8mg/l and MIC90 =32mg/l; range 4 - 64mg/l; breakpoint =2mg/l for E.faecium and 
MIC50 = l6mg/1 and MIC90 =64mg/l; range 4 - 128mg/1; breakpoint =2mg/l for E.faecalis. 
4.1.2 Nitrocefin testing for f3-lactamase production by Isolates 
Resistance to ~-lactam drugs is a major problem and the resul ts show some resistance 
in these populations [Fig 4.1(a) and (b)]. It has also been found that some E.faecalis 
strains with high-level gentamicin resistance were also ~-lactamase producers 
(Hindes el al, 1989; Patterson et al, 1988 ). Therefore it was necessary to test the 
isolates by using nitrocefin. Nitrocefin is yellow normally but when the ~-lactam 
ring is hydrolysed, it turns red. However, since nitrocefin is a substrate that can be 
read ily hydrolysed by P-lactamase, it provides a sensitive method of detecting ~­
l.actamase. Based on the MICs results of susceptibility test in section 4 .1. 1, 81 
isolates were tested against ~-lactamase production and was found that none of 
the isolates was a ~-lactamase producer. 
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4.2 Antimicrobial Combinations and Synergism In. Vitro agar method 
The effect of in vitro antimicrobial agents combinations against Enterococcus 
isolates was investigated by the agar dilution method with combinations of two drugs 
in attempts to enhance biological effects. There is also a general concept that by 
employment of the two drugs, it allows lower doses of each drug to be used so that 
undesirable toxic side effects would be reduced . Alternatively, the combinations 
could take advantage of the separate effects of each either by the spread of onset of 
one drug and the prolonged dw·ation of the other or simply to overcome resistance. 
The emphasis of combinations is not only to enchance biological effects (Synergy) but 
also to use in the treatment of serious infections such as meningitis before laboratory test 
and in the mixed infections ( Jawetz eta/, 1952; Moellering et al, 1971; Simmons, 1975; 
Berenbaum, 1978; Rahal , 1978; Lambert et al, 2003 ). The use of antimicrobial 
combinations to achieve in vitro activity and clinical efficacy against organisms resistant 
to drugs continues to be the subject of intensive investigation and is still a matter of great 
clinical debate. It should also be noted that certain combinations of agents may yield 
antagonistic effects (Lepper and Dowling,1951; Moellering,1983) The combinations of 
some antimicrobial agents (Table 2.2) were tested against all isolates to establ ish 
possible synergism. The results are shown as at MICsso and MICs9o {Table 4.2 (a) and 
(b); Fig 4.2 (a) & (b) 
4.2.1 Combination of ~-lactam with Aminoglycoside by agar method 
The combination of amoxicillin at a fixed concentration of 16mg/l each in each of the 
serial two-fo ld dilution of gentamicin ranging 0.25-256mg/1 was based on the method in 
section 2.2.5.1 and was done in order to establish synergistic activity of the combined 
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drugs against 81 isolates. The results show that there was more than four-fold reduction 
in the MIC of the combined drugs as compared with the MIC of the single drug alone 
[Table 4.1 (a) & (b); Fig 4.2 (a), (b)]. The original observation that penicillin combined 
with aminoglycoside (Streptomycin) resulted into synergism was in 1947 (Hunter, 
1947 ). However, several investigators have demonstrated a synergistic effect of 
penicillin or other ,8-lactam drugs to various aminoglycosides including gentamicin ( 
Calderwood et al, 1977; Moellering et a!, 1971; Weinstein and Lentek, 197 6 ) . In this 
study, the combination of amoxicillin and gentamicin revealed the four-fold reduction in 
the MIC of the combined drugs showing the synergistic activity of the two drugs and 
confirmed the fmdings of other investigators (Basker and Sutherland, 1977; Russell and 
Sutherland, 1975). 
4.2.2 Combination of Aminoglycoside with Glycopeptide by agar method 
Vancomycin at a fixed concentration of 4mg/l each was combined with each of the serial 
two-fold dilution of gentamicin ranging 0.25-256mg/l using the method in section 2.2.5.1 
to show the synergistic activity of the combined drugs against 81 isolates. The results 
indicate that there was more than 4-fold reduction in the MlC of the combined drugs 
compared withMIC of single antibiotic alone (Table 4.1 (a) & (b)). Vancomycin is a 
cell-wall active agent which can enhance the entry of aminoglycoside such as gentamicin 
into enterococcal isolates (Moellering and Weinberg, 1971 ) resulting in production of 
synergism when combined with aminoglycoside. The four-fold reduction in the MIC of 
the combined drugs showed the synergistic activity against the isolates. 
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4.2.3 Combination of Streptogramins and Glycopeptides by agar method 
4.2.3.1 combination of Teicoplanin and Synercid 
Teicoplanin at a fixed concentration of 2mg/l each against Efaecalis and 0.5mg/l each 
against Efaecium was combined with each of the serial two-dilution of synercid based on 
the method in section 2.2.5.1 in order to demonstrate the synergistic activity of the 
combined drugs against 81 iso.lates. Since Efaecalis is more resistant to synercid (MIC 
range 4-128mg/l) than Ejaecium (MIC range 4-64 ), different fixed concentrations of 
teicoplanin indicated above had been selected for the test based on the sensitivity of both 
species against the teicoplanin. The results showed reduction of more than 4-fold in the 
MIC ofthe combined drugs as compared with MIC of single antibiotic alone [Fig 4.2 (a) 
& (b) Table 4.1 (a) & (b)].Teicoplanin is a cell-wall active drug; while synercid binds to 
the 50s ribosomal subunit resulting in inhibition of protein synthesis. Perhaps teicoplanin 
also enhances the entry of synercid into bacterial cell-wall; thus, the combined action of 
the two drugs resulted into synergy. Hill eta!, 1997, established the synergistic activity 
ofthe two drugs which resulted into the reduction of more than 4-fo ld in the MlC of the 
combined drugs against isolates. This finding agreed with the result of this study with 
respect to the reduction of more than four-fold in the MIC of the combined drugs in li ne 
with others findings indicating the synergistic activity of the two drugs. 
4.2.3.11 Combination of Synercid and Vancomycin 
The combination of vancomycin at a fixed concentration of 4mg/l each with each of two-
fold serial dilution of synercid range 0.25-256mg/ l to establish the synergistic activity of 
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the combined drugs against 81 isolates using the method in section 2.2.5.1. The results 
showed no or little reduction in MIC of the combined drugs as compared with MIC of 
single drug alone. Vancomycin is a cell-wall active agent; while synercid acts on 50s 
ribosomal subunit resulting in inhibition of protein synthesis. Hill et al, 1997 could not 
find the synergistic activity of the combination of the two drugs since there was no 
reduction in MIC of the combined drugs significantly. These findings agreed with the 
results of this study which found no significant reduction in the MIC of the combined 
drugs. This is an indication of antagonistic activity of the two combined drugs 
4.2.4 Combination ofFluoroquinolone and Glycopeptide by agar method 
Teicoplanin at a fixed concentration of4mg/1 each was combined with each oftwo-fold 
serial dilution of ciprofloxacin range 4-256mg/1. The test did not include the sensitive 
isolates against c iprofloxacin with MlCs range of <0.25-2mg/l because they were 
considered sensitive against the ciprofloxacin. The method used in the test was indicated 
in section 2.2.5.1 to demonstrate the synergistic activity against isolates. The results 
showed reduction ofmore than 4-fold in the MIC of the combined drugs as compared 
with single antibiotic alone (Fig 4.2 (a) & (b); Table 4.1 (a) & (b). Teicoplanin acts on 
the cell wall of the bacteria; while ciprofloxacin inhibits bacterial activity by interacting 
with type II topoisomerase (gyrA) and topoisomerase IV (parC) ( Shen et al, 1989) of 
the bacterial DNA; this combination results into synergy. The combination of the two 
drugs in this study resulted in more than four-fold reduction in the MIC of the combined 
drugs indicating the synergistic activity of both drugs 
4.2.5 Combination of Streptogramins and ~-lactam by agar method 
Amoxicillin at a fixed concentration of 4mg/l each against Efaecalis and 2mg/l each 
against Efaecium was combi11ed with each of the serial two-fold di lution of synercid 
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range 4-128mg/1 based on the method in section 2.2.5.1 to show the synergistic activity 
of the combined drugs against isolates . Different fixed concentrations as above for 
synercid were selected based on the sensitivities of the isolates (Efaecalis MIC range 4-
128mg/1 and Efaecium range 4-64mg/l) against the drug. The results showed that there 
was a 4-fold reduction in the MIC of the combined drugs as compared to MIC of single 
drug alone (Table 4.1 (a) & (b) synercid binds to tbe 50s ribosomal subunit of the 
bacterial DNA resulting into inhibition of protein synthesis. In this study, the 
combination of both drugs resulted in the reduction of the MIC of the combined drugs of 
more than four-fold . This result shows the synergistic activity of both drugs 
4.2.6 Combination Fluoroquinolooe and Streptogramins by agar method 
Synercid at a fixed concentration of 8mg/1 each was combined with each of the serial 
two-fo ld dilution of ciprofloxacin range 8-256mg/ l against Efaecium based on the 
method in section 2.2.5.1 to demonstrate the synergistic activity ofthe combined drugs 
against isolates. Isolates sensitive to ciprofloxacin range <0.25-4mg/ l were excluded 
because of their sensitivity against the ciprofloxaci n. The results showed the reduction of 
4-fold in the MIC of the combined antibiotics as compared with the drug alone (Table 
4.1 (a) & (b)). Efaecalis isolates were not tested against the combined drugs because 
Efaecalis is intrinsically resistant to synercid. Ciprofloxacin acts on both gyrA and parC 
of the bacterial DNA and synercid binds to 50s ribosomal subunit ofthe bacterial DNA 
and inhibits protein synthesis. The combination of both drugs by Hill et al, 1997 resu lted 
into synergism. A similar combination of both drugs against 26 Efaecium isolates in this 
study resu lted in more than a four-fold reduction in the MIC of the combined drugs. This 
indicates synergistic activity of both drugs, thus agreeing with the findings by Hill eta!, 
1997. 
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Table 4.2 Combined Antibiotics at MIC5o and MIC9o for E.faecalis and E.faecium 
(a) Enterococcus faecalis 
Antibiotic MIC Range (mg/1) MICso 
Amox*/Gent <0.25-1 <0.25 0.5 
Teico*/Syn <0.25-0.5 <0.25 0.5 
Teico*/Cip <0.25-<0.25 <0.25 <0.25 
Vanc*/Gent <0.25-32 1 2 
Amox*/Syn <0.25-16 0.5 4 
Vanc*/Syn 8-64 16 32 
Syn*/ Cip 1-64 8 64 
*=Fixed Concentration of Antibiotic (Amox= l6mg/l, Teic=2mg/l, Van=4mg/l). 
(b) Enterococcus faeciwn 
Antibiotic MIC Range (mg/1) MICso 
Amox*/Gent <0.25-4 0.5 2 
Teico*/Syn <0.25-0.5 <0.25 0.5 
Teico*/Cip <0.25-<0.25 <0.25 <0.25 
Vanc*/Gent <0.25-2 0.5 1 
Amox*/Syn <0.25-8 0.5 4 
Vanc*/Syn 4-64 8 16 
Syn*/ Cip <0.25-8 2 4 
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4.3 Synergy testing of the combined antimicrobial agents by Checkerboard 
method 
The Checkerboard technique is probably the test most frequently used for analysis of 
interaction between the antibiotics (Holm, 1986 ). Beerenbaum in 1978, proposed a 
mathematical way to describe the results of checkerboard test which he had called 
fractional inhibition concentrations ( FIC) index. He gave the value ofFIC index o£0.5 
to mean synergism while 2:1 wouJd indicate additive or indifferent effect of the combined 
drugs and >2 would mean antagonism. The FIC method allows a more objective analysis 
of the result than the mere drawing of isobologram lines and therefore widely used 
(Holm, 1986 ). The selection of the isolates used in this investigation was based on the 
fact that all the isolates ( Efaecium and Efaecalis) collected from RIE were sensitve to 
glycopeptide drugs but resistance to gentamicin and therefore, there was a need to use 
isolates with resistance to both gentamicin and vancomycin to establish synergy. Thus 
resulted in getting some isolates with vanB type of resistance from Dundee for the test. 
In this study, Owing to the labotious work involves in using the checkerboard agar 
dilution method to assess synergistic activity of the combined antimicrobial agents 
against isolates, only three strains and the control NCTC12202 of vancomycin-resistant 
Efaecium were tested against the combination of ciprofloxacin and synercid. It involved 
measuring the MIC of each drug for each isolate by doubling agar dilution and then the 
known MIC for each drug was fine-tuned by re-measuring in an arithmetical progression. 
The MIC was taken as fractional inhibitory concentration (FTC) of 1.0 for each antibiotic. 
Agar plates containing mixture of both drugs were made up. The plates were inoculated 
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with isolates using a multiple inoculating device (Denley A400) yielding final inocula 
of approximately 104 CFU per spot. The plates were examined for growth or non growth 
after 24 hours of incubation at 37°C. The resu lts showed isolates had the following FIC 
indices: D002= 0.4, G051= 0.4, 788/5/905=0.3 and NCTC12202= 0.3 (see also Figs 4.3 
, 4.4, 4.5, 4.6 and Table 4.3 ). These results are in complete agreement with what 
Beerenbaum had proposed in 1978 with respect to synergism. The results confirm the 
existence of synergistic activity of the two drugs against four strains of Efaecium. 
However, the correlation between the FIC indices of these unrelated strains and the in 
vitro agar dilution data suggest that synergy between the two combined drugs might be 
common in enterococci. The clinical efficacy of the combinations and the conlTibution 
of the synergistic activity have yet to be proven clinically. 
Table 4.3 FIC of Checkerboard and Types of Resistance-E.fttecium 
Isolate # FIC Types of Resistance 
D002 0.4 VanB 
G051 0.4 VanB 
788/5/95 0.3 VanB 
NCTCI2202 0.3 Sensitive 
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Fig 4.3 Fractional Inhibitory Concentration for E.faecium D002 
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Fig 4.5 Fractional Inhibitory Concentration for E.faecium 788/5/95 
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4.4 Synergy testing of the combined antimicrobial agents by Time-Kill Curves 
method. 
The time-ki II curves technique measures the microbicidal activity of the combination 
being tested. It is presumably more relevant for clinical situations in which bactericidal 
therapy is desirable. It also provides a dynamic picture of antimicrobial action and 
interaction over time based on serial colony counts. However, the procedure is tedious 
and laborious. The selection of the isolates (17 Efaecium and 22 Efaecalis) used in the 
investigation was based on their MICs {Table 4.4 (a) & (b)} and also limited financial 
resources available. The experiment was performed with a final inoculum of 105 to 107 
cfulml produced by diluting an overnight culture growth of each isolate in BHI broth and 
adjusting to logarithmic-phase culture; then diluted a second time in fresh BHI broth and 
added appropriate amounts of antimicrobial agent(s) in each tube. The initial sampling 
for colony counts was done as soon as antimicrobial was added in each tube by removing 
0.1 ml from each tube and diluting with saline in series of marked tubes (1 o·l' l 0"2' 
10"3and 104 ) to make 10 fold dilution for each tube. Using the sterile pipette, dropped 
approximately 20111 of each 10 fold dilution in each corner of a triangle marked on the 
bottom of each BHIA plate (i.e a total of three drops per triangle for each concentration 
of 10 fold dilutions for a single sterile pipette). The plates were incubated at 37°C for 24-
48 hours. Colony counts was done based on the colony growth shown in Fig 4.7 (e.g at 
concentration of 10·4 dilution for Contro l Iso late at 8 hours). Whi le Fig 4.8 showed no 
growth for the combined antibiotics (eg, gentamicinlamoxicillin) at 24 hours. Time-kill 
curves log10 graphs for 22 Efaecalis and 17 Efaecium with gentamicin, synercid, 
vancomycin, teicoplanin, ciprofloxacin and amoxicillin in various combinations 
including alone are shown in Figs 4.9-4.32 and appendix B. Bactericidal synergy was 
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defined as the killing of at least 2 log10 CFU/ml in comparison with most active single 
drug. In this study, There was a 2 log decrease at 8 how- of the combined amoxicillin 
(8mg/l) and gentamicin (64mg/l) against isolates ( 17B/235, 17B/72 1 and 18B/234-
Efaecium) and isolates (17B/407 and 18B/309-Efaecalis) indicatng synergistic activity 
of the combined antibiotics (Figs 4.9--4.13). However, regrowth occurred as shown in 
Figs 4. 9, 4.11 and 4.13 at 24 hour for amoxicillin alone. When combined teicoplanin 
(2mg/1) and synercid (64mg/1) against isolate (18B/254-Efaecium), there occurred a 2 
log10 decrease at 8 hour and a complete killing of bacteria at 24hour (Fig 4.14) indicating 
synergistic activity. Teicoplanin alone had regrowth at 24 hour (Fig 4.14 ). The 
combination ofteicoplanin (2mg/l) with synercid (64mg/l) against isolate (l7B/686-
Efaecalis) resulted in a decrease of2 log at 8 hour and the occunence of complete 
killing ofbacteria at 24 hour (Fig 4.15) and regrowth ofteicoplanin at 24 hour (Fig 4.15). 
The combination of synercid (32mg/l) and amoxici !lin (8mg/l) against isolate (18B/960-
E.faecium) resulted in a decrease of2 log at 8 hour and a complete killing of bacteria at 
24hour (Fig 4.16). There was regrowth ofamoxicillin at 24 hour. Since isolate 
(19B/39 1-Efaecium) had MICs for both synercid and amoxicillin at 64 mg/1, test was 
made first at 32mg/l for synercid combined with amoxicillin (8mg/l) resulting in a 2 log 
decrease CFU/ml and a complete killing of bacteria at 24 hour (Fig 4.17) and regrowth 
occurred at 24 hour. Combination of synercid (64mg/l) with amoxicillin (8mg/l) against 
isolate (18B/376-E.faecalis) resulted in a 2 log decrease at 8 hour and a complete isolate 
being killed at 24 hom (Fig 4.18). Regrowth of amoxicillin occmTed at 24 hour. Since 
isolate (18B/309-Ejaecalis) had MICs of32 mg/1 for each amoxicillin and synercid, test 
was first done with combination of synercid (16mg/1) with amoxicil lin (8mg/l) which 
resulted in a 2 log decrease in CFU/ml at 8hour (Fig 4.19). Then the reverse was done ( 
i. e 16mg/l for amoxicillin and 8mg/l for synercid) but there was not much difference. 
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Ciprofloxacin (64mg/l) combined with synercid (8mg/l) against isolate (I 8B/294-
E.faecium) had 2 log decrease at 8hour and a complete killing ofthe bacteria at 24 hour ( 
Fig 4.20) and regrowth occtmed at 24 hour. Similarly, when ciprofloxacin (64mg/l) 
was combined with synercid (16mg/l) against isolate (18B/5 1 7-E.faecium), a 2 log 
decrease occurred at 8 hour with a complete killing of bacteria at 24 hour ( Fig 4.21 ) and 
regrowth of synercid occurred at 24 hour. Combination of ciprotloxacin (64mg/1) with 
synercid (8mg/l) against isolate (I8B/414-E.faecalis) resulted in the decrease of2 log10 at 
8 hour and a complete killing of bacteria at 24 hour (Fig 4.22). Regrowth for synercid 
occurred at 24 hour. When ciprofloxacin ( 4mg/l) was combined with synercid (32mg/l) 
against isolate (18BI745-E.faecalis), a 2 log decrease occurred at 8 hour with a complete 
bacterial death at 24 hour (Fig 4.23). Combination of vancomycin (8mg/l) with 
gentamicin (64mg/l) against isolates (18B/314 and 18B/578-E.faecalis) resulted in 2 log 
decrease for each combination at 8 hom and a complete killing of bacteria at 24 hour 
(Figs 4.24 and 4.25 respectively) and regrowth occurTed at 24 hour for vancomycin (Fig 
4.25). When vancomycin (64mg/l) was combined with gentamicin (16mg/l) against 
isolate (G05I-E.faecium), a 2 log decrease occmred at 8 hour with complete killing of 
the bacteria at 24 hour (Fig 4.26). Combination of gentamicin (64mg/l) with 
vancomycin (4mg/l) against isolate (1 8B/33-E.faecium) resulted in a 2 log decrease with 
a complete killing of bacteria at 24 hour (Fig 4.27). Combination of teicoplanin (2mg/l) 
with ciprofloxacin (64mg/1) against isolate (19B/471-E.faecium) resulted in a 2 log 
decrease at 8 hour and a complete killing ofbacteria occurred at 24 hour (Fig 4.28). 
Similarly, combination of teicoplanin (2mg/l) with ciprofloxacin (64mg/1) against isolate 
(19B/412-E.faecalis) resulted in a decrease of2 log1o at 8 hour and a complete death of 
bacteria occurred at 24 hour (Fig 4.29) and regrowth in teicoplanin occurred at 24 hour. 
However, combination of vancomycin (8mg/l) with synercid (64mg/l) against isolates 
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(18B/487 and 18B/506-Ejaecium) resulted in a 2 log increase for each combination at 8 
hour. This indicated antagonistic activity of the two antibiotics (Figs 4.30 and 4.31 
respectively) and regrowth occurred at 24 hour for vancomycin. When vancomycin 
(4mgll) was combined with synercid (16mg/1) against isolate (18BI79l-Ejaecalis), there 
was also increase of2 logs at 8hour (Fig 4 .32). Again, it indicated antagonism of the 
antibiotic combinations and regrowth occurred at 24 hour for vancomycin. 
Fig 4.7 Arrangement for drops of 10 fold dilution in triangles marked and colony 
growth on BHIA plate at 24 hour indicated by Yellow arrows in a triangle for 
counting CFU/ml 
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Fig 4.8. YeUow arrow indicates no colony growth at 24 hours for combined 
antibiotics ( eg Gen/ Amo) 
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Table 4.4 (a) & (b) MJCs (mg/1) for enterococci ( E.faecalis & E.faecium) used in 
Time-kill Curve Technique 
(a) 22 E.faecalis 
Isolate # Genta Syner Vanco Teico Cipro Amoxi 
-------------------------------------------------------------------------------------------
17B/407 >256 64 8 1 >256 1 
17B/452 >256 32 4 1 >256 1 
17B/686 >256 128 8 0.5 >256 1 
17B/761 64 64 4 1 >256 4 
17B/819 128 64 4 <0.25 >256 4 
18B/89 256 128 4 2 >256 4 
18B/309 128 32 8 1 0.5 32 
18B/329 64 32 4 1 0.5 4 
18B/337 >256 128 8 1 >256 4 
l8B/358 >256 128 .8 1 >256 2 
18B/376 >256 128 8 >256 0.5 
18B/379 >256 128 8 >256 4 
18B/382 64 32 8 0.5 2 
18B/387 64 32 8 1 0.5 0.5 
18B/390 >256 64 4 1 >256 4 
18B/414 >256 128 4 1 >256 4 
18B/506 >256 128 4 1 >256 4 
18B/555 128 64 4 1 0.5 4 
18B/578 >256 64 4 0.5 >256 1 
18B/745 64 64 8 0.5 0.5 0.5 
18B/791 64 32 4 <0.25 0.5 1 
19B/412 128 64 4 0.5 >256 4 
Genta= gentamicin, Syner- synercid, Vanco= vancomycin, Teico= teicoplanin, 
Cipro=ciprofloxacin and Amoxi= amoxicillin. 
97 
(b) 17 E.faecium 
Isolate # Genta Syner Vanco Teico Cipro Ammci 
--------------·- ·----------·-----·-------·-·--·--·--·----·---------------------
17B/235 >256 8 4 1 >256 16 
17B/721 256 16 4 1 64 1 
17B/849 >256 8 4 0.5 0.5 16 
18B/33 >256 8 4 1 0.5 16 
18B/234 256 16 8 1 >256 64 
18B/254 >256 128 8 I >256 0.5 
18B/294 >256 32 8 1 >256 32 
18B/298 128 32 4 I 0.5 4 
18B/487 >256 128 8 1 8 32 
18B/517 256 8 8 1 >256 32 
18B/632 256 8 4 1 >256 32 
18B/749 >256 4 4 2 0.5 1 
18B/960 >256 64 4 <0.25 >256 1 
19B/391 256 64 4 0.5 >256 64 
19B/471 >256 64 4 0.5 >256 1 
D002 32 4 32 2 16 8 
G051 32 4 >256 2 8 16 
Genta= gentamicin, Syner= synercid, Vanco= vancomycin, Teico= teicoplanin, Cipro= 
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Fig 4.9 Kinetic kill curves of E.faecium (17B/235) exposed to gentamicin (64mg!l) 
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Fig 4.10 Kinetic kill cu rve of E.faecium (lSB/234) exposed to gentamicin (64mgll) 
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Fig 4.11 Kinetic kill curves of E.faecium (17B/721) exposed to gentamicin (64mgll) 
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Fig 4.12 Kinetic kiJJ curves of E.faecalis(l1B/401) exposed to gentamicin (64mgll) 
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Fig 4.13 Kinetic kill Curves of E.faecalis (lSB/309) exposed to gentamicin (64mgll) 
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Fig 4.14 Kinetic kill curves of E.faecium (18B/254) exposed to synercid (64mgll) 
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Fig 4.15 Kinetic kill curves of E.faecalis (18B/686) exposed to synercid (64mgll) 
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Fig 4.16 Kinetic curves of E.faecium (18B/960) exposed to synercid (32mg/l) 





















Fig 4.17 Kinetic curves of E.faecium (19B/391) exposed to Synercid (32mg/l) 
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Fig 4.18 Kinetic curves of E.faecalis (18B/376) exposed to synercid (64mg/l) 
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Fig 4.19 kinetic curves of E.faecalis (18B/309) exposed to synercid (16mg!l) 
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Fig 4.20 Kinetic curves of E.faecium (ISB/294) exposed to ciprofloxacin (64mgll) 
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Fig 4.21 Kinetic curves of E.faecium (18B/517) exposed to ciprofloxacin (64mgll) 
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F ig 4.22 Kinetic curves of E.ftzecalis (lSB/414) exposed to ciprofloxacin (64mg/l) 
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Fig 4.23 Kinetic curves of E.faecalis (lSB/745) exposed to syoercid (32mg/l) 
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Fig 4.24 Kinetic curves of E.faecalis (18B/314) exposed to gentamicin (64mg/l) 
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Fig 4.25 Kinetic curves of E.faecalis (18B/578) exposed to gentamicin (64mg/l) 
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Fig 4.26 Kinetic curves of E.faecium (Ql51) exposed to vancomycin (64mgll) 
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Fig 4.27 Kinetic curves of E.faecium (18B/33) xposed to gentamicin (64mgll) 
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Fig 4.28 Kinetic curves ofE.Jaecium (19B/471) exposed to ciprofloxacin (64mg/l) 
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Fig 4.29 Kinetic curves of E.faecalis (19B/412) exposed to ciprofloxacin (64mg/l) 
combined witb teicoplanin (2mgll) 
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Fig 4.30 Kinetic curves of E.faecium (lSB/487) exposed to synercid (64mgll) 
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Fig 4.31 Kinetic curves of E.faecium (ISB/506) exposed to synercid (64mgll) 
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Fig 4.32 Kinetic curve of E.faecalis (lSB/791) exposed to synercid (16mgn) 
combined with vancomycin (4mgll) 






CHAPTER 5: Results-Identification of Resistance among the 
Strains against ciprotloxacin 
The purpose ofthis chapter is to identify, with the aid ofPCR technique, the 
mechanisms of resistance to ciprofloxacin in those strains shown to be resistant, based 
on the MICs results in section 2.2.3. eiprofloxacin was the first fluoroquinolone 
drug widely used in the clinical settings. 0Iiginally, it was developed for treatment 
of infections caused by gram-negative bacteria. Its activity against enterococci 
appears to be moderate but the resistance against quinolone drugs by enterococci is 
common among clinical enterococcal isolates. Quinolones inhibit bacteria by 
interacting with DNA gyrase A and topoisomerase IV, which are required by 
bacteria for replication. Quinolone resistance has not been as well studied in 
enterococci as compared to staphylococci and pneumococci. Kanematsu et al, in 
1998, found an Efaecalis isolate with a mutation in parC but not the gyrA gene with 
intermediate level of resistance to qui no lone but it had higher MIC than an E.faecalis 
with no pare or gyrA mutations. However, this isolate had lower Mie than 
Efaecalis isolate with mutation in both pare and gyrA . 
5.1 Identification of gyrA and parC Resistance among Isolates by PCR Method 
Resistance to quinolones appears to be due to mainly the alteration in the gyrA 
subunit of DNA gyrase or in the pare of topoisornerase TV ( Kanematsu et al, 1998 ). 
It has been demonstrated that qui no Iones resistance in Efaecalis is associated with 
alteration in gyrA ( Korten et af, 1994 ). Kanematsu et al, 1998, suggested in their 
findings that the alterat ion of gyrA and pare is associated with the development of 
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high-level fluoroquinolone resistance in the clinical isolates of E.faecalis. 
All the E.faecalis isolates (including those found with AME resistance gene -aac(6 ')-
aph(2 ") in Section 6.1) were selected for the investigation of the presence of gyrA based 
on Mie >256mg/l for each isolate. Freshly extracted DNA using Helena BioScience 
extraction kit from each isolate grown ovemight in BHI broth at 37°e based on Protocol 
in Section 2.2.1 0 was used as template for ampl ification with a set of primers for gyrA 
(Section 2.2,15). In many occasions, PeR products did not show any fragment when 
examined in agarose gel electrophoresis with the aid of a computer system. After several 
attempts, suddenly, there appeared fragments size in one group at 241 bp (Fig Sa) when 
examined in gel electrophoresis. The results showed that 4 isolates (18B/379, 18B/414, 
18B/911 and NeTe29212) had fragment size of 241 bp in agreement with the predicted 
fragment of the primers; but one isolate (18B/376) had faint banding at 241 bp. The 
experiment was repeated with the same group to get a good picture of the results in gel. 
Unfortunately, the saved gel pictures in the computer were lost when the computer got 
spoiled beyond repair. The repeat of the experiment with freshly extracted D Aas 
template resulted into observed fragment size of 24lbp in agreement with the predicted 
fragment of primers for 5 isolates when examined in gel electrophoresis (Fig 5.b). The 
results showed that three isolates ( 18B/314, 18B/390 and 18B/946) which had fragment at 
241 bp (Fig 5. b) were also found to have AME resistance aac(6 ')-aph(2 ") in section 6.1. 
NeTe29212 isolate was used as control. Six E.faecalis isolates (3 canying both gyrA 
and aac(6 ')-aph(2 ') resistant genes, one carrying only aac(6 ')-aph(2 ") and two carrying 
gyrA only ) were further selected for the investigation of pare among the isolates. 
Freshly extracted DNA from each isolate was used as template and amplification was 
performed with the primers for pare indicated in section 2.2.1 5. The examination of the 
PeR products in agarose gel electrophoresis with the aid of a computer system showed 
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that all the isolates hadparC type ofresistance with fragment at 191bp in agreement with 
the predicted fragment of primers. The fragments at 191 bp for all the isolates were 
further sequenced forparC mutation and the results shown in Table 5.1 and Section 5.2 . . 
Fig 5.1 (a) & (b) Diagrammatic representation of Gel electrophoresis PCR Products 
for gyrA 
(a) 
Lane-1 -DNA ladder-lOObp, lane-2-RTE-1 7b/407, lane-3-RIE-17B/452, Lane-4-RIE 
17B/686, lane-5-RIE-188/337, lane-6-RIE-18B/358, lane-7-RIE-188/376, lane-8-RIE-
18B/3 79, lane-9-RIE-18B/414, lane- I O-RTE-18B/911, lane-11-RIE-18B/946, lane- 12-
RlE-18B/976 and lane-13-NCTC29212. 
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(b) 
Lane- l -NCTC29212, lane-2-DNA ladder 1 OObp, lane-3-RIE- 178/452, lane-4-
RIE- 188 /390, lanc-5-RlE-188/314, lane-6-RlE-1 88/358, lane-7-RIE-188/946, 
Lane 8-RIE- 188 /976, lane-9-NCTC29212 
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Fig 5.2 Diagrammatic representation of Pe R Products of Gel-electrophoresis for 
pare 
Lane 1-ladder; lane 2-RIE-18B/314; lane-3-RlE-18B/376; lane-4-RIE-l8B/379; 
1ane-5-RIE-1 8B/390; Iane-6-RJE-18B/414; lane-7-RIE-18B/911 and lane-8-
NC TC29212 
5.2 Sequencing for pare From PeR products for E.faecalis 
The sequencing from the products such as PCR allows researchers to identify 
Mutation(s) that might have occmTed in the D A of a certain species whether bacteria 
or othetwise . The mutat ions in the DNA could be lethal or not, depending on the 
situation. However, the significance of the mutation in the bacterial DNA against a drug 
is important in that bacteria usually become resistant to such a drug and as a resu lt the 
treatment of a serious infection caused by such bacteria becomes difficult. The 
fluoroquinolone resistance in gram-negative organisms is associated with the mutations 
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in gyrA gene (subunit of DNA gyrase) or with a reduced accumulation of the drug. In 
gram-positive organisms, fluoroquinolone resistance can be associated with mutations in 
gyrA or pare (subunit oftopoisomerasel V). Although, ciprofloxacin is the drug used 
frequently in the treatment of infections caused by many gram-negative bacteria, it 
becomes inactive against the mutated bacteria. In this study, pare PCR products of 5 
isolates with Mies >256mg/1 against ciprofloxacin and one isolate sensitive to 
ciprofloxacin with Mie of 0.5mg/l (Table 5.2) were sequenced to establish the 
existence of pare mutations in their genes. The results show the existence of changes in 
their DNA with respect to pare. The Overall sequencing appears to be very good (Table 
5.1 ). Isolate RIE-18B/314 with lower Mie of 0.5mg/l had two changes at Ala-80-Val 
and Ala-85-Ala in its DNA sequence and no change in amino acid. However, Ala 
subsitituted Ser at position 80 and Val substituted Ile at position 80; whereas RIE-
18B/376 had three changes in its DNA sequences at Ser-80-lle, Ala-85-Ala and Val-87-
Val and only one amino acid mutation occuned (Ser-80-De). RIE-18B/379 had the 
change at Ser-80-Ile, Ala-85-Ala and Val -87-Val with one amino acid mutation (Ser-80-
Ile) while RIE-18B/390 had three changes at Ser-80-Ile, Ala-85-Aia and Val-87-Val and 
also only one amino acid mutation (Ser-80-Ile). RIE-18/414 had four changes in its 
DNA sequences at Ser-80-Ile, Ala-85-Ala, Val-87-Val and Glu-110-Asp with two amino 
acid mutations (Ser-80-Ile and Glu-110-Asp). RIE-18B/911 had mutation at Ser-80-Ile, 
Ala-85-Ala and Val-87-Val but only one amino acid mutation occurred (Ser-80-I1e). 
The partial sequence of Efaecalis parC gene obtained from GenBank nucleotide 
sequence database under the accession no. AB005036 was compared with sequences 
from test isolates (Table 5.1 ). Green capitals in resistant sequences indicate nucleotides 
and amino acids different from that of Efaecalis AB005036 and also some green capitals 
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were observed in AB005036 organisms indicating nucleotides and amino acids different 
from that of test organisms. 
Table 5.1 Amino acid changes in ParC of E.faecalis 
RIE-188/314 
101 110 120 130 140 150 
·--------·---------+---------+---------·---------· 3418-parC GACAGCAGTATTTATGAR6C6ATGGTCCGTCTAAGTCAAGACT66RAATT 
AB005036 GACAGTRGTATTTATGAAGCRATGGTCCGTCTAAGTCAAGACTGGAAATT 
Consensus GACAGcAGTRTTTATGAAGCaATGGTCCGTCTAAGTCAA.GACTGGAAATT 
151 160 170 180 190 200 
l--------·---------·---------+---------·---------1 3418-parC ACGGGAAGTRCTRRTTGRRATGCACGGAAACRACGGARGTATGGATGGCT 
AB005036 ACGGGRAGTACTARTTGRRATGCRCGGAAACARCGGAAGTATGGRTGGCG 
Cons ens us RCGGGRAGTRCTARTTGARRTGCACGGRAACRRCGGAAGTATGGRTGGCg 
RIE-188/376 
101 110 120 130 140 150 
·------+-------+--------+---------+---------· 3522-ParC GRCRTTAGTRTTTATGAAGCGRTGGTGCGTCTAAGTCARGACTGGRARTT 
AB005036 GACAGTRGTRTTTATGRRGCAATGGTCCGTCTRRGTCARGACTGGRAATT 
Consens us GRCRgTAGTRTTTATGARGCaRTGGTcCGTCTRRGTCARGRCTGGARRTT 
151 160 170 180 190 200 





101 110 1.20 130 140 150 
1--------·---------·---------·---------·---------l 3623-ParC GRCRTTRGTRTTTRTGRRGCGRTGGTGCGTCTRRGTCRRGRCTGGRRRTT 
A8005036 GRCAGTAGTATTTATGAAGCAftTGGTCCGTCTRAGTCAAGACTGGARATT 
Consensus GACftgTAGTATTTATGAAGCaATGGTcCGTCTAAGTCAAGACTGGftRRTT 
151 160 170 180 190 200 




















101 110 120 130 140 150 
l--------·---------·---------·---------·---------1 3827-parC GRCRTTRGTRTTTRTGRRGCGRTGGTGCGTCTRRGTCRRGRCTGGRRRTT 
88005036 GRCRGTRGTRTTTRTGRRGCRRTGGTCCGTCTRRGTCRRGRCTGGRRRTT 
Consensus GRCRgTRGTRTTTRTGRRGCaRTGGTcCGTCTRRGTCRRGRCTGGRRRTT 
151 160 170 180 190 200 




101 110 120 130 140 150 
·--------·---------·---------·---------+---------· 3960-parC GRCRTTRGTRTTTRTGRRGCGRTGGTGCGTCTRRGTCRRGRCTGGRRRTT 
RB005036 6RCRGTR6TRTTTRT6RRGCRRTGGTCC6TCTRRGTCRRGRCTGGRRRTT 
Consensus 6RCRgTRGTRTTTRTGRRGCaRT66TcCGTCTRRGTCRRGRCTGGRRRTT 
151 160 170 180 190 200 
·--------·---------·---------·---------·---------· 3960-parC RCGGGRRGTRCTRRTTGRRRTGCRCGGRRRCRRCGGRRGTRTGGRTGGCG 
RB005036 RC66GRR6TRCTRRTTGRRRTGCRC66ARRCRRCGGRR6TRTGGRT6GCG 
Consensus RCGGGRRGTRCTRRTTGRRRTGCRC66RRRCRRC66RRGTRTGGRT66CG 
Table 5.2 Susceptibility of E.faecalis against Ciprofloxacin 
Isolate # Resistant (MIC ) Sensitive (MIC) 
RIE-18B/314 - S ( 0.5mg/l) 
RIE-18B/376 R (>256mg/l) -
RIE-18B/3 79 R (>256mg/l) -
RIE-18B/390 R _( >256mg/I) -
RIE-18B/414 R (>256mg/I) -
RIE-18B/911 R (>256mg/l) -
R= Resistance, S= Sensitive 
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Chapter 6: ResultS-Identification of Aminoglycoside-Modifyiog 
Enzyme By PCR Method. 
This chapter focuses on plasmid or transposon-mediated enzymes involved in the 
resistance of enterococci (ie Efaecalis and Efaeciurn) against an aminoglycoside 
drug( gentamicin ). 
6.1 Detection of aac(6')-aph(2'') enzyme by PCR Metbod 
Resistance to aminoglycoside dntgs usually involves enzymatic modification of the 
drugs by aminoglycoside-modifying enzymes (AME) which are found in some 
plasmids or transposons (Ferretti et al, 1986). There are three classes of enzymes 
involved in the modification of the drugs: acetyltransferases (AACs), 
adenylyltransferases (ANTs) and phosphotransferases (APHs )(FetTetti et al, 1986). 
The first high-level gentamicin- resistant E.faecalis isolate was reported in France in 
1979 (Horodneceanu et al, 1979). It was confirmed in the subsequent studies that the 
resistance was due to the fusion of AAC(6 ')with APH (2") resulting i.nto bifunctional 
resistance enzyme with AAC(6 ) - AP H (2 " ) activities (Ferretti eta!, 1986). The 
gene aac(6 ')-le-aph(2 ")-Ia is responsible for encoding a bifunctional enzyme 
[ AAC(6 )-APH(2 ")] (Azucena et al, 1997; Tsai et al, 1998; Kao et al, 2000; Chow et 
a/, 2001). The gene is generally found on transposable elements such as Tn5281-like 
transposon found in Efaecalis (Hodel-Christian and Murray,l991). The studies by 
Simjee et al in 1999 found Tn5281 -like transposon to be present in Efaeciurn isolate as 
well. The three other aminoglycoside resistance genes present in some 
Enterococcus species are aph(2 ")-lc, aph(2 ")-1 b and aph(2 ')-1 d . These genes 
together with aac(6 ')-le-aph(2 ")-la gene eliminate the synergistic activities achieved 
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by combination of gentamicin with the cell- active antimicrobial agents such as 
ampicillin ( Tsai et all998; Kao et a/,2000 ). The mobile nature of these genes, 
permits intergenus transfer to the other gram-positive bacteria such as staphylococci 
as well, where it will result in the production of a high-level-gentamicin resistant 
organism (Thomas and Archer,l989 ). In order to detect the presence of AME resistance 
gene aac(6 ')-aph(2 ") among the isolates, Thirty-two Efaecalis and 20 Efaecium with 
MICs >256mg/l each for gentamicin were selected for the investigation with the aid of 
PCR teclmique as per section 2.2. 7 and Table 2.4. Freshly extracted DNA (using 
Helena Kits) from each isolate grown overnight on BHI broth at 37°C was used as 
template during the amplification with the pair of primers having the predicted fragment 
size of248bp. However, in each case, the PCR product did not yield any fragment 
observed in the aga.rose gel electrophoresis with the aid of a computer system. Attempts 
were made to optimize the PCR and repeated the experiment but without success. 
Therefore, another pair of primers (forward-5'-CAGGAATTTATCGAAA 
ATGGTAGAAAAG-3' and reverse 5'-CACAATCGACTAAAGAGTACCAATC-3') 
with predicted fragment size of 369bp was used in the amplification of the DNA 
sequence of the freshly extracted DNA for each isolate grown overnight at 37°C on BHI 
broth. The examination of the PCR product of the first amplification with the new pair 
of primers on agarose gel electrophoresis showed some iso lates ( 5 E.faecalis and 2 
E.faecium) with fragment size of369bp (Fig 6.lb) in agreement with fragment 
predicted in the primers above. The repeat of the experiment with the iso lates which had 
positive results (Fig 6.1 b) and another isolate (18B/900) which had not been amplified 
before and using the san1e procedure as above indicated that all the isolates had fragment 
size at 369bp (Fig 6.1 a) when examined in agarose gel electrophoresis and thus in 
agreement predicted in the primers above. Subsequent amplification of the D A of the 
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remaining isolates with the above primers and following the procedure as above yielded 
4 positive results (18B/976,18B/946, 18B/911 and 17B/452) (Fig 6.l(c)). Only 10 of32 
Efaecalis and 2 of20 Efaecium isolates were found to be harbowing aac(6')-aph(2 ") 
enzymes which showed high-level gentamicin- resistance among the isolates in this 
study [Fig 6.1 (a), (b) & (c)]. However, Multiplex PCR technique was used for the 
investigation of other aminoglycoside resistance genes that mediate resistance to 
gentamicin such as aph(2 ")-1 b, aph(2 '')-1 c and aph(2 ")-1 d among the isolates (32 
Efaecalis and 20 E.faecium) selected on the basis ofMICs >256mg/1 each. Unlike the 
standard PCR that uses single PCR primer pairs for each resistance gene in each reaction 
tube, this teclmique combines all three primer pairs of each resistance gene in a single 
PCR tube mixture for single reaction. In this study, 5j.!l of the freshly extracted DNA of 
each of the above isolates grown overnight on BHI broth at 37°C was used as template in 
the PCR mixture. The examination of the PCR products on gel electrophoresis showed 
no banding with any size of the resistance genes indicated in Table 2.4. Therefore, none 
of the isolates ( 32 Efaecalis & 20 Efaecium) harbours res istance gene shown in Table 
2.4 
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Fig 6.1 (a) Diagrammatic representation of Gel-electrophoresis PCR Products of 
AAC(6')-APH(2'') 
(a) 
Lane-1-DNA-ladder 1 OObp, lane-2-RIE-18B/294, lane-3-RIE-18B/298, lane-4-RIE-
18B/309, lane-5-RIE-1 8B/314, lane-6-RIE-18B/329, lane-7-RIE-18B/358, lane-8-RlE-
18B/390, lane-9-RIE-18B/900 
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Fig 6.1 (b) 
lane-1-DNA ladder-lOObp, lane-2-NCTC29212, 1ane-3-NCTC12202, lane-4-RIE-
18B/234, lane-5-RIE-18B/254, lane-6-RIE-18B/294, lane-7-RIE-18B/298, lane-8-RIE-
18B/309, lane-9-RIE-18B/314, lane-1 0-DNA ladder-1 OObp, lane-ll-RIE-18B/329,lane-
12-RIE-18/337, lane-1 3-RIE-18B/358, lane-14-RIE-1 8/376, lane-15-RIE-18B/379, lane-
16-RIE-18B/382, lane-17-RIE-18B/387, lane-18-18B/390, lane-19-DNA ladder- l OObp. 
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Fig 6.1 (c) 
1 2 3 4 5 6 7 8 9 10 11 12 13 -
' .. ...... -
- 4~--
Lane I-DNA A 1 OObp, Jane 2-RIE-17B/407, lane 3- RIE-17B/452, 
lane 4-RIE-17B/686,Lane 5-RIE-l?B/849, lane 6-RIE-18B/33 7, 
Jane 7-DNA A lOObp~ lane 8-RIE-18B/376, Lane 9-RIE- 18B/379, 
lane 10-RIE-l8B/387, Jane 1l -RIE-18B/414, lanel2-RIE-18B/487, 
Jane 13-RIE-18B/911 , 
bp 
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6.2 Screening of E.faecalis for Tn528J-Like Transposon by Long-PCR Method 
Since Hodel-Christian and Murray in 1991, identified enzymes aac(6 ) -aph(2 ' ) as 
being part of a transposon and designated it as Tn5281 , Long-PCR protocol was 
established to identify the presence ofTn5281 (Simjee et al, 2000) and other 
Transposon such as Tn4001 (Hodel-Christian and Murray, 1990, 1991). It is also 
documented that Tn5281 -like Transposon which harbours aac(6 )-aph(2 ") gene is also 
flanked by 1S256 sequences in inverse orientation. Therefore any PCR primer used as 
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f01ward primer would also anneal to the inverted IS256 sequence and in this situation, 
only a single IS256 primer was required for amplification reaction. In order to screen 
Efaecalis for the presence of Tn5281-like Transposon using L-PCR technique, seven 
Efaecalis isolates detected ( Section 6.1) to be carrying AME resistant gene- aac6 '-
aph2"were selected for the investigation. Freshly extracted DNA (using Helena 
BioSciences Kit) each from the seven isolates of Efaecalis grown overnight at 37°C in 
BHI broth were used in the amplification with a single primer (Section 2.8 ) based on the 
protocol of ABgene, Epsom, Surrey, UK. The examination of agarose gel electrophoresis 
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6.3 Detection of IS256 Elements from L-PCR Products with Restriction with 
BamH1 Enzyme 
Lyon et al in 1984, described IS256 as inverted repeats flanking the aac(6 ') -aph(2 ") 
bifunctional aminoglycoside modifying enzyme found in Staphylococcus aureus 
which was designated as Tn4001 transposon. In 1991, Hodel-Chritian and Murray 
were first to describe the Tn5281 which was flanked by inverted copies ofiS256. 
IS256 was also found to be involved in the mobility ofMLS8 and mercury resistance 
in addition to aminoglycoside resistance in Tn5384 (Rice et al, 1995). The products of L-
PCR of the seven Efaecalis isolates from Section 6.2 were further studies using restriction 
endonuclease BamHI desctibed by Dyke et al, 1992. The L-PCR Product of each of the 
seven isolates was incubated with BamHl restriction enzyme for four hours at 37°C. 
The examination of the agarose gel electrophoresis of the restricted L-PCR products of the 
seven isolates stained with Eth.bromide indicated the presence of the fragments at 468bp 
(Fig 6.3) as predicted in the primer. 
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Fig 6.3 Diagrammatic representation of Gel-electrophoresis of Restricted L-PCR 
Products for 1S256 
Lane I-DNA ladder- I kb, lane 2-RIE-18B/314, lane-3-RlE-188 /376, lane-4-RIE-188/ 
379.1anc-5-RlE- 188/390, Jane-6-RIE-188/414, lane-7-RI E- 188/9 11 and lane-8-
NCTC29212 
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Chapter 7 : Discussion 
Enterococci have emerged in the late part of 20111 century as a major cause of nosocomial 
colonization and infections in Europe as well as in USA. Whilst, within the enterococcal 
species, Efaecalis causes the majority ofhuman enterococcal infections while Efaecium 
accounts for 10% overall. The infections usually include abdominal wound infections, 
urinary tract infections, bacteraemia and endocarditis. However, the acquisition of 
resistance to multiple antibiotics including vancomycin, penicillin and arninoglycosides 
by enterococci has made these bacteria a major health problem and also contributes to 
their pathogenicity within the hospital settings. On the other hand, the use of antibiotics 
such as vancomycin and avoparcin in animal feed for growth promotion and infectious 
disease prophylaxis (Witte, 1998) may also contribute to prevalence of some multidrug-
resistant organisms harbouring plasmids and transposons through the food chain from the 
animal products although no evidence has been established. However, there has been 
controversy with respect to the use of avoparcin in animal feed which led to its 
withdrawal for use in livestock animal production within the animal husbandry and 
pharmaceutical industries in European union. The same kind of five-gene vanRSHAX 
resistance to avoparcin occurs in animals and can be transmitted zoonotically (Witte, 
1998). Many studies are addressing the level of relatedness of van A GRE of human and 
non-human areas. Since 1988, a rapid rise in the incidence of infections and 
colonizations with vancomycin-resistant enterococci (VRE) has been reported by 
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National Nosocomial infections survellance system (NNIS), 1999. This is a cause for 
concern since there is a lack of availability of antimicrobial therapy for the treatment of 
VRE infections and most VRE strains harbour resistance to multiple antibiotics such as 
gentamicin, ampicil1in and vancomycin which are often regarded as antibiotics of the last 
resort. The major concern is the transfer ofvancomycin resistance genes fromVRE to 
other gram-positive bacteria such as Staphylococcus aureus (i .e now called vancomycin 
resistant S.aw-eus) which is a serious public health concern (MMWR, 2000) because 
there are no good treatments for S.aureus strains with both MRSA and YRSA 
phenotypes. Enterococci are relatively resistant to P-lactams. Efaecium is inherently 
more resistant to penicillin than Efaecalis (Moellering et aL, 1979; Gordon et aL, 1992). 
However, the resistance to multiple antibiotics by enterococci has prompted the search 
for newer or combinations of antibiotics which may result into discovery of the most 
powerful antibiotic(s) to aliviate the problem of infections caused by the resistance 
organisms. The application of technique such as PFGE reveals heterogeneous population 
of bacteria within the hospitals unless the strains are associated with a defined outbreak. 
Bacterial diversity is thus at the root of any significant resistance mechanism. The 
diversity ofHLGRE and GRE isolates points to the disseminations of AME {e.g aac(6)-
Le-aph(2 ")-fa, aph(2") -lb, aph(2")-lc and aph(2 ")-ld} and Van A types of resistance 
respectively tbJ:ough transfer of plasmids and transposons. The investigations have 
turned into looking at the diversity ofTn5281 elements for AME and Tnl 546 elements 
for VanA respectively. It has also been documented that the combination of 
aminoglycoside with gylcopeptide or P-lactam resulting in the synergistic activity has 
helped to aliviate some problems of endocarditis although, high-level resistance to 
gentamicin has emerged in USA creating therapeutic problems for patients with serious 
infections such endocarditis which is usually treated with a cell-wall-active agent 
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combined with aminoglycoside (Murray, 1990). In this study, 52 Efaecalis and 21 
Efaecium isolates of gentamicin resistance were collected from RIE to gain some 
understanding of the combinations of antibiotics with aim of establishing synergistic 
acti vity based on the techniques such as Agar dilution, Time-kill curves and 
Checkerboard. In addition, isolates were examined with respect to acqu isition of AME 
resistance genes such as aac(6 ')-le-aph(2 ")-Ia, aph(2 "}-lb, aph(2 ")-lc and aph(2 ") -tel 
and also the presence of gyrA and parC mutations among the isolates against 
ciprofloxacin as well as PFGE technique for diversity among the isolates . 
7.1 The composition of Gentamicin-resistant Isolates Studied 
The composition ofthe gentamicin- resistant clinical isolates from RlE consists of 52 
Efaecalis and 21 Efaecium. Since Horodniceanu et al reported in 1979 the 
Efaecalis isolates with resistance to gentamicin with MIC ~ l6.000mg/l , high-level 
resistance to gentamicin involving both Efaecalis and Efaecium, has now been 
shown to be endemic to many regions of the USA and countries outside USA 
including Thai land, Japan, Italy, Chile, Greece and UK (Hoffman et al, 1987; 
Bendall et a/, 1991; Woodford et a/ 1993; Paparaskevas et al, 2000). Most of the 
enterococcal infections such as endocarditis, urinary tract infections, bacteraemia and 
intra-abdominal infections are caused by multi-drug resistant enterococci. Efaecalis 
is the most predominant in enterococca1 infections ( 80%) and I 0% being Efaecium 
Perhaps, this is an indication that Efaecalis is more virulent than E.faecium. In most 
cases, the collection of enterococcal isolates gathered to show gentamicin resistance 
which reflects the prevalence of either E.faecalis or E.faecium or both. For example, 
a total of 158 enterococcal isolated from AHEPA University Hospital in Greece 
during 1993-1994 had high- level gentamicin resistance with MIC >512mg/l 
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( Tsakris et al, 2001 ). 45.2% were found to beE.faecalis and 31.2% were found to 
be E.faecium. Similarly in a tertiary-care hospital in Athens, Greece, where a total 
of 55 E.faecalis and 21 E.faecium were obtained, 22% of E.faecalis had high-level 
gentamicin resistance ( MIC > 500 ) but none was found in E.faecium (Paparaskevas 
et al, 2000 ). However, the rate of enterococci isolates from teaching, associated 
teaching and district general hospital in UK in two consecutive years ( Oct, 1996 -
Jan, 1997 and Oct,l997 to Jan, 1998 ), showed increase in high-level resistance to 
gentamicin by E.faecalis with an increase fi:om 10.5% year 1 to 15.1% year 2, but an 
increase in high-level resistance to gentamicin for E.faecium was not significant ( ie 
12.8% year 1 to 22.5% year 2 ) (Andrews et al, 2000 ). In this study, 67% of 
gentamicin resistance organisms ( MIC range 32->256mg/l) were E.faecalis ; while 32% 
were E.faecium ( MIC range 128->256mg/l ). This agreed with other fmdings that the 
majority of gentamicin-resistant isolates are predominantly E.faecalis . The 
predominance of E.faecalis in enterococcal infection reflects the fact that 
E.faecalis may be efficient at acquisition of the resistant genes which are more 
virulent than E.faecium. However, the result ofthe MIC range of 128->256mg/l of 
this study may reflect the fact that E.faecium are more intrinsically resistant than 
E.faecalis. All the isolates in this study were speciated with the aid of 
API 20 Strep tests. They were identified as either E.faecalis or E.faecium or E.durans 
with the indication of strong certainty of the API profile showing excellent to good 
scores. Ling et al, 2002, had similar results when they used API 20 Strep test in 
their study with the scores of API profile showing an excellent to good in the 
identification of their enterococcal isolates they collected. In a similar study, Ling et 
a!, 2002, also identified 286 isolates ( ie 239 E.faecalis, 45 Efaecium, one 
E.gallinarum and one E.cassiflavus) using both API 20 Strep and PCR techniques. 
132 
However, commercially-available kits including API 20 Strep system appear not to be 
reliable in the identification of enterococcal species except for Efaecalis (Miranda et 
al, 1991; Monison et al, 1997; Ling et al, 2002 ). Although PCR could correctly 
identify clinically Efaecalis and E.faecium as in the case of Ling et al, 2002, in 
this study, the PCR could not reveal the difference between Efaecium and E.durans, 
which was identified by API 20 Strep method. Again, PCR method might not be 
suitable for use in routine clinical laboratories because of the special techniques and 
equipment required, and also not cost effective if only few isolates are tested at one 
time. However, under certain circwnstances such as testing for the presence of VRE, 
high-level gentamicin resistance or ~-lactamase producing enterococci, PCR could 
be used. As expected, cultural characteristics of some strains of enterococci on horse 
blood agar may show alpha-haemolysis or beta-haemolysis ( Ananthanarayan and 
Paniker, 1996 ). In this study, all E.faecium showed a -haemolysis; while E.faecalis 
had or showed a mixture of o.- and If-haemolytic characteristics on horse blood agar. 
The isolation of the coexistence of high-level resistance to aminoglycosides and beta-
lactamase production in rare strains of enterococci, particularly E.faecalis has been 
reported in USA in 1981 ( Murray and Mederski-Samoraj , 1983) and subsequently in 
Argentina and Lebanon. These strains had also high-level resistance to gentamicin . The 
spread of these strains is, of course, worri some because the spread of both high-level 
gentamicin resistance and fi- lactamase may be responsible for the elimination of synergy 
of the combined drugs for the treatment of serious infections by enterococci such as 
E.faecalis and Efaecium. In this study, based on the MICs of the P-lactam drugs used, it 
was necessary to establish the presence or absence of the fi-lactamase producing isolates 
in the isolates collected for the study. However, it tumed out that none of the iso lates was 
found to be a fi-lactamase producer. The isolates used for this study were also collected 
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on the basis of gentamicin resistance and are more likely to be multi-drug resistant than 
the enterococcal collection which are not specifically gentamicin resistance. 1t is 
therefore essential to establish antibiotic susceptibilities of the collected isolates. Lavery 
et a!, 1997, found in their retrospective study of enterococcal isolates that 2% were 
vancomycin-resistant but found that high-level gentamicin resistance was in the increase 
from 17% to 60% and that of ampicillin resistance from 22% to 51%, none was found to 
be a .8-lactamase producer. This study also found that none of the isolates was a /3-
lactamase producer but had high-level of gentamicin resistance as mentioned earlier. In 
this study, 69% of E.faecalis and 66% of E.faecium collected from RIE were found to be 
resistant to ciprofloxacin (MJC>256mg/J). It is assumed that the spread oftbe resistance 
was due to clonal spread in RIE although no any study was done to establish the fact. 
This findings agreed with the the findings of Tankovic eta/, 1996 which established the 
increase of resistance of ciprofloxacin from 0% of E.faecalis isolate in 1986 to 24% in 
1992 reflecting the clonal spread of resistant isolates. Since 69% of E.faecalis and 66% 
of E.faecium were found to be resistant to ciproDoxacin in this study, the newer 
quinolone drug- moxifloxacin, had more improved activity against isolates (Efaecalis 
and E.faecium) with only 28% resistance in the same study. This agreed with the 
previous findings by Hoogkamp-Korstanje and Rollofs-Willeme, 2000. Both 
vancomycin and teicoplanin are drugs belonging to glycopeptides group which share 
similar antibacterial spectra and potencies which are confined to gram-postive bacteria. 
Their activities are not identical. Whereas, vancomycin binds to the growing cell wall by 
dimerization thus enhances its activity against bacterial cells, teicoplanin, on the other 
hand, bas fatty acid chain which acts as a membrane anchor and increases affinity for the 
growing cell wall of the bacteria. In this study, teicoplanin was found to be more active 
against E.faecalis (MIC=2mg/l and E.faecium (MIC = 1 mg/1) while vancomycin was 
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found to be relatively sensitive to both isolates (MIC=8mg/l) in agreement with the 
previous findings by Cercenado et al, 2001. Linezolid is most active drug against gram-
positive bacteria including enterococci. All the isolates (E.faecalis and E.faecium) in this 
study were found to be sensitive to linezolid in agreement with the previous findings by 
Eliopoulos et al, 2002. Piperacillin is one of the ureidopenicillins active against 
P.aeruginosa. However, it can be used against E.faecalis infections. This study has found 
that piperacillin was relatively active against E.faecalis (MIC = 8mg/l) but more resistant 
against Efaecium (MIC =256mg/l). The resistance against Efaecium appears to be the 
intrinsicness of E.faeciwn against fi-lactams since none of the isolates was found to be fi-
lactamase producer. Combination ofpiperacillin/tazobactam (Tazocin) may have some 
advantage over co-amoxiclav, ticarci ll in/clavulanin or ampicillin/sulbactam because 
piperacillin is easier to protect against TEM beta-lactamases as a result of lower affinity 
of piperacillin for these enzymes (Livermore, 1993). fi-lactamase producing Efaecalis 
strains are usually susceptible to tazocin but E.faecium strains with higb intrinsic 
resistance to penicillin G are resistant to this combination (Chen eta/, 1993 ; Okhuysen 
eta!, 1993). Since this study did not detect any ,8-lactamase producer among the isolates 
of Efaecalis & Efaecium, it was found that Ejaecium was more resistant to the 
combination (tazocin) (MIC =256mg/l) than Efaecalis (MIC= 16mg/ l). The 
characteristics of E.faecium isolates being more resistant to /3-lactam drugs than 
Efaecalis appear to reflect the intrinsic resistance of Efaeciwn to the drugs. Beta-
lactamase producing strains of Efaecalis are sensitive to co-amoxiclav (also known as 
augmentin) (Ingennan et al, 1987). Augmentin was found to be relatively active against 
E.faecalis (MIC=l6mg/l) by this study while E.faecium was found to be relatively 
resistant to the combination (MJC=32mg/1). Amoxicillin also known as alpha-amino-p-
hydroxybenzyl-penicillin is twice as active as ampicillin against E.jaecalis (Neu, 1974). 
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My findings in this study shows that amoxicillin was relatively active against Efaecalis 
(MIC= 16mg/l) while Efaecium was relatively resistance (MIC=32mg/l) to the 
combination in agreement with Neu. The combination of quinupristin and dalfoptistin 
(Q/D) which is also called synercid is used in the treatment of infections caused by 
multidrug-resistant Efaecium. Virtually all Efaecalis isolates are intrinsically resistant to 
synercid (Chang et al, 1999). However, resistance to synercid among E.faecium isolates 
can be due to the presence of a single gene vatD (Rende-Fournier et al, 1993). This 
study found that all E.faecalis isolates were resistance to synercid (MIC = 64mg/l) while 
E.faecium was fotmd to be relatively resistant to synercid (MIC=32mg/l). 
7.2 Antimicrobial Combinations and Synergy by the i11. vitro Agar method 
Although resistance to antimicrobial agents may be due to drug-inactivating enzymes 
(Benveniste and Davies, 1973) or an insensitive target site (Zimmerman et aL, 1971) or 
acquisition of resistance genes, it may also be due to permeability banier. In such 
situations, a given drug could be active if another agent alters the permeability of the 
bacterial cell in order to permit entery. It has been postulated that agents that act on the 
cell-wall may enhance the entry of aminoglycosides in this manner in a number of 
bacterial species including Ejaecalis and E.faecium (Moellering & Weinberg, 1971). 
The original observation of penicillin/aminoglycoside synergism was probably made in 
1947 (Hunter, 1947) and subsequently many other investigators have demonstrated a 
synergistic effect of penicillin plus aminoglycosides against enterococci (Moelleting et 
al, 1971 ). In this study, the combination of amoxicillin and gentamicin against both 
E.faecalis and E.faecium shows the production of synergism (MIC=0.5mg/1 for 
E.faecalis & MIC=2mg/l for E.faecium). It is assumed that synergistic activity between 
amoxicillin and gentamicin occurred due to amoxicillin active on bacterial cell-wall and 
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facilitated the entry of gentamicin to act on ribosome 30s subunit thus ki ll ing bacteria. 
Similarly, when vancomycin-active cell-wall dmg- was combined with gentamicin 
against Efaecalis and Ejaecium isolates in this study, synergistic activity occurred 
(MIC=2mg/l for Ejaecalis and MIC= lmg/1 for Ejaecium.). This agreed with the findings 
by Moellering & Weinberg, 1971. Such results may indicate that the combinations of 
amoxicillin/gentamicin and vancomycin/gentamicin may be suitable for treatment of 
infections caused by both isolates. The combination ofteicoplanin active cell-wall drug 
with synercid against Efaecalis and Ejaecium isolates in this study produced synergistic 
activity. The combination ofteicoplaninfsynercid was more effective against both 
Ejaecalis and Efaecium (MIC=O.Smg/1). The results agreed with the findings of Hill et 
al, 1997 which estab lished synergistic activity of the combination of the two drugs 
(MIC=0.25mg/l). The results indicate that combination may be useful for treatment of 
infections caused by the strains of both isolates. When teicoplanin was combined with 
ciprofioxacin against both isolates (Efaecalis & Efaecium) in this study, production of 
synergy occurred. The combination of the two drugs (teicoplan in/ciprofloxacin) was 
found to be most effective against all isolates (MIC=<0.25mg/ l) than all other 
combinations in this study. The results suggest that the combination may be useful in 
treatment of serious infections caused by Efaecalis and Ejaecium. Combination of 
amoxicillin and synercid against Efaecalis and E.faecium isolates in this study produced 
synergistic activity (MIC=4mg/l). It is assumed that synergy occurred because 
amoxicillin being active on cell -wall of bacteria facilitated the entry of synercid into cell 
and inhibited bacterial protein synthesis by binding to 50S ribosoma l subunit and killing 
bacteria. It is also interesting to note that Ejaecalis iso lates are intrinsically resistant to 
synercid alone but the combination (amoxicillinfsynercid) had made isolates sensitive to 
the combined drugs. This combination could be useful for treatment of infections caused 
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by both isolates. On the other hand, the combination of vancomycin and synercid did not 
produce any synergistic activity against the isolates in this study (MIC=32mg/1 fo r 
Efaecalis and MIC=l6mg/1 for E.faecium). This indicates the antagonistic activity of the 
combination against the isolates. The ftndings agreed with the previous findings by Hill 
et al, 1997. Although it is assumed that vancomycin (active cell-wall) might have 
permitted the entry of synercid to bind 50S of ribosomal subunit ofbacterial cell and 
since synercid is bacteriostatic, it appears, its activity could not withstand the level of 
bacterial resistance against it. Such combination is not good for treatment of any 
infection caused by any isolate. The combination of synercid and ciprofloxacin in this 
study resulted in synergistic activity against Efaecium (MIC=4mg/l). However, it is 
interesting to note that the combination of synercid and c iprofloxacin against E.faecalis 
had reduced the MIC of ciprofloxacin from >256mg/l to 64mg/l and also the fact that 
E.faecalis is intrinsically resistant to synercid shows that activity of the combined drugs 
was effective against isolates and resulted in bactericidal effect by more than 2 log1o CFU 
unit indicating synergy. 
7.3. Time-kill curves Test for evaluating synergy/antagonism 
Drug- resistant enterococci present a major therapeutic problem especially in 
immunosuppressed patients (NCCLS, 1997; Rice& Shlaes, 1995). Since the development 
of a new drug for use in clinical therapy takes a Long time (ie approximately six years), 
the other alternative may be to use the combinations of drugs currently being used alone 
for the treatment of infections caused by the drug-resistant enterococci such as E.faecalis 
& E.faecium. One of the techniques used in the evaluation of drug combinations is the 
time-kill curves. This technique measures the bactericidal rate, duration of the 
bactericidal effect and if the bacterial regrowth eventually occurred. It has been 
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documented that time-kill curves studies more aptly reflect the clinical outcome. The 
present study was performed with an inoculum size of 105-107 CFU/ml, mimicking 
clinical conditions (Bingen et al, 1990) and colonies were counted after 24hom of 
incubation. Inoculum size and bacterial growth phase did not affect the assessment of 
synergy/antagonism at 8 hour with Ejaecalis and Efaecium isolates. The combinations 
were most efficient at 8 hour with 2 log1o unit decreases in viable counts and showing 
synergy observed in the study. The activity of the combined amoxicillin and gentamicin 
against Efaecalis and Efaecium in this study had resulted into synergy as observed at 8 
hour (Figs 4.9- 4.13) while a similar result with the same combination was also observed 
against the isolates in agar dilution technique in this study. The results show that it may 
be possible to use the combined drugs for the treatment of infections such as endocarditis 
caused by E.faecalis or Efaecium .. The synergistic activity was also observed with the 
combination of teicoplanin and synercid at 8 hour of antimicrobial exposure against 
Efaecalis and Efaecium isolates (Figs 4.14 & 4.15) in agreement with the similar 
activity shown in section 4.2 and previously reported by Hill eta!, 1997. Whi le 
bactericidal effect of the combined amoxicillin and synercid against E.faecalis and 
E.faecium isolates resulted in synergistic activity (Figs 4.1 6-4.19), a similar activity by 
same combination was observed in section 4.2. The results may indicate that the synergy 
between combinations may likely occur in vivo situation as well. Exposure of 
Ejaecalis and E.faecium isolates against the combined ciprofloxacin and synercid 
resulted in synergistic activity (Figs 4.20-4.23) and was simjlar to bactericidal activity of 
the same combination observed in section 4.2. The combination of ciprofloxacin/ synercid 
may be useful clinically. Combination ofteicoplanin and ciprofloxacin against EfaecaLis 
and Ejaecium isolates resulted in synergistic activity (Figs 4.28 & 4.29) and regrowth in 
teicoplanin. This agreed with the similar activity of the same combination in section 7.2. 
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Combining vancomycin with gentamicin against Efaecalis and Efaecium resulted into 
synergistic activity (Figs 4.24- 4.27) in agreement with the previous findings by 
Moellering and Weinberg, 1971 and also same activity of the combination observed in 
section 4.2. On the other hand, combination of synercid with vancomycin against 
Efaecalis and Efaecium isolates resulted into antagonistic activity (Figs 4.30-4.32) in 
agreement with the findings by Hill et al, 1997) and a similar activity was also observed 
in section 4.2. 
7.4 Synergy Testing of the Combined Antimicrobial Agents by Checkerboard 
Method 
Patients with infections which are life-threatening or resistant to treatment with single 
antibiotics tend to do better when treated with antibiotic combinations shown in vitro to 
act synergistically against the pathogenic strains (Beerenbaum, 1978). One of the 
teclmiques used in testing the combinations of antibiotics is Checkerboard. This 
technique has been used most frequently to assess antimicrobial combinations in vitro 
with respect to synergistic therapy in the treatment of neutropenic patients with gram-
negativ septicaemia (Klastersky et al, 1972; Lau et at, 1977). The results of checkerboard 
test is interpreted in terms of fractional inhibition concentrations (FIC) index with the 
values of0.5 for synergy, 1 for additive and 2 for antagonism (Beerenbaum, 1978). The 
PIC index method allows a more objective analysis of the results than mere drawing of 
isobologram lines (Holm, 1986). In this study, owing to elaborate nature of setting up 
each checkerboard agar dilution method to assess the interaction of the combined 
antimicrobial agents, only four strains of vancomycin resistant Efaecium were tested 
against the combined ciprofloxacin/synercid. Synergistic activities were observed against 
the strains tested (Figs 4.3-4.6). Two of the four strains (D002 and G051) were fu rther 
tested against other antimicrobial combinations of gentamicin/vancomycin for G05 1 and 
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teicoplanin/synercid for 0002 and synergistic activity of the combined drugs was 
observed (Fig 4.26 for G05 1 and appendix B for 0002). Although synergistic activity of 
the combined drugs against the two isolates (G051 & D002) was observed, the in vivo 
test should be done to establish clinical usefulness of the combined drugs. 
7.5 Detection of Aminoglycoside Modifying Enzymes in Aminoglycoside Resistant 
enterococci. 
Aminoglycoside modifying enzyn1es (AMEs) are major factors which confer 
aminoglycoside resistance on bacteria. Since its emergence in 1979, enterococci with 
high-level gentamicin resistance (HLGR) have been disseminated in most countries and 
its prevalence was remarkably increased in 1990s (Sin'ljee and Gill, 1997). HLGR is 
recognized as a clinical serious problem and routine examination including surveillance 
of clinical isolates of enterococci are necessary for the choice of appropriate treatment 
and infection control. HLGR in enterococci is previously known to be caused by one 
gene (aac(6 ')-le-aph(2 ')-La) encoding bifunctional enzyme AAC(6 ')-APH(2 ") in 
clinically useful aminoglycosides ( Fenetti eta!, 1986). In recent years, three new 
aminoglycoside resistance genes (aph (2")-lb, aph(2")-lc and aph(2")-Jcf) that also 
mediate resistance to gentamicin have been detected in enterococci (Chow et al, 1997; 
Kao et al, 2000; Tsai el a!, 1998). The aac(6 )-le-aph(2 ')-Ia appears to have been 
conveyed to both enterococci and staphylococci via plasmid and transposon (Simjee and 
Gill, 1997). Incidence of recent enterococci isolates showing HLGR varies depending on 
countries as well as medical facilities. In a large scale survey involving 27 European 
countries, the percentage ofHLGR en terococci varied by country ranging from 1 to 49% 
and by species 19.7% Efaecalis and 13.6% E.faecium (Schouten et al, 1999). National 
survey in USA indicated the incidence ofHLGR as 26% E.faecalis and 30% Efaecium. 
Another survey from European university hospitals reported the incidence of the strains 
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with HLGR being 32% Efaecalis and 22% E.faecium (Schmitz et ai, 1999). In this 
study, the distribution of genes encoding four AMEs (ie aac(6 ')-le-aph(2 ") -La, aph(2 ')-
1 b, aph(2 ")-Lc and aph(2 ")-ld) was investigated by multiplex PeR for 32 E.faecalis and 
20 E.faecium isolates from RIE. 31% Efaecalis and 10% E.faecium were found to be 
resistant due to presence of aac(6 ')-le-aph(2 ')-La gene. However, the remaining three 
genes were not detected. The use of multiplex PeR for the dectection of AMEs was in 
line with the previous findings by Vakulenko et al, 2003. However, based on none 
detection of the remaining three genes, It could be suggested that there could be existence 
of the resistance mechanism other than AME including ribosomal mutation which have 
not been detected with the present techniques. Seven isolates (all E.faecalis) which were 
found to harbour AME gene were further screened for presence ofTn5281 elements 
responsible for canying and disseminating AME resistant gene and presence of IS256 
elements which flank the enzyme both sides in inverted repeat in line with previous 
findings by Schmitz eta/, 1999; Simjee et al, 2000; Lyon,l984. The results established 
the presence ofTn5281 elements as well as IS256 (Figs 6.2 and 6.3). 
7.6 Alteration in GyrA and ParC subunits in Quinolone Resistant enterococci 
Resistance to fluoroquinolones appears to be due to mutations mediated via altered 
amino acids in QRDR ofDNA gyrase subunit or topoisomerase 1 V. Specific amino ac ids 
within gyrA or pare QRDR appear to correlate with sensitivity against quinolones 
because two sequences code for a specific part ofD A gyrase and topoisomerase 1 V 
which may be, probably, the molecular targets of quinolone antibiotics. Previous studies 
by Korten et al, 1994; El Amin et al, 1999; Kanematsu et al, 1998) showed that mutation 
in pare of Ejaecalis occurred at position 80 and 84; whereas the findings by FetTero et 
al, 1994 showed that mutation in pare of E.faecalis occmTed at position 83 and 87. 
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However, findings from this study showed that mutation in pare of Ejaecalis occurred 
at position 80 and 87 for isolates with Mie>256mg/l and at position 80 and 85 for an 
isolate with Mie 0.5mg/l. These results appear to show variability with regards to 
positions of mutations in pare of Efaecaiis. Owing to financial limitation, I was unable 
to sequence and confirm mutations in DNA gyrase among the selected isolates identified 
in PeR technique which could have detected gyrA along side pare mutations. However, 
the findings by Kanematsu et al, 1998 indicate that gyrA mutations in Ejaecalis occur at 
83 and 87 positions. Mutations are associated with a profound increase in the resistance 
to all quinolones. The factors which influence mutations of pare at positions 80 and 84 
or 85 or 87 which indicate resistance may be due to topoisomerase 1 V being the primary 
target (Kanematsu et al, 1998) based on the position of the mutation and the number of 
mutations involving types of amino acids. Mutations at pare positions 80 and 84 or 85 
or 87 are usually more infuencial when the topoisomerase 1 V is the main target, for 
example in Efaecalis (Kanematsu et al, 1998). Pare 80 codes for serine which appears 
to be direct quinolone binding site of the enzyme (Maxiwell, I 992). Mutation at this 
pos ition is, therefore, appears to be the prerequisite for high res istance. Posi tion 84 or 85 
or 87 might be another binding site for quinolone as mutations at this position alone 
seems to have effect on quinolone sensitivity. Fluoroquinolone resistance appears to be 
higher when mutations occur at positions 80 and 84 or 87 than only one mutation in 
either 80 or 84 or 87. It appears as if in a very high quinolone resistance (eip 
Mie>256mg/1), at least two mutations at pare 80 and 84 or 87 are needed (Fenero et al, 
1994). The effects of pare QRDR are insignificant on sensitivity. Mutations in QRDR 
not involved at position 80 and 84 or 87 do not play an important role on the level of 
resistance. It is assumed that two mutations at 80 and 84 or 87 for pare may be the most 
efficient way a bacterium can develop high resistance to quino lone drugs. Therefore, the 
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more mutations, the higher level of resistance can occur in gram-positive or gram-
negative bacteria. In this study, 36 Efaecalis and 14 Efaecium were found to be 
resistant to ciprofloxacin with Mies >256mg/1. However only six isolates (all Efaecalis) 
were chosen for further examination and one of them had Mie of0.5mg/l (sensitive) 
and the remainder had Mies of >256mgl each. PeR teclmique was used in 
identification of gyrA and pare in the isolates which were involved in the QRDR in line 
with the findings ofKorten et al,1994; Piddock,l999; Kanematsu et a/,1998 ). This study 
established the existence of JD~rA or pare or both in all isolates identified by the PCR 
method. The products of PeR for pare were further sequenced to establish the amino 
acids involved in the mutations in pare. The results revealed that four isolates had 
mutation with a change of one amino acid each at Ser-80-lle and two silent mutations 
while another had mutation with two changes of amino acids at Ser-80-Ile and Glu-110-
Asp and two silent mutations. The sensitive isolate (Mle=O.Smg/1) had mutation at Ala-
80-Val and a silent mutation. However, sensitive isolate had subsitituted Ala for Ser at 
position 80 and Val fo r Ile at position 80 of pare. The subsitituted amino acid appears 
not have any important role in the level of resistance but the loss of serine at position 80 
that is most significant than the subsitituted amino acid because position 80 is a basic 
requirement for the bacterium to become resistant. This subsititution of amino acid (Ser) 
in a sensitive strain such as RIE-18B/3l4 could provide the strain with intrinsic 
resistance against ciprofloxacin. Four isolates (RIE-18B/376, RIE-18B/379, RIE-
18B/390 and RIE-18B/911) had each one amino acid mutation (Ser-80-Ile) while one 
isolate (RIE-18B/414) had two mutations (Ser-80-lle and Glu-110-Asp) in line with the 
previous find ings by Kanematsu et al, 1998. However, the effect on resistant level of 
subsitituting amino acid in certain position of quinolone drug requires futher 
investigation. 
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7.7 PFGE Analysis and Interpretation 
Several techniques have been used in medical microbiology for acquiring information 
on the spread of pathogenic bacteria within the hospital envi ronment and outside in 
the community ( Antonishyn et al, 2000 ). The PFGE technique used in this study 
was to analyze the degree of clonality with the gentamicin-resistant isolates (Efaecalis 
and E.faecium) obtained from RIE. The interpretation was done based 
on the criteria described by Tenover et a /,( 1995). The criteria arc on ly used in the 
hospital laboratories when examining relatively small sets of isolates ( ie not more 
than 30) which are related to putative outbreak of the disease. The interpretation 
criteria was used to show the number of fragment differences that would be expected 
within the PFGE patterns showing a defined number of genetic occurrences either as 
point mutation resulting in the creation or loss of restriction sites and insertions or 
deletion of DNA. T hus, PFGE patterns that differ by two or three fragments are 
deemed to be closely related on the differences that occur through a s ingle genetic 
event. According to Tenover et al, 1995, two genetic events wou ld result into four to 
six fragment differences showing unrelatedness. Tenover eta/, 1995 , proposed that 
these criteria are reliable ifPFGE resolves at least ten distinct fragments. According 
to Tenover eta!, 1995, a point mutation that would lead to the criteria of an additional 
restriction site may result in a three fragment differences. This might be taken as 
closely related to the o riginal pattern. However, transfer of large chromosomal 
clements associated with vancomycin resistance could alter the biochemical 
properti es ofthe strain ( McAshan eta!, 1999 ). The study by Morrison eta!, 1999 
shows that a sing le strain can differ by up to seven fragments based on the 
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temporal, association ofthe isolates representing a single strain. If the criteria defined 
by Tenover et al, 1995, were widely accepted, they would not be applied to all bacterial 
species because it is recognized that different bacterial species vary in degree of 
polymorphism that they exhibit (Struelens et al, 1996). Although criteria defined by 
Tenover et al, 1995, provide some interpretations ofPFGE patterns by allowing easier 
comparison of the conclusions reached by different epidemiology studies, it is upto the 
individual to accept conclusions drawn from such interpretation. It was unfortunate in 
this study that information related to the gentamicin resistant E.faecalis and E.faecium 
strains from each ward were not obtained at the time of collection from RIE in order to 
establish colonial or heterogeneous infections. The visual comparison of patterns and 
interpretation were done in this study based on criteria described by Tenover et al, 1995 
for gentamicin resistant clinical isolates obtained from RIB. However, Diversity database 
analysis was undertaken based on images digitized from the original Polaroid 
photographs that were used for the original visual PFGE gels. Isolates which were 
deemed to be identical by viaual compatison ofPFGE patterns had wide ranging 
percentage similarities according to Diversity Database analysis from Bionumeric 
Software Version 3.0 computer. The computer software identified iso late RJE-1 7B/849 
and RIE-18B/33 as nearly iden6cal ( 80% similarity) but failed to detect identity between 
RIE-17B/235 and 18B/149 ( 40% similarity). It also failed to identify between RIE-
18B/662 and RIE-ISB/749 (50% similarity). RIE-ISB/517 and RIE-lSB/567 identity 
with 76% similarity and closely related isolates RIE-18B/815 and RIE-19B/471 showed 
68% similarity. Isolates RIE-18B/536 andRIE-lSB/632 had only 66% similatity. All 
the isolates identified as unrelated to any other isolates by visual comparison ofPFGE 
patterns were confirmed by computer software as unrelated. However, the computer 
software calculates that the two isolates have 66% similarity, such a percentage similarity 
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shows that the strains are not related although it may be that the percentage may be 
significant given the variety observed in the percentage similarity of identical strains. 
7.8 ConcJusiou 
The resu lts presented in this thesis have demonstrated the existence of synergistic as well 
as antagonistic activities of the combined antibiotics against enterococcal clinical isolates 
(Efaecalis and Efaecium) obtained from RIE. All the clinical isolates were gentamicin 
resistant with the majority being Efaecalis. Owing to lack of information from each ware! 
at R.IE where clinical isolates were obtained for this study, the gentamicin resistance 
outbreak within the wards was not established. However, analysis by PFGE appears to 
show the diverse nature of the isolates in the wards ofRIE. This study revealed the 
presence of AME resistance gene ( aac(6 ')-le-aph(2 '')-la) responsible for HLGR among 
the isolates as well as Tn5281 harboming the resistance gene (aac(6 ') -le-aph(2 ")-fa) and 
flanked by lS256 in an inverted repeat on both sides of the gene. The presence of AMEs 
in Tn5281-like transposons flanked by IS256 in some isolates in this study with high 
level of gentamicin resistnce were overcome by antimicrobial combinations resulting in 
synergism. These are very interesting results but it might suggest that these isolates 
might be at the border between high-level resistance and moderate-level resistance to 
gentamicin although they had AME. Most of the isolates in this study were found to be 
resistant to ciprofloxacin (MIC= >256mg/l). This study also revealed the existence of 
gyrA and parC responsible for higher resistance among the isolates. Further sequencing 
ofPCR products ofparC of six selected Efaecalis (5 isolates with MIC= >256mg/l & 
one with MIC= 0.5mg/l) revealed the presence of mutations in QRDR at positions 80 and 
87 with one amino acid change and two silent mutations for four isolates ( MIC= 
>256mg/1) and one isolate with MIC= >256 but with two amino acids mutations at 
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position 80 and Glu-110-Asp and two silent mutations. Silent mutations were either at 
position 85 or 87 or both. Sensitive isolate (MIC=0.5mg/l) had mutation at 80 and 85 
and Ala substituted ser at position 80 and Val substituted Ile at 80 which appeared to 
have played no role in the resistance of this isolate but showed intrinsicness against 
ciprofloxacin. The combination of syemcid and vancomycin revealed the presence of 
antagonistic activity of the combined drugs in this study and indicating that one of 
antimicrobial agents might have cancelled out or interfered with the activity of the other 
agent. The presence of AMEs in Tn5281-like transposons flanked by TS256 in some 
isolates in this study with high level of gentamicin resistnce were overcome by 
antimicrobial combinations resulting in synergism. These are very interesting results but 
it might suggest that these isolates might be at the border between high-level resistance 
and moderate-level resistance to gentamicin although they had AME. This study also 
revealed that some isolates tested cmTied both AME andgyrA or parC resistance genes 
or all which resulted into high-level resistance to both gentamicin and ciprofloxacin in 
this study. This suggests that these isolates may cany more than two resistance genes. 
The iJwestigation by PFGE did not establish source of the outbreak of gentamicin-
resistant isolates in RIB since information about the wards in which these isolates were 
collected was not available at the time of obtaining the isolates. However, similarity 
analysis showed a diverse backgrOLmd of the isolates. 
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Appendix A API Profile and Haemolysis on BA*(a &p.Haemolysis) 
Isolate # Species API Profile Category Scores % a or f3-haemoloysis 
17B/235 l:-'.faecium 7 3 5 7 5 1 I 98.69 
17B/377 E.durans 7 3 53 4 I 0 94.9 
17B/407 l:-faecalis 7 1 0 3 3 1 I 98.4 
17B/452 E.faecalis 7 1 6 3 3 I I 98.5 
17B/686 E.faecalis 7 1 5 3 7 I I 95.9 
17B/721 Efaecium 7 1 57 5 1 0 97.1 
17B/76I 1:-faeca/is 7 I 4 3 3 1 I 99.3 
17B/8 19 E.faecalis 7 1 4 3 3 I I 99.3 
17B/849 £.faecium 7 3 5 7 7 I 0 99.7 
I8B/33 E.faecium 7 3 5 7 7 I 0 99.7 
18B/89 1:-'..faecium 7 l 4 3 3 I I 99.3 
18B/ 149 E.Jaecium 7 I 6 7 5 I 0 81.2 
l8B/234 l!-'.faecium 7 3 5 7 6 1 0 99.2 
18B/254 Efaecium 7 I 7 7 7 I 1 98.3 
188/294 l:-faecium 7 3 5 7 7 l I 99.9 
188/298 Efaecium 7 1 7 7 7 I I 98.3 
18B/309 E.jaeca/is 7 I 4 3 7 1 1 99.2 
188/314 Efaecalis 7 I 4 3 7 l I 99.2 
I88/329 Efaecalis 7 1 4 3 7 1 1 99.2 
188/337 Efaecalis 7 I 4 3 3 I 99.3 




















188/376 £.faecal is 714331 1 99.3 f3 
188/379 £.faecal is 71433 11 99.3 f3 
188/3 82 l!.:j aecalis 7 1437 11 99.2 a 
188/387 E.faecalis 7143311 99.3 a 
188/390 l~faecalis 71737 11 95.7 f3 
188/414 Ejaecalis 7 I 4 3 3 I I 99.3 f3 
188/487 Efaecium 735771 1 99.9 a 
188/506 £.faecal is 71437 11 99.2 f3 
188/5 17 Ejaecium 73577 10 99.7 a 
188/5 19 1!-faeca/is 7 I 4 3 7 I I 99.2 a 
188/526 1.:-faecalis 7 143 311 99.3 f3 
188/536 E.faecium 73575 1 0 98.6 a 
188/55 1 Afaecalis 7 I 4 3 3 I I 99.3 f3 
188 /555 F;jaecalis 7 I 4 3 7 I I 99.2 a 
I 88/556 l~faecalis 7 143711 99.2 a 
188/567 },faecium 7 I 7 7 7 I I 98.3 a 
188/569 1-.faeca/is 71437 11 99.2 f3 
188/570 Ejaecalis 7 I 4 3 7 I I 99.2 f3 
188/578 l~faecalis 7 14 3711 99.3 f3 
188/6 12 Ejaecalis 7 I 5 3 7 1 I 95 .9 a 
188/632 tfaecium 7357510 98.6 a 
188/642 J .. faecalis 7 1637 11 94.8 f3 
188/643 tfaeca/is 7 I 4 3 7 I I 99.2 f3 
188/647 J~faca/is 71437 11 99.2 f3 
175 
18B/662 Efaecium 737710 99.7 a 
18B/713 Efaecalis 7143311 99.3 ~ 
18B/745 Efaecalis 7143711 99.2 a 
188/749 Efaeci 11111 7357510 98.6 a 
18B/777 ~faecalis 714331 1 99.3 ~ 
188/791 Ejaecalis 7173711 95 .9 a 
18B/807 Efaecalis 71737 1 1 95.9 ~ 
18B/813 Ejaecium 73577 1 0 99.7 a 
188 /8 15 ~faecium 7357710 99.7 a 
188/825 Ejaeca/is 71437 1 1 99.2 ~ 
188/854 t;jaecalis 7 1 733 1 1 93.6 ~ 
188/869 Ejaecalis 7 I 4 3 3 I I 99.3 ~ 
18B/900 i:.,faeca/is 7153711 95.9 a 
188/91 1 E.faecalis 71433 1 1 99.3 ~ 
188/946 l!,'jaecalis 71733 1 1 88.9 ~ 
188/960 J~.faecium 7 I 7 7 3 I 1 98.8 a 
188/976 J:.,faecalis 71733 1 1 93 .6 ~ 
19B/082 Ejaecalis 7 I 53 7 1 1 95.9 a 
19B/l83 i:.,faecalis 7143311 99.3 ~ 
198/300 E.faecalis 7 I 7 3 7 l I 95.9 ~ 
19B/315 ~faecal is 7173711 95.9 a 
19B/336 E.faecalis 7143311 99.3 ~ 
19B/343 .tfaecalis 7143711 99.2 a 
198/369 1:-faeca/is 71437 1 1 99.2 ~ 
176 
19B/391 E.jaecium 7357711 99.9 CJ. 
198/412 t:.jaeca/is 7143711 99.2 CJ. 
19B/ 471 E.jaecium 7347711 99.9 CJ. 
19B/491 E.faeca/is 71437 1 1 99.2 ~ 
6155/6/95 E.faecalis 7143711 99.2 CJ. 
154/11/95 E.faecalis 7143311 99.3 ~ 
ATCC 51299 E.faeca/is 7153711 98.3 ~ 
NCTC 12697 E.jaecalis 7143711 99.2 CJ. 
NCTC 7171 E.jaecium 7 1 5 7 7 I 0 98.8 CJ. 
NCTC 12202 l!.,faecium 7157511 94.9 CJ. 
D002 E.faecium 7357510 98.6 CJ. 
G05l 1<.-'.jaecium 7377711 99.9 CJ. 
Gl42 Efaecium 7357510 98.6 CJ. 
788/5/95 Efaecium 7377510 99.8 CJ. 
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2 3 4 
Lane 1-lambda DNA, lane 2-RIE-1 8B/382, lane 3-RIE-188/387, 
Jane 4-RIE-18B/390, lane 5-RIE-18B/414, Jane 6-RIE-18B/487, 
lane 7-RIE-18B/506, lane 8-lambda DNA, lane 9-RIE-18B/519, 
lane 10-RIE-18B/526, lane 11-RIE-18B/55l,lane 12-RIE-18B/555, 
Jane 13-RIE-18B/556, lane 14-RIE-18B/569, lane 15-lambda DNA 
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(b) 
1 2 3 4 5 6 7 8 9 10 
bp 
Lane 1-lambda DNA, lane 2-RIE-18B/570, lane 3-RIE-18B/578,Lane 4-
RIE-18B/612, lane 5-RIE-18B/642, lane 6-RIE-18B/643, Lane 7-RIE-











Lane 1-RlE-lSB/946, lane 2-RIE-lSB/975, lane 3-RIE-lSB/976, lane 4-19B/082, lane 
5-RlE-19B/ 183, lane 6-RIE-19B/300, lane 7-RIE-l9B/315, lane 8-RIE-19B/336, lane 
9-R1E-19B/343, lane 10-RIE-19B/369, Jane ll-RIE-19B/412, lane 12-RIE-19B/491, 
lane 13-A. lambda DNA 
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(d) 
1 2 3 4 5 6 7 8 9 
Lane l -RIE-18B/777, lane 2-RIE-18B/791, lane 3-RIE-18B/807, lane 4-18B/825, lane 







Appendix D. Analysis of agarose gel electrophoresis of amplified ddl 
E.faecium and ddl E.Jaecalis PCR Products 
bp 
(a) 
1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 
Lane 1-lambda DNA, lane 2-RIE-18B/379, lane 3-RIE-18B/382, 
lane 4-RIE-18B/387, lane 5-RIE-18B/390, lane 6-RIE-l8B/414, 
lane 7-RIE-18B/487, lane 8-RIE-18B/506, lane 9-RIE-18B/517, 
lane 10-RIE-18B/519, lane 11-RIE-18B/18B/526, lane 12-RIE-
18B/55 1, lane 13-RIE-188/555, lane 14-RIE-18B/556, lane 15-
RIE-18B/536, lane 16-lambdaDNA 
(b) 
1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 
Lane 1-A. DNA, lane 2- RIE-1 8B/569lane 3-RIE-18B/567, lane 4-RIE-
18B/570, lane 5-RIE-18B/578, lane 6-RIE-188/612, lane 7-RIE-18B 
/632, lane 8-RIE-18B/642, lane 9-RIE-ISB/643, lane 10-RIE-lSB/647, 
lane ll-RIE-18B/662, lane 12-RIE-18B/710, lane 13-RIE- ISB/745, 
lane 14-RIE-18B/749, lane 15-RIE-18B/777 
194 
(c) 
1 2 3 4 5 6 7 
Lane 1-RIE-lSB/791, lane 2-RIE-18B/807, lane 3-RIE-18B/813, 
Lane 4-RIE-18B/8 15, lane 5-RIE-18B/825, lane 6-RIE-18B/854 
Lane 7-A.DNA 
bp 
941 
550 
195 
